var title_f34_46_35552="Small field RT portal seminoma";
var content_f34_46_35552=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Limited or small field radiation portal for seminoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 357px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small-field or paraaortic lymph node (PALN)-only radiation therapy field for stage I seminoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Clair Beard, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_46_35552=[""].join("\n");
var outline_f34_46_35552=null;
var title_f34_46_35553="Mevalonate kinase mechanism";
var content_f34_46_35553=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F79953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F79953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    A schematic of the proposed catalytic mechanism of mevalonate kinase",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 444px; height: 440px; background-image: url(data:image/gif;base64,R0lGODlhvAG4AfcAAP///wAAAPz8/P7+/v39/fv7+/r6+vj4+Pn5+ff39/Pz8/b29vX19fT09O/v7/Ly8uTk5Orq6ubm5qqqqtnZ2fHx8fDw8Onp6ezs7LS0tNvb2+Xl5XFxcWZmZu7u7rq6uuHh4efn5+jo6LGxsePj4+3t7djY2ISEhN3d3UhISNDQ0M3Nzevr6+Dg4N7e3srKyszMzHZ2dsbGxoyMjIKCgjAwMNra2r29vdPT04ODg1xcXNzc3LKysp2dnbu7u3h4eEJCQlNTU4mJieLi4qmpqZSUlHx8fG1tbcjIyMTExM/Pz7i4uKysrJqamn5+ft/f32FhYaGhoWpqamRkZC8vL8fHx2BgYKenp8nJybCwsMDAwGtra39/f3R0dG5ubnt7e9XV1be3t2NjY7m5uba2tl1dXWJiYiYmJtTU1MXFxZWVla+vr8vLy2VlZaurq8HBwdLS0ry8vLOzs8LCwsPDw46Ojl9fXy4uLr+/v6amppeXl3JyctfX14iIiM7OzjU1NTc3N76+vq6urpmZmXl5eYaGhtHR0Q0NDTk5OdbW1qKiol5eXldXV6OjozIyMnd3d6CgoKioqJOTk0NDQzo6Oo2NjWlpaYGBgTY2NktLS4WFhXBwcHp6ep+fnz8/P0VFRZCQkDMzM5GRkXV1dYqKillZWZ6enlBQUCsrKykpKbW1tTs7O1hYWBkZGWxsbFpaWjQ0NCoqKoeHh1VVVVtbW2dnZ6WlpZiYmJKSkq2trX19fUBAQEFBQRoaGjw8PFRUVJaWlnNzc09PT0lJSSQkJD4+Po+PjzExMW9vb5ubmyAgICgoKDg4OB8fH2hoaExMTA8PD6SkpEdHRz09PYuLix4eHk1NTSUlJSMjI5ycnFFRUSEhIVJSUi0tLU5OThAQEBgYGFZWVhERERwcHCwsLEZGRicnJ4CAgERERBcXFxISEkpKSgoKCh0dHRMTEyIiIhsbGwcHBwICAgEBARUVFRYWFhQUFAwMDAYGBgsLCwUFBQgICAQEBAkJCQMDAw4ODiH5BAAAAAAALAAAAAC8AbgBAAj/AAEIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzaNOqXcv2Ip8eg9IUaEu3LtsozTCVO2OGhd2/gMOOofdoyIMP5KYkOPigQeDHkJsq8MSI4I1WVQgOILIo07MpPiKLHi00CTYyBEMsazSQhQ5EleL4OBcqhgHSuHPfdLMsEUEbzbIIPEBrVoSBA0wUMzJAt/PnLfG8o0MQWDMNAqNMg2AQRygk0MOL/ydZQVoKCQJhtHo09wAUIQBkhFFAENmo8fjzc0RTDNAPL71o44FAEAShCgA9eMINKTgQAIAppegn4YQUbVCHHa/g4phAG/wiHANoZFPGHyMAkA0tFKaoYkMMMCCACiUIZEAH5xBUwQstDLCFESv26KNBAnASRXMAuDENGAbJAIsKP5bVAgwCCCQAHA4kAAcGA0mAw1xNXqRFLR5AgOQWKTApEAFJYNJHQRaI4GCXW50gTokAPEDJEihMssZARfAyIJwVCWDJDdFcN8ARiBDSxC3IwJLDmwAkoEYmKbSBB6BZcbIPIMdZkMoIGoRCxEB11BAjphQF4gwGwxBjCABa/P9QyyaapEFQAluAM0oTdjTTA6pWxcBNCnsAoMAxGWgASAYDNcHMqcBGREAHN0RwSiubYCEBGnrIUdAt36AGwACaYPNqtFJxsMccZ6QxQA0ZDFEDLGboYEUqvFiArkRktAFAA4NQskwsd8SiCZcAOMCMJQQ1cAco+0bFgb9bZHIBMxm04Ig3snBxAi+eNDAEDRwEEjFDCrSxhEAImPBGGk9gcMEOSUy5jXDIIXLJyU9xAAUAKPyhCSWq2MBMLgMkrUYxFUhByhXCwMCzQrlsgkACIdigxAfAdGEGLXtUsIIycRCEAjFRTN2UF3YIlEc16nxggyOjCkQNMy0oIkAEvwj/ojZCBXizSR97WCIFIXUQscKpEdTABUGcvPPE30shY4WUOgTggw2w1A3ADDU4AAAayGzyJ+UE6eENKVnMYcIDCEFCjyxPkCAENLcQifpRSZQt0BDAkGCBGzsMZIggBMyxhSmL7S7QAl/QYkNDAvTwxx81VCNKlM4nRQCkCW3gCQ1sJAEt5RCYsYlfD20QRxYUdK+UAJHQqRAIjxASgxHYoc6GNqRonvy4goBC4IIhAyhAAhaQAPBNbQ3DsMUAv2KAGehhggoRgCS0oQUMeqWCF/SgQR4wCjtMT4RcASEKCdICK4yCfSvUigpjiAVuqGEBMUyhBVcoAB5YQxC6y2FW/2YowjcIIzNC1GEIRUgEWSSxJw8AAXIuQB+MFKETK6yCEXD4RJ3YAhEfeJ4VPFeRHTzDDqIToQu6QIIu6kQWAcCEXxTQjTpYhAHZWAQuZEELJjiweyz4gR/cmBNN+AIRj2MAItRAkQEEwg6bkJoA8NABV5hpgA+gwYEIeZMcsEIOypABACjBSGnZYBSsUMUBAHAA0R3gCuEoBHfkZwBJJIOTnbTGAmohjATwoggRGYIogiAKLgKAD2KwhegwcIlSKOICAzmA7giAgCACSxBOdEgBYIdLkuQgEwB4AiBEsY4LioANAkQIAxqhgx/EjyAFyMArxBBGAMBgC1OYAwAWIP+EcyBAIDjIwRAiJgNC/HMhDcDFL6xhh0sBgAKSYN8AcpGLbmLkm7dRRCp6oQgA4KAWR0iGCrhXkBu0oQ1jSEgFmhCOLqBBILa4AgA8MI0A1G0EZ1hBxNDQhVkm5AFlUIYTmkALeEQCAHIwB5IAIIAgBMGiF+ECEBaDgFIE4FcF0IAccjAFV6hhkAJBQQxYEY00KgQFQhCGEGDXHBb84gzTmBwZlhQxEsSADQvRwzjeIJAEPOIaIvBBDd4JAB1UBqoVUYUkuEQBLySBIAcAQRhOYAUzZKMJs6CGFB+igiPQYrMiWAcpuLEJACyBrvtiwCU2iZADAMEVBHkCKiagBXL/xEECGiDBKcqAWIkwIAMoSBpBBPBHABggAkmwQzFwYM2GLAAGp7oAL5qQiG0ggQ6o3VcRWHOQCogAA3c44EAIMIkTIEEcdygGInxxjw70NiJrCAIKjAuRSLiCAAfwQHMfcgEgVAIAXBiGKnwB1n1FYgYOfAAZjhAFAzgCPgNhwCpAMYdURAILdKjCJxbx3odQQBiXugERiouQPGwBAFXIAcIkcoFJzAAAJfiEJ4Bwrn354Aun80AeatGGTqDHCuhAmBbSgYUbwGKzABDDKzrckAKI4cVDOIXfHmJiAIxhCrehiAhgQQOB3CAAxODDyeAQjBYAQAR6sIMXsnAcgbwA/x4ckIABqnCHXxRgCVRYqgAYEQ4mM0QNYljAATZRiP0mpMo3QEaWJ+IBKURjIEawRhsjxoIv+EASjODEHMw6kBFQgQrTUAYr0BMHIJyQAFuQgp8V8gZrmLkHZjhfQxDthUVLhAAWMOYBIkBSdHmAG5ToQyIOehARjGECbDhoAkSwaA+cbtUFCUEQSvSCIEgtIrS2NUUSoa+pkYADsZAptEHSgBhoggAQsIK4sX3iG9T6IgaohSh55gdaSAISt1jluD0yAmv4BQ9rmki2L1IAefNsCd5IGx6MUIF9ewQOv6BOAlYMkYFbpACWmPe+GnGK0AAADsiYtMM5MgFGiMAiFv+vSAGkgMRoGaAQZXipQDCwhUuOXCMCMEIMSDzrdr/74ixH1wW8sIUQFKQLHr/5Rh5QCu4K3OfalgjGNY4pPljhBOkUSB+wqHSOGOIZNWY3AOLgiqhHZOUtBxQdwvGrgzSCCxTv+kUUEY5nU/nEH2iD2R2ymKmj6gpBWBlCkNCBvct9IgUIhhF67RAmbGIAKBgB4x3yAGBkY1xHSPuPClAHWlwbIRhgRZsPnxESBMENEpEEbyviAzEEQ6cAWIQ+4aSHNiA5IVIoMOkxooIXOGQALYiCM2aRAhpAMyIu2EMZMuAYCCCjFOiBEzUg0ZAQbGj3GoFDNk5VgDXI/F98aAT/B1ixB1U4OwfaiAI3GVIBNXBDDw1XQDKEQQ27/4gI1DA09kNCjQAUy1jHADEeEA2bIAacIAjHNxAvMAVToAXElhAq8AXYcQA+AAVHgAPAcgM/gCVYQQAOoH9dQgrpUA03YCyLBACG8AVMYHSHVgpGgIENsQKPsAj2gyqJgAwmsBAVQASXUATvRAKGoDtK4FM70Qi/sA6sQAQgeBEV8AF58AaTxxEesAREkAY8FxQ5EA6bsAoNgAAn+BAhQA1lIArRFwEuMF5DsAAEEAm/AAqyhikVsAefdxA78AndUAq7gAoHcgtBwEUE4AmSwBMF4ATg4AXAIAXwQANLSBFYsAtU/yANy6ANZ/gRMoAIVPAJZ8AKImcUOfALIBAK1AAAqwBMEbECwbCBAGAMsPBYxiIMY0AAPoAFPMMF3oIQCXAKmAAHDyABrhALJLA0zTMAqABhOjEG6pA2AEAAyQAOfNURKFADjAAGEMAGqwAEDOARYLAMi5AIQ/AGVHAK13gU3wQAE3AHbJACpBgRDwAG1/gIATAJ+mIB1yBBaiMJahB3AhEI2xAGAxECtyACwCANFbAABIkJdqQTBeAFn6BvxsILHOARhUAOp6MC73BUHDEAj+AI0KIF77An4pgJAoAAbfALiHBLFvEIw+ALTvQANTABf5MFl7B+BdEEsTCJ1UEP9v+yCK8ADYGYMIbnEg+QCbVQEFYQBPhYEQOwDv83ENJwBB3hANLwAwRhAZ7wCEjhBOWwGCbQDQFAfRbBAcggB9fAJC35NzCwBzBUEMDQDbfHAAagBs3wBefABbqQDmqAAEwQDH2wiTKxALPAYQTBCKwQhRVhAKvQZQQRBJfDESzgCwH3POtwYkdRCaygb53QCvRYERxQCwLwCmWwAJjgkmoDAa5QPAcxAthQYBAgBTgwCOA0EJRwC4aQCVnwCHtAmC0xAMZADCwIAC5ADOK1EQNACxEyEAaACLrQEQygmATBAo6QTUbxBHAQTXOwARfBAWYAAGDQDYPgCainNgcQDA7/ZRAegAmrBwDIgA0QcAvo0DwCEAqiwAJsUAE0cA5XyBIk0A3SwAcEYAi8AAtpqRFuQA/NCABNUA82pxGmQA++JxCk0AzTmRQPwIEZ4TMCIQrX0Ao1yDOaYJEH8QHYMAmPoA3bsCczAARcJAB3EHC24Ag9aRMw4Amp4AuoMAlK8BEHYAnV4ARE4ArfcAIfwQBW0A5cEA1ioA7BiRQ8kKQXcQSrhwDSEAAeqTamAAo8BwdGAAWcAHsqIHkCMQCCgAMUoAQCwAbrkIA1wQB4cAUycH0F8T0XgQCDwA2fwAi5gJsX0QCS4A3S8AojcJ9AcQU7oxE8IJoo+AW+8TdjEAMP/0gRbhAOYJBH4VgTCPCBA6BfBfEASWAMozAKoJAE3UYRApB1ICEADLkUEwCk42YDtfCGvqUGbcABMGgTKqALEAABo4CmfPALAdCrvmoNvjME9pcQIoAaLOADw6oRLhAIuzYGiwgUqepwVvB9F2FMN/ECWwACLWAGvSkBmBAAd+CpotAFuxAA0NAEC+iqCMEGHLYCbUBYHkEGm+AAL2AFgAqtqgptPhAOtxcVZzkEIOAMvSkK72iaApEEZeAP/9AMwwARSsAwhsAB8wUSccBwfnAEeCoU0QptkKADsEcVWGAJLfAEixB9AuAN/NBRBBEINTAPvSqVD/GwKLgJE/sRY/8wChbABpzJFBvLZAlADWLQP1WxAfPxADwQjgVwDqyQg5C1BsQgD/PQdg7hB/6iAq4gtB4hA3WgAGDwKDybr+8VAjGwBxRaFA0AAhBwlJqBAArQGARBAISJB+AQAKzoEA4gNQ3gB5NqFz3bWxQABZqQsT2xBL+wC0DQAbOKEErgDDoABTpgBHz5prbACOSQD1NgnQ4hAA0QARHAaQqxAzBgkw4hAcfGBCMArwiBBpJwAj0QuTXRt1BFB7NgCkmRBemwCG6gCLuQCkuFEE2gDl1QB5dADtrgucghCsA7Bm5QA7yApgrxAd4gDKfwCVOAtQYhAVIQCpTgCF1gvAmBC+D/sAuZQAl3MGUIcQXv4AmlgAnHQHU2AbvdlAvcUItHIQJ3MAUD4QCYoAOnqpbF0G0ZoA7uOxCJ0AukMBBgcA1gqxCV0Ao9MAGKEArr0L/5Kww1YAtzEAVnUAakihBGMA1oAAE2AAVUMHoFsQL00AURMAAuoA3H0Jvvu8BJNABh0AFlUATHwQTgkRQfoAy2MhC3YA4uwAAfUMRFTAZMcguUMEugoAwmwAA+YMQZYAgEcAt3gKaP4Ak/ORCiUAwDMQH0YGYHYQrN8LFx0AvMUgACsMZszMYF0By6EARZFg3jgB1wu8ZvTAB74AskhQLLcEF33MZs/KwgAb85RADnIA6z/xADlFADMnCvOpEAEDAECqAIxwCvPGAOcBACP9DJnbwJHUUE9oAOjPAJ8FAHBPAEX/AInXwEeWAARoAOvTYIrQAJIzABuJzLudwIvlcEzHABFWABXZAKCiACRHAFE0AEeVA8s1AG4CMM0oAMUMCA1EzNbaADMlUINRAFIzAIVGAHZWoGZjAF9TIHAsALMUAQCyAMzgAAuDBP1cyAdkALAwwRCpBrE2HIMRQJ4iBuFaADsOC8QoEFzKAMo0AGy/CxAKAIZ5CDgiwAzdEJ11AH0dAJOzwAgtwcM4AJoQoAlSAOj+AEXzDSJD3SnLAJFZUN/1AM6PAH5nBUJqA/X0AIo/8gSiJaEDqQAoaABVjwAi/Q0z7N01UgRZXwDZPwDLtwBOjBAkiABD+NBBFgAMXwBZAVBG2jATLw01r9AjAAAx3QBBTBTLtACcOQB4JbEPoMKAqAQ4RsEA5QDP4yEBqACshYFCVwAxkABiBADIWAHNwwDFV0EHowDSfHEEhAD4aKAZjwkA2hBrEwAUxAPArxC3YQRCnglA3BBesgkwhBAFPQsAMRAd3wmAhRB1ILERVwCmcgCmvwCOlwwBCR1nByStYLETjQDPw4EBeACcSIFAMgCt8gBCpQBR1gDyWYEJJABZPDEAaADOMACWgQCMKwDDW7EKKwCw5hCuNQYDdAD+L/whBGMAzJWhB48A09iQBegA3LnRBCcNoPcQu9QFhN0AoR6hCynR8JMAQvsASCwARrsARY8AT0YQBA0A3UMRFIoAyyOBAmEAteqRQGUAdUEArHsAo4kxBrMAUwrBAP8Aip8AdUkAkN2hCk4AiBzeGZcAaQ8AJ6AA860KgJYQTSoK5vSg31EAQc8AntMKXs7d7U8wySKRAMEAoyrBD3HR47oAhH4AnYAA7fkA/scA/fkA7bAAg6UAnaEADPDREHMAYo8ATmUNcAIATEYLBL0QJV8AICbRAMgAFt/VBpoAQdzRByEAMUjBAXwAGUgAiAYARzrhBKEAcwjhADEAddUAtc/6B7PS4RCxCAmiENQd4QR64bBkAHdtAK/CAP8qAOxyANs8AKQSANjkAP/iAP+xAP8hAA8RAMZhUmugMBokMAHwAFruACA/AD2IAEC8AAbuAOsH0UA5C2DeEBNpB1fDBQIqFAECEAEJAIIfDmMnLWUiJNDtHeD0EAGPAABcALyTkQBUAJhDAAkDzppDEAL2BVAWAP5SALeLABC2AAxCUABrAAIvACTJA5vhoAvvACUWIMmXBQCLAOwFQCoKAK3FMBrnAN1pAC6cABFnAD/RoUEVAI1XDhZ+IgA9AAJEAHpHAMTqBtQkISAwADvSsSsmAyH2HtDGEBfgAKQeA353AHgf/tA+3wBhGQDKDKEOQuGhZQCIcQAMtACHOYEDswDAGgD9AwDstADpZwHDngCwdlAJTQ2wUhA5pwCZfCBAEwC3fOEwmQBZQQAN/ApA2QBScQA6VwDPEQAPWg6ADwBWIOEgnABekoEmZARhyh8gmRCI2ADK9ACDUDNHdwRHzAA6mgAzBmDHYwChOw3gex85CBArx6CDGAuglRS7RAA4MwAjJgAiEgAteoCbxAENMQigxRAGTQDgEgCkJxAW3gsikQBllnACNQDPkeAJYweYQQ9x+RALJweSQhBebbEaTg4wJRARlgBIuwCbaA7Aoo6pRABZZwOiIQCcHQBtQw4mhd5Lr/gQbfWgOCp000norgYAUnZQX28KIJYQFm8Ap1IA7fkHQ+sQGxIA6SQOMP4AT40KvfABBjAAwkCKCLqYIJFS5kqDCBpmQNJU5cWOYKRYwLhfRQCAeUmSlF2BRgyOCNHCULD6QhZWVPlgcJJ5zIWNPmTZw5dU7UgCnAOg07GdZpx+ERIQ6tcFF88CnAiEoBiKkQWjUnASwyJsLwFcDrtAULZfCxSvFhk7IUSWlJq3AjwQaCjug4FyhE2R2RvECRBIHgzLaBBQ+uySJFgEwbBmvaxaCAAAPTSGHsEUAMg0UBPJEg3NaBAZtMegV41cYfF4YHGhzoXHADhtYFEYAmTErR/4FEpMI5IwKBdeAKVWj8esQmwQiasZUvr6omAKwdhE+s+m0AkRCMJqrVM1GiKzcPzHE6MHYsS0YGQvjxs6RAST0yDk0Jm/Sr0W/CAjbYUBxbBbBCIBlisEqc4aIUWcAYQLkIBqElBg76EG9CCinagYYbOrsEkAQGQgCWQjBaoIwA9AAgkTsCoKWCCicS4INhAtgHFIyGsCIAaGYQAAALgjEkIQT2qIeQKGKo5xHaBBMBGV+KoSSHmAjroZpiZqECEyQEu8QfW0ii0A18NGlxTDKVk0GRHQEQIIosMWpEnhQaAGCFMwKwg8UyC5Jgj34CQCQSOSeig5kArhGkIAgsSP+IDHuYICiadHwYzAFvqIBkDlzqmYKAwd4QhwbWNhAGENjaqoMdZBwoaIAlOCurgThUJeiBI3LM89bOENgAP1wX2uGdALQCoApzAiij1FuHICYfGvyaCAFcWgkgBRwmMkAKaTgd6IBPjhgsmV5MIIiHetgKDIFagCiIgm0QamuQGK5JQQKCBNDBXKskECOogTAIBxxOKul14LKImOQOXipRgOCECOhjCxcIkiGWALwBodc38MAIBR34CSAGZBtS4BlnEjKDmwIU8CCssoIQIyFPuhCsBF7OKaiBTzgIjBQeeAhgEhQGKgCKOdIKwZnoAAjBmgBM+SA5hqO2SQ17kLn/oYk7fglU6tkSgiHFVX6sUAFtaxKAiDqrccPLiRYoRYeCBAjCEkEQoUKUsgx4MqEgzEAADkNC3gkDT2goiIEUfoijFmcCsaqPTgBwJQBKqhVADDqMliI6EA7TIQFBoJZ6dIn8aIXGgWxIpQ7SGUoEiAC2yWBCBXpYZYkFM9KggwD44Ubcmop4B3gA4LimBwmyYAKNtE6pJSEguFgDnl4UKesAM54paIdlevigDCg+sOotEf4I4I4VAKgl87JC2EIEEnYplCzAWrdfoVFW2RqATT65XyEJZCYfoNhfZ7DAiADIoxJlk8gDOlEsZeCCVxjZADPKIQMUJAEI07iLYIrQ/46IDWQMrbiBA5CAhQukJQP20ANrLmAFVLQgMG8BwBj+EQByBMIVSUjLnsIgP3w0YiD1+9//pkGIhHxhGkVMyAFy0KdSEG8wJXCCOwLQjWSEhyJvCIJXSuEHnYABHcvwRCysQZbBRKAcfyBCGiChjDKkKTAOq0cQvOCJdyxBMDQEwAm80gxKiM0qB3hFNbwChd8QkYmt84XNCDIAbyzCfgcAw8UUwgSKoSIKcgyMCJrBj2DYACNoOAI9AkAFRXRoJw24QS60wDLCgEAMmPDFH34gK8KMoQsd0ATzBNOHbBCkAocJgDuqwAAHJFOZy2RmM5WpgAqswivkeMJfRLfI0f/FQH8ECYM49LgQEmiggC1yQzO8tRAT6EBGjKDKYOKQAQYyhARf2EYA7sEFSxaxADbwQwiVE8+28BEAbKhnPABRDl4AQaELZWhDHarQTwBBHAFgRx4KokhsSg0Ef9AGDC5AhHG0IZ4JgEQKfLELXowiaGQKBDSsAMuEJKAHzQiAPbhAL6HAFCMDAAENDMmPMqgAoEKRQRnk0JkHqDKjbuFIQXChD69EVapTpWpVpSoFBmJ0qQzjwyu6cQdldCFKBFFAGXwBCRdIIBB2YAb7WoSARExQIbuDRgDOYIx82iQBTHiG4zDSADY8AhwBOIQ2bpC7wDghALUYalUSYId1UGD/qwkRKAASMAt/lCEYm+BAZz37WdCGtrN7QAY9UOEsa062dWDAg6v6FYIB7CEFgisEIPxJOh+cIh8BMMcJVMA2iuBgCl4J0URA4AZW9Ckd4RBIZ1ygixcQxgWwqEcVVEsQUrirIIYARDutIoBh2EIhbhDTdUfHgBZ4SQCcOIEf/sCvghTgFT/g5OgKIAhh4KOmYiCCDCVigTooIwDvmAFOF7IBMnSBCl4hBjKKploVqMK8A+GCGhbSAR6WRQReyOtAGvGFCUsNCXsYEAAw4IsZgMJbLziHdQniBmsYuEI4QEYYMtKAMHQgHV6pQS2ioIRxAkACo3EGHBZSghdAwhKw/9AvPoYhCTCEWMo9cFRCCsAKv1plA1aAL0GWMAgpMwwEHUgJAFqACSIQAm98aAMguHELelXhGdUaUzICEIQgMwQBOChCObyCj3H4og2V4AEcLvCbD7hhIAN4wBCQcIUc0AITrYCqZvogAy2GecIKGCcB9CBFoTggGyJQyALGqulbFWAU5moBLASRgxwMhAE2UMMnOAGAGzxDlGNKxCjI0FiJKMAQdXjGaOQRj3uIoxXdKEYmXqGDIHwCEMSwxyHiIY8A6OMd4VADHE7dogKUALGozhVwq3IAc5ObYbKwnomncYsMrEOpADgAbPqgg4VNdgAbeMMgFvyNZqgDGvcg+P89/vENe7wDEbN4hCmSIG5cDWAGlMiwUEDgB7miugA+cMIeiuBfCJABP2ko80QSkIUfBCMbKQQABeKQJgHEQbLqHlMPCtGhAtRiFiwoB+oKAoNQHMq8Q9DERLsAASXggQwjyIIcfCADNJDAAcAm0wBmsY9bVIUBOmBHfGgOAAT8oBfCgMIxHAEDAIwAGwZmhMwm0gBn9GIWVljGLiImCkDkWwGYYN3XKxSHLmhREPCAARZQIYQOHiAD03hEurH5gB50IwC9+AJqscmHCeBpJw8wAzE09vVGHEKIAIiANHhRgTAQIwIEKcUeJjKASrgjDgNxASaCQABJAIJlCfjDDPz/XiETSAGnCvjEKQCghRSUwxIc+MUqhJBxbJLAkIxIw+8xUgI01FfTDciEFQrih3H4QAup2AAB0M2KUUyEBYAAMUE+UA0cmAIRHjgAAR7Ad+tPyAGWKPkLWvED0hMEUiiETjCygSEBkcuJAoiGHtC8/HtAXzkGMCMIB6ACPZCBf5iGYfiEFFAHJ5gIE9iGoyIIF4iFXHADceCFT9jAfkALCFwOIxiBi6oHSyiBgaC6FnmATDiE6MIIHHzB1IgABFA3FAgFYCgID6CCW5iDcUgGQZiAXGAGJJIICniHNSgIDUiFNcgDc1AEIhCEK3iHIgDC2AiBKdiXsYqDbkiFb2KY/wHYggC4tdfTAktoE3IbABeAgyTBiSf4AjHQBRtEtQY4hVcoCBmABy14g1hgAYLQAbdrCA+ImYJYA2IAg2xYBQYYiARYhb4jQ8GggCZYhFGgATvoAiLgA9DwgByQQakhg36ogXxjiA3QhEMIACf4wa0SgS0ABsfDiAJwgi4IgQ4IEQPYgHkzr0hwh2R4AAGgAE+YBAtQhWroDwAIAp2ZCDVQByZYgALwgxooBQAQBUfItwY4hsnwxLZYgT7QLHMRAVvgADNwgjWgRoIwAB/ohDGIxTHxgGOIhxFUCAUgAkoIAHGQAl8iNxbwA+2riQPQgtWbAjFRAGOQMfMiAJ86Bf8zqAFAYB45QIUOAoBFkEOJWIAjaAZGsANyKAcZKgJPIMdiWAp0tAoZGIUy0AQsWAglyIZgmAIn8AHaCIFZaIZywAR0sMMx+YEA8AKGuAABy4TZi8mMMIEt8IINkAFj4IYZwINxM6834IIuaIIOuoA3wA8/SAQfDAMjiIFGkJUnkIE0KYA0qCao1Ik3sARuQ6OGcAAYaIIyABkCOIVj0AIIMAS6AzUKQQJ5IIcSSwgBUANQyDS/g4Bo6ASWE6YoiALXWggkqIUJkJM3OAFv0IQx2Mq5LE3lWIAMaANGiIKPxIgLMAEDyAN4sMMH2IVHBDdm+AcJU5OEIM2vk4N0iIf/IyyISNgHcZgdhmgAKLAGW9ADJBAAF/iC7DNN6lSOC3CDRdABIlAUndCGQiwITuCFPAkDSAjELCg5IJSDbwgAaUAsAigFwkJOlSADUCiCOrAuBlgBB6xO/kyLAVCFX7ACHlhIm0AEwykIV0gBgkECScBFcsuCVsCEdkgf2jOHO+iF8wAAAkCCJsgFBQiBlepPEY2NHZiGSEgLIHA9YSIHWRiCNACB/RyTDSDQ38sCd4gBcjACghiEbTACcTgPBDCCQxCHerCDTGCFEU1SwhgAYNiEtiiCXgCjgTgCYrABMXCHGkAHWsiBxVTSweABdiiCRaAEOSmAX/CGRvAHGewE/3nYAjhIA2EIAP/xUjq1CgN4heYqiwWAgncYhSJ4BmgYgQRABmzYrQBQBwodCAmQhSbAAwrAgCGsU5zggX4oAkH4hqKxgXaIhgkIgPiQhlj4DRWoBwWVVFPFiSqYhTzTiQTIg1KQBisomgFQgAiggKtpAlyqIX/Qh3twh2v4wIIwgAPwzVMFAEo1BggAh0sAgEFohQ24ggD4gARABSQdCANYBXUpVm2liEuQkMEogPrLCBQ4h0XwBGX4hpKpl0oAhFqQhStAAu7UVjCtBAQIB0T4y3UAAEWYB2mNBUkiiHUQz20d2IVwgCBAu4EhgBJQgttKgC0wVK/4R7BTgkSQAP+dKoghsDxPBFNqAIAeGIcoQAUa6YR50CNP8IR6oYRJIFiWLQg5sINjlBoCSARBGAROoIVTOEgAMIF0aAVAKIJezINceMECIINHcC0wnQwNCIVeuAazZFMeAAAu8AfxAYBIYId8bdmWdQUXXKQCeAAG2oFPIIYA6IJ0awE90IFFGASK/DoG8LMJBIBcCADDEYDhEoYhHIQAcJQQCAV3eARLaAZ80B6tJVgUOIVduy4BKAEUeAF6JAgRkANX2IQwYMT8IwBbGAXioTFJAYAksIQMGZYtEJshsIRUYAY1oIR8VYA9LFxJ1QNkyMT8a4QJAEIC4KQBQAA5ilQNRQBOWYL/XBAAB2iAITgDDjABRCAFB3Xd0kQAMagyv3uAPgiDB1i9F0AIOjAF2bWAZLhJ1aqAaEACYq0JTWAHZN0BWjiEFbiCeMA35pXUKqCFLqM5CWCHVgAeUfAFAMiBP7DcFggFvFGtRpgW2R0cK6CHamgFbACzCpiApHlfOjUGTmhddZMAcugFM+gQNRBPIUCHfIuAYhhDCMuEGYA+myAAGbiCLOgwCKZTDBADoQuxAmAADHgCFXgDHugEshgCZgAGQOCIDQaASvgDNqAAG6ADRxhO1dLHFm5iivABVmhbbEKAMVCDOqABTuiCzooBTnACWWCeIUAFNigCKggBUxDPQYiH/1XgBV74g36IHARQgcpsHQqgA96tkDdohDt24pgUAFwoLtX6AFrQAyLgAS1g2A24gBKogATglCFYBjxAgGLgAkXwnzqoATpQARUYgztIBgPogjYQg4obHQigBHDowQrZgFDYB6/jY6gcABHI1aVygFHIBQIY34EYgljQozEIBR3IVyGAxoEIAV+IBjzoggVQg3MinQdgBFSgswpBgC9IAf9yZWtejkDwgkCciBaoBuQ0Aj/Z3/4diBY4BlwwgAoIhFmICPthAciskAGI2Wue58A4ACOIhozYAF4wlwj4BEYAAD2YhUCUgFkQLwCQg1KggVVtEQHAgW+jZ4gmNz8Qg/93bggD0IBYlICgYYEneEsXcIArkDA4mIRqvhUBuAVi6AMavZUKwOWIfumGIAAu0C7BkANhAIVa0AQThudbwIdbHJ0bAIQFgmmizohEsIJ4FQwCSAM1yIKLpZABMAC2qYAXkGWCyYYAOIWdLuoiIgAFQDcDUIAHoOCBUIACpkDLVQgBYMYW0YRgio3l7Qw2sARpeIY+WL37eYBcMEuuvi4FSAYO6II9OAFQoAFBwOt+0YR1KIU84N0s+AJOaIKLNYZMmLkJsdLMJLcxqAZuaAIhQAUgEJy+dmICgIEFY4dswIJHuIdPeIOBqIBSiAeviAcXJALh1IJ/0AVOYoJ88Af/VBYPapAEv7OAUPC+gXgCcwBAhliAN3ADN0DY0WZZMQiAVEiaIwgAZQCjJrCCD+iEdggAX0AAEUAFdgiaWDiE6hsIMICFAEgHKRWPIYCCxFW3DKgGywYAUgiFGAUAPKCPWdCGaRCDEM2TKsgDso5u0iEAEjkDOjMBdQiANlAAHygVLjgfBvAZbAgKdAiAKWQBQviCfFCH92YOXBjqr7uFWNgfVTCH+QUAJriDEzAEEZCAKuiAYtDZMSkBWLiHqEXwrlYnBh8ICxhIYjABxMLqWSgAP6pSADiMZxhCJ4iGMPAHEZ8QF6gF9FS3KMCGbbbabuhSAMABR4CEJtoDa3hq/6vAgWAIUUgghZg1ACdIgRb38dEhACCnswc4BcIySh3ABx8QgOtm8sPwhAXggRgw1nlwB0FaDkjIgT0mNzh4B4siCEbwhnFbLztYiAbYhaEdjCVoBzs8gnV4aDWRZzqX2Tsvaz2HBjbwMneYDAKAQyaXBvb0A0IICkGQB3fwriVdAA+QABmohVH+Og4ghla5kFZow4GIAG24iBYwBDTAARkHgHNQUcH4gFTgawB4BG9g4lPHJju3KzqrgEkIgFgIIQnIhGWlty8oFFGKkVcQAkQ4AlcoB3nABx3IbJwQAAaIgCdAAyQIBFUggmwQhT7ggh+AAmN4dHWrAFcwB15ABP9yIPOEgIBnKBoj2IVMSIFiIPMeMAPCwANsmAFVyAA5yAStwQgPcOlvb5FwD3IAIIHv9oIhTIATcEElkINICABsEKVyLwRgkCps24f0xokKMIUT0AQnIIQf+AFC4IJCMIYemAAeeDpUfEEZiIIrGHAM4AIwwIBTqN1EoAMZSAM6uJgccNLBSINeQIVPSKhvoIWzZogqmARSWOmWbxEooG40kgTeirL9VYZNCIYtIAdbIIFUgAayIAdoeIMIyAIeiINgsCdgWGiJ6IQ2WIMxSIMVAAMUkAAHYPiYVARWDAFiSAYB+IE2WAgGAILadadlYAIbMGIo0AbLB4BoCIBh6MX/vIfnJ5AmcWCCEDAGeuCF9BkAavCYqNKHH8mGeYgGHBAHLwCuAYYGwMeJFqiFovfSJJiFFCKAWch0FTiGSX+kH1iHuc+JDVAFuRwIbBekGOh2AQAF+QTIXMDx3ieTCjCGRQCIRYs26SIkiAEAAB42hbOyyA6jRxYADDDlJVifBgk3JgnSYcjGkCJHJrT1hSTKlCpXsmzp8uVKAeeEJIQ0zgQAIqhmkHDgwYalP0pgimQAp1MZcAFAhVwyrsrGLdIULEhxT4oLolq3cu3q9SvYsF0HDPBqIYLYkBekyEjr9m1aG6WGLgBiTaMWa0BoMdo1ZYdXIt8CzBvna01IJNzA/2ykxmEBgBKFxoETxQIu5syaN3PurDlXMM+iPRPQ4+UAABXtTmUFwIaInBYjn/gJgTIBCQMhx8DipkeJ7pAFFAjYuKBB2YRgygTAxEMkBDIjKIyubv069uwhFUjBo/271xKLVCWU4ejapSQkIOCRkiy5hC2AiiE6gTChhSpqgoR6EfLAEwR4tcY0+ugAQ0KNYLKKL90UEhx4EUo4IYUhhXEEhBVqOBITYqAFgAQ0AEKMOde8w4scCZUwCSpEpFGEMkck1IkvvQQQwD0+wFWCJO60AQAP9XCBhgm3pFPJhkkqueRbW4zB5JIGSBFFSCzgkEQVNjywkSTVwLGRIPZ8AP+ALgFUAwUROySQmQ0aLFAOFCFp0o0EUNp5J54kxWEJAnlqyEYQpsgxAg9hfHDoGBnkAsEA3OgQkgOUcAIAChlEUFxnaDSTQUgmvLOEn6GKqqEBR6Q4qoQ8lLMHF7o48eqruhgRAw4EoENISAyw8qN1SIyTREghbOMGqsUaa90NzmBwrHaCZJIGSwRYE+dGDEwTw3UuXGNLYspAyyy44aaFACG2JCeuaHKkMIdLlbwDwUZx1EOedQLYAYgCG7EyjUbo+vvvS1V0IBvAnMlhDbAuReAJFWugkUwzzqB23Q7H7HILJMK0413BHXu8kQAn6HHux25lYA1UMD0BRTewHKP/S77ZueDFJJ6U4V/JOf8Lhxk26OyWHN6kTFQBEJgQAcnYCWCBAwX8/HS4LdABdVhZWPPtsXEwQTXXXXe9RiZtgVvED16bfbbHI1gjNrhN0IA23HEzO4I2SKDbxCVy6703nnKcgrO4ePM9OOEVxhEO4IHnXTjjjV8XjCkAC+445ZVrBoksAvo7ueWds8RHGEnIEMcbBuAwxhyq+BBzQligACkPjdyQYdeJQLHl5ot7vjtKfNTSyzjTjCCABs6Iw0ouGpUgCC3VRN66NuoEkM4o/XotgBiG/Ms57903hU8AR/SJASvIbOB0BJ1oc2MPyn0hBx2fBPCP3WdrMsj2unu//78M4gTABQAqgIzMbSQBC/BBOgIAiYSgwGcAIEMA1IEFtN3AC/nbHwYBQIfBFIIBwaAGSeiglAWKxBjzIITTziYCK4ggdxncHx2gEQBkcAAaHBPJG0aoFi58wx9GsJ7XDtAFeinuhd7bYACwcSNmgGAkOVRgSEAghVbcCBiaM1sPSOFCI/IOibUgxI1+4QAc6lA4MghFANBRAbTN4Qj3Cdcg9MdFyyGxEAeYxY1+kKEnklAkRNBHMSZyNggcgTHiAoYR5ri7KvjvHAB4wh8CoA8qbSQNVIxGQhxgAsikBhqjwJTZGsAFYonLBENRpOUGEIZ4zBA1b7BHANyxBKcRgP8Hh1hKWWIQgFeAQAGiAIQh0RaFt/mLdmBJGirFBQcrtAIe02DCAbQgjV6AAxMvOMAHdNCLXngjEAgogo2K0YdRIChuLzjCGMMFAjfYYgKG8MMGQiKBKrDOOLnQnkg0EIYXgDKZ6OIDGeiQBh/MoQEw0AIdkrCETb4hDHOgwwe0sAACzKETReCBB/RGAi8M7VhVAIIR4qCGcnQjDgAggApAUQwmjqQQ8UjkRkBACG4UInH+vCm4BGAMUh6rAsW4w5oAEAl6gAoLQthGAFIBr5CsgR0BcMJGfECFZcRhYji9KrguIUZm8UEfVGhhQmLwnLMcIQBUiOdG+GAFeASAmG//GAc7tIDVuTJLBeIoBSeNlYh/zGMVS4AMC5aVEDCedSMieAQTytFWAFxAsTpgwRvpKtk8KWAYxAAMsxjAiBv5wxthsCoAdFlYAAiABrd4ACYWOwJ8zOMX3piEIow52dluSBb8EIS4NOCNedyIH3t4o2jRGgdcWQARAagDAM4RQTL8ER8ToC10k8QGaLjCXw9owjRuFABKhtas8SwBIyDhhwygIgC12EAwArCN1xmXG32KLnwjVAJKkEOw4PJDwiRwi3EEYBEbCS4A4GCPVrTCHvqYBztkQYoAKAMnpwhAMdIZ3wljxwn6GJO4IuGMkNQhANQCwA8CUIM6bcAOKRBG/zmgMQ9s5GIN00sEAIIQAEakkMI2Fs0S/nESdGXhG2QozgAqcQhiDcAAlgjAGTRAkQMk4AAUIEcAjEAACERyDgPgRTwweeMtcyYCqGBGRtFFhnoUYxBJaAQzclAWEEQDFuDYxiVccC4SoMMeM0hIIMxhCR6QQ49c/jNmjJyPqfnLBTLQDzCKQGgAgOADeEBCGpZAgXMhwBCBIMFGSEAERSShn4D+NFjcEIA+AMAQI8CDFsLAAx7kYgQwAK0KqgAhD6whCmR4b0Kq0IMo4BPUvpbbB34wkRVYIR3gsEYybrEHeHgC0x5QxSaIAYX72GAaOvgAIsqAFgPgAhFOJUYufv8tbrQNAJQuDsAJEHAABzQBEHwAkhFuaQfUMIA5egDAJgJQtiv0wQ9MsFEQgDjugXftBjdCkgH4gAFZfEkBEvCEh1GDBnoEoBEAKEJSNYCCdFohADoQOMFD/rMP3IgpcMCWCHBnAXREHAA32EcAImeKCIZhI1ROBxtErnOokTwAo9DCKcwgEgdMouU4cEcAQNiIABxiawCYAxDUmwFk7rzq//oAb7lRVqFDquhQQA0CphAAWGDBCBEEFQCW8AyYgwMHVn97wXreBwxwgVcbIXrLAbCBGHjCFVQIwB3ACoAFDGIwt4A74tHVcyRBQBYAcIASEOKAqH99IwS4QBWUUoj/kYghAPdOPOiPdQPeIjcyAEiGEdb0APlNgXZg1AYDCEABHGCKC+ywaehzjycCMOFGTlhAAiJwhXrcewAgcEQAtCHhEORAHTpoIQqWsY8ZYMAF1ujCFXWvfTshQQfVqIY0mpAMV2zjDBNkAxfO0IxQACMEDMjAEazRiOBIoBTQwAcUvoCLyG6//0oyxAcgARJowaEsQRwowZoowRikwQvMwRJIQAXIgRbQjgWoQhQ0wpf4nwZuIAd2oAd+IAiGoAiOIAmWoAmeIAr+mgREww2loAtqiBy4QyZ42gvW4HeMQD+gAw3aIA9aRwYcQgrsYA8OYWf8YBASIRKOhhEKYRI2/2FaLKETRiFmQKEUVqFYUKEVZmFXYKEWdiFMcKEXhuFKgKEYluFIkKEZpiEAoKEaliEbtmEYviEcdqEczmEW1qEdViEe5mEU7iEfNqEf/iESBqIgDiEhFiIPHiIi1qAiLqILNqIjoiAkRqIJTiIlgiAoUeEAZN8l1qAFTEA8hcE/DENCxEEaMGEnmiACBEUgLIE4nIIE7EEqoF0q8iAe6EM6rAI7bAMzBIA3gFYt5swAOEAioAELcGLcNMCDBYA83Mg+XEEwPo0I5MAk7AIQ7MIeONDeNAJvyQNvhUIJRCO6kMAKJIIxucAweEMGSEAEzAEUAMIE7Q0E/B1vzYMmiP9juBwANfwBIDgCK+DERlRAEJhBUG1EDqzCBfANFxBGALQDjOEjs3xBL1QCHuQCJWBCEyVEHvACWoUEAZyC4+3NC1CRhyEjRIbKCyhDNmzEBpyBLgiIAGzCSRDAAdTkAThNHngDKnJNAbxCAPTDqZxksQhBDdjGRhACOmRUA0zB4fVAMaTAMKwCFxgAFkiDIKkIJPwAKbhd11zBPmBCQQrlqMTALqzRRqiBI9jGKpKaC8SBFrxBHLhdGKyDVa1AKFBBGUhDO4gC1ZXMBtzBPYplsZDCMSTkUU5COhlDEPBfQiCDjCREBVDCOoQjADQBUXVNNlCHYKLKC4zDSiZECFz/wzloDggggjGMxBiQgwpsBBMog5JtxCkwgklu5q8RgBPQgxDMgRtgAizUyUaoAjnkgGE2QA+gAv5sxDkAQgkxg4TRJsEdQCWswh/AghmgwAb4QUjggTXwgh1MQTmkwAiIhBNQgkjgAiDYl3OG3AXwwRP0yQ68Qs2tQBF4QAVUgSn0gAyAQQ7EowEQABG0Q2tQBCPMwmymJ8ENAAz8Ah4YwjIAQhSgAQiowC04wh0YggDIwBc8wQP8wStggAA0QB70QrgZKOKxgTZ8wAVYwjLcgSPEQirowgOggCacAi5oRCCggicEAys0AzHRJgE8ACghAHIIaXIMQAMA45/JgDCQ/wGIfMAEBIIADIAiMEIMvGZCuMAJmMEm1Fx6hsAU9KgqxIAAuAEhcFIFfIHT+RoSCANi/KYVuIJckWhK2EA9BIBJAUAddIMB6EINmGUEhIIjiRsSWEN4qkAt2MEI1JOcjkTF+IIvLIsaTEMBFAIQvJcDoENIihsMLIIzlIIpoOeikoQGUMEITIIuAAAw+IIBzIA52MII1Bo5nObA/QAjGGWoqoQGxMJ4mQMYNMIqGEARsMM0fAI6+II64I8LRAId1NifKQE3YNqtroQGpAIdGEB3JsMkGIAsPCqTbcAuSAIE0EIMlEIn9GV8HQAUtE+0rsQOxIJcaQAl/MEwCEAheP/CfZQAOhRBFtxZGAyDbE0YEZSBWa5rSlAAPOgIAERBAPwBAXBBKPgpINCAAhCAC4iBJhRodEFAKXApwaaEBFgCV5JLMAzABPyAmXICbqkCLRQB7nBZHXQBrnUsSRAAAwQpQiDAAhTpAhgAGfzCGyxAzNoYHITDCsgsSzjADVxlSlTCJ3BAG9yCudLWADwCqRntSiSCHWCWSsRoIiTCUt3YHMyC4Flt77RBgOpcAyxCm5JtSphAB5ytyHWCMzAr246E28ItwUlAEKxm3bbt2+7cAOiCEERt3d7tzmkBFIwtSxzAG0CCLXDlADwBtAJAAiSCooqj4ercKDQBTLCAGJj/AxAggjngAgEMgBV0wUaAwTRgDURmrshlwQ8wJkoYwBZgwwdUwAVUgjoQyzNMwUbgADEEglhqgCsQjMgZwCbw1EqswDgorxVMggcwAjJsBAqgwht0IQPcAjQmBA4kQ8t2hR+sA0DqnApAAWWuhCJ0g5UCQCekAgiYwRlsghS4wiw0Q8JkoQg4Qj6IjSKgAkh0RQFkwCusgx3EAcaCmiyIQkskQyicbSTEwsrcwQnoAhd0gLd0oQSsAjx4w5pEwzF8LVEIgAq4AiP4gAFkgTeMgg0Q7p+1wCJoY0r4wDiwrhMcQwiwggUlxA5YbxdugC/owR/cWTQ4wuTCxA4UwjPs/99JAQADUAM3SEIRj5spTMpKOIAvCEM6KUE1nAMCBMGGcW8qXK8WSsAffAATvAsPHEMUs4QH6EE4xEBrFMAadIJy7IEdNEJeiRsLmAG7pAQEKAAbLIMn5MAjbMMphGMmfJgKKEMLViEZM8EAeDEZIAKmHfBGjMAiSEGcJsQAaAEj1EL9LIEzdMANgCYPfIgAKAHf3lgWbMHAikQc2IFs8IERhMMrSMIYDQAZ3BAGNEJHWqEEYAIRAAAM7AIr8IIEGAAo6MIcXO5GoIEzvIIgOLMEDMIv0MBlOEAUWIKSjQE0bEKfJIAYdACXPQAHpGlIzIE61tgDyK4ZSkAoREJCDP/CPKACCwwADkiCFIhBIdABA5yLBwjBKaiB4o4EBThBOMgzY0GGKvQDNNTcAdCCf3FZHJyXSPhAJpTyIorAJ7TpA1hDDQjWjyrBLXRAGfQBFmDAGmjDD7xOSwiAwJhBBgJALqQAFHwCCxSAHYjBnxnAKNDxRqidRhcibhQAClwlC9gA3VIEGNRBB3wCLbCuS0hpNKTQBJRDtTnSTgMaDugAwWRACgx1IUrC5hEFAbxCOX2FGzDDBcyBMoCBFHwYl8kCTazBMAjvIuJBJjAGEoDqSoyCEiAAGQTTVrgBIgDGFMzCFHzxn0WAM1SCgjqiBPwCk2rBK/zyShDAEcCAOaP/s1YYNmBIACy4wyOAmh60QjwuIgeQGggktCVbnhfAgAI8QhZ4xQQwgwNdQQDk8J8hgHzgHh8OghkYwADEgJTBBAHEtgL8QHh2xRD4wH3wLHBTmCkEgxaIAcjZYRp4w7tFAysUdGYrN3ODxQEgh6+FQBDAAAJ8gSQUIgu8gjyzwTqk9Uskt2yP91f4QBPk8Z/pQg4UhxKwwvrO4XLTQAEsgBccp1mLd3N7RRR0wfdyGRvQgmYKQB9cQtC2oQJYwb0hABxkeEvY93I3eFdcgRNkN4UxwChA7Ua4QCmwjR2ywS+k9laIOH57hYmj+IR9gB0Y5kb0gBQ4sxoqQin4uFbY/ziJc0WOA1oJiEFQGkcZ4NYfxsCpcgWSg8WS/1kUHAHV3YA3gPAcsgA3jOiRKzchJPlWZPmWSUA4rPJIDAIaJISQlyEWDMP4IndsP4AXKK+Sn/if9UFZp8QA8AA3XLFCZ0AeBEcJFEHRduEgLEKEh7gXsMECSMImmzUZPAEAqLmNrUApnC9KqEErbMIEGEEzKPARLGZCaAAqfKYWMsARXAILj8QRFC0DgDhLqEAHIINtTAAnRDp8FcARbG9KJMI11AGQNYEnGAAHsEJyQIAjqGsX2sA5GO9KFIAHyCcgaAKov8QQFMIsRILTSEAH0ACSwlckQPhKZAMxXGUCAEYXoP8DEqiACsgBKlicGBbAEFyGnJ9PSEBAEhiDM0ABKcTBD7wCE+j4SIRAIzBCDiyLBVzBLHwBeMPX5rKELiACSdjeHyBCg0BDbZcAHfxvFmLAMJSDWWbBOtiGCPgANXTAFBTCDQzsCLyCK0g1ShAANdRCPM6BFEyBWN8YFoiBb6ZEH1DBuRyAHzBADAABHojOBMQCE5CAJWxBG9C4FErAMQQATQAAJJwBBBgAKdhBJfiA0m6EBUhCEDiBpqsEAYBBn2iAEdACJIQll53DnakEGbQDVwKAKsCCBQQDLWxECGACE8jBJUQAF2yC2dy6ZzDAv47Kw9ECOQyFLTgCBAgAGID/OUmAgS5wQyccMAIMQjjMgNZ+WgSwwimhRFVQgg0QAAx0gzMMwBHAXkLYQCz0AFVcgTDw+c+kASOsAiK0wem/xQ2cAiKsgiu0/bFIACCEgStIg1ARMUwYQBKIwSu4HQsEw+HhWebYQA5UwWtPmC1sAsbawDOkAiWkwhRsySVsQVC1QCa4gdNkAS3Iwk4CTBj0QhkAxIhIu+5QAHAQYUKFCxkizEVv0Ygoq5i1aHgRY0aNGy9K+MMDRKorY0KR4Jiwgq04AHY0g4bkIC5YCgQYOHkTZ06dO3n2xMjA0oiMB+YQWTHgoAgISAEgIKGgEw8AcriV8HkVK84Gq8wgfLDK/wqBrAgv/KmFMIJZpmPZcpSAaQIASehE7TLJc8edVMISAFCz6kFbwYMJF16IR4cHrERm3YKix3Bknh/GwUho6s7dsWSawUkoKhQEyZE9RgJgwQw8RCJ6ajh2hUolv4BH17Z9m2EBI8ayagGlSgBu4QyjnNmQkM41y2whLcOQkMwZNsPZQjDX6KAKdu4u9NwRy1CjMxCiUFJAHX36sXBoJVL//qqgZiYSCkJlkG2ubSgSKrpDHz6eFAAGB4QmoKaB1lJJowBvHjFlmvMCnJDChgaoxAkEKtwwoydQkQ2hMso5oC0KlikCoQN+eaYADtXTIBUtAJDBl0ykSdDFHOEbwv8OPHT88aAZemkiBAi4SEeqtgigARxIREAhhmp8AJKjByAJISsNlFkJAFACYGYBKsXE7QopAhtzQwH6iMWXP6iwhbAEnLhmlT9gEQpNjETQwT2sQHgGi4MU+GWWvvI8lLADxIgLUQovCCMJHAuTYAkkGGi0oQhqwe8qAiyw6aADHFgL01J9QoKV7kxNr4UKAHDAKsIEAOE8Ec5c9aAIOuAU114npAFEX3GjQagi4CSMgULCAMCIG4TVlVdhpaWOhiamvS0GIgDoI5nCGuBkDQC8IOPZXa89F7ckLJEUXcO+yAWASiApjAFdhOJgiXKjbZffthJwRpV+IwvGNFmsRfb/HDkAGGUMfQV+mLlgLs3TARQMfa8RGQAYwVlZwYgAABxA9hVaiE32SQIzND40GURWfpgABDyIoIIWNcIgjRcudrHkk33GaQBQaLA5Txr4yRerAmypZRFNJMBJgEhocEKXGVzIaAMawmGEGlc5usAMWHaZZpdOMmriGEdqmARpns39Ge6N0FikQESFgKZjnxowAxtnfoDFETQAYIMM1jJagApMLGkDEEwAZAiMP/7ggpMzPnl6IxuwOeKNMTh5p+GGeqBHFhwM6aAdOnLsOe7WGVpAF1EwnQGaN7DCpZokDBDAA2tSeGAGWgLNiIE7ejDAgAuo0KUhA2bxZSkCTLjD/4vgNKKAinABaACRLhoK4Y5zEEJglkzE4pB119U/SAtaWECTgQtYYKGEc6DJwoP5WSAxpwaYcSIhb9hGGgCwOwloYAcoUOACNeCCAxzgGNgBQAVqQAgCHFCBOwDB4NqRhYQUIRa5WMMEmFDCCZCQCSdcgwF2UANRgMAFglBGFAYQiDyUsBGBKIAW4PE4AOSBHCBggRuIkEIjpjAPVbAebtK3Pte9YA5oIgAuuhGKUABiHPxYBiJCcQxmLCsnO9gGng5SgmNABgAHUIMzNsEBN77REjF4AgBCkQkh0GAdqFCCAfRQiz1s4ggnAAAPiKGChGgBFcHQBA1y0EgaMDIHj/8UggVAcIdrBEEafVtAATrxhUYSwhQJEMQZsISQQKBCBTuYWiRZmQNNWGEWhstJBLIRgy9kYIkcaaITT4aDIsjCFmGSYg/KMYxhCCMV+qDEKYaRAmHIKCdPUIb2DsKCGnQLAAQAARhM0E1vmgAMFFiAAULhiWCIYRMvAMAAhoAGE/AhEfxRhTIMiZAwxIIPG9kBFfYwhgwo8SJaaIXgEBINc1jkIjaQwhxzogFeUMEMrFDGEXamkV3y8mGmaIYnWNGNYngGTQZQwALG2Ydv+EAAC2AAA3J5EgQAgQMJGQM8/HCSBRwjGhvhAzGweRBChGJkGaFADZKUEQfUIKYHQcD/MH5BqoWsQAoIvQkCgkAJgxBADuJA0UkuilF+BaIdTquADYDAi1sdagbfsN1VFFEPbQFAA39gBNE0soA7mE0jAhjFOLgkiHoYw6kN4cM7osARN9DjCDLwwS/OYIiMQFWqJ5FBK6KIkE14oqIY6apXzyUAM6AjIX6ohmkadbe89UQAXBiHN1hxjRSIxqbMUARHFNCBZjyjHOMgBP80IgEOVFYjA+BBOWpwjFIsByOQzYkpzOG1g2QhFjvg6ts4KzALFKMPCfHAKoyAKRr4I3RYgQE1uMCDzGaEAHxQDEcGUAVcFGEFUAssRgwgggic77FRneoATHEG5wIgC6mQri6p/1tdfm2XNwipwC5igClIeGI6ATIABPBbGBAEQphtUe5GXGALXDyADb14GQCCUYwEoKGeGdmsgYVVgF8wIiFDOMMtcKIEHsDkIALAAG8X4IGWEqYBIdBQgFAwiokZZgxSeI5gNnwRAgTiBGLwQiQYYIAgMGPAqhAHZGzxCycEQsUFZjG68qCODByEAB1Yhiw1EgIxpAIQ5AhCPp/wiry5wQ5shhgFoCAhw9xgD7HSsH4b4oJstEEMoqiCn58wjW6YIRztcAWJFvCCSuigDbYQtEJWPOZeIeAR4LACFyaxjYBxJAFBcMQNKFCFcviiAiYgxhUQYgxUbNBnGpACuwgTiP9gbHosTUbIAsIQgzIYwQeaSYgIOtEFI4xhyAgBgSBcwYhCgGEhnfY0rhDAA1fYgQsE5YggehFhAAzhGsDYABUEgZBBAGIIPzOBGPxcmEB0AdhZafICdiCKV3RAERbLiAAqrJAGKKEQvzhCHG6l7W0LSwGBKPhF9gCEhAzADHa4QCgWkYwimOIUlDiOz0QQDboCWdlsgcERWCAAFGQhGIxwAgxO7hMWKGIRVuiECQ7QACn48OH8CgErprSRNoTj4l8IAgkAgQptWCMI2PBFKYOekwusQAVHHosKOpAFY5jhCNGwgGF8EIwy0IAMYq46uiZQCj03hBPMUEg42hACR7j/AQDB0QMz4n2yIcgCCmbQQ73bkgxMAAIWKQBuVmzgiFNEgQ3zHQwaIBGOUIx87fxqQBfIyJAGkIEFMkiHBw/CBngwgQTZcze8T4YGOxmhC8TgxpLbogd10OANH5gFMZCLlSdU4w8ZPogFNiD5nGBABKRiACaw8fbMX6sEtF9IGhaB7wF0IR1CuAEwzvAKBCRiGaQFgCioENl+FUAbxbiLEojBCcG4oBvdHT46YDwWE5QBFeiwQUJ8oAlQXSUP1CDaWmASyIEW+OP5+iUBRqAIigAUbOF9SoAQTiEXJOQABmEXYKEYZCEwJOAL1OkgbuAS8q1dZKAdPiAh+uAP3oct/7KgGfYPIbKBCq5G3wiBB96BCvoEADLgB2puJ0yBGvhnB1bhHnxgD/IpAfkF/kKhFGYhFj4BAmxAFFQlIQTgAXwwbqLhGvruIPDgDJSAASxAASZOJzrBORJCFWIBCRLhA1Yg2nZiBbbAAkxhHsghCQ5CFXQBC3MiCupAQxJhFQJAFB7AGfYlCaUFBRwhdJ6gHWSn6q5gGyLrA9SwCyZhD1jQJ3hAGWDwIAaBEmCAFbChDNaLJ6AKBAZgEQJgG/LlA4xgD3EiCkABAFQgFALAGx7gATblENtlBxwBzF4FG0hh7XCgGmgNIbpgFS4AFzigCMbuKkAgFh4BIRigGOwAAf8oAAYo4BU3QrlaIBUCoBc+oArOYRtPIgo6gQ26IQDSASYcbhcb5QmOQRicgBOK4Q6wreoIwBXOAMeYwB3UYDCS4RC6YA4yIBPMoW70jdB44B4CoB104BJ+bCeYoBS+ER/qIFfU7h17pQVqgBe2wAyCIb4yzwPK4B2sAR3gwQjecCwIIBomARMwgRV6Dyua7AsCACflDyvIQBxwUhsMxR03UkwGoEV6cQ0S4LyCbgFuABeAgQ0kciwcQAOeICl7osku4BNwkhdAoRJmwCu/EizDUiy/Ug3EIB4CgJ7QQiOFElESQBJgwgZQIVwYYAigki1/RNiSABxwki/70i//EjD/+1IeAFItDfEu0QQBaMAKROMJgCBgNgAZVOcw0UTYAMAY5EEd1KYGNpMzO9MzP5MzmS8AgoC3ACAoJ7NCFMAI7OB9PMADYOA5CEAUjkDrUFNHKpMBnsEKJAACetM3fxM4g/M3S+AWsGEkC9M2D6UJxABLMoAQ/ssCyqCokjNHKhMA1oB5siIPcuDkTpM63wMNWMMHnsEHCm4NaIEEvzNA2GAKGEqmvqAcOcIURIElL8AKkFA9OWQD9GALHqFjkmAdoEkh9BEXjC8/0QMDqoDXAOADCiE+NyIS9IAlEyANnPFAKYQN7iAUnCEc6uERDOAFRkwh4EAYNOBCqYQAhM8n/xDg/040Rx5gF6xhybLAHmYrIz7AJELABv7LRSfEED4AD0ZmAELAARAiASAgPgUABsZgDpxRACDAzxRAAuyyRyVDELbhOAGgDYaB8BjCAzjBE4ohBZLBQKvUNipgD8wBEKiAEpxlALZgEBAiDdYB8y5iA8xgi+7gE9TpAkqhqNzgF4LKTG9DFmCBCgEgGcgBti7CArThDPSABzihFYRgKjggEMp0UAUDAVyhGPkAC6BgGwxpF3RSFdLBPRtiARhhGcKAAtLAGsqPBVChBxBCEogh5TJVMkghFKgOAAahG+qUIYBhoBAiGbYBDlagDiIPV21DBpTBGLenGCyBAJ4hu/8OIhDMAdcuIgPAQUAl4A5ywAAA4a0AABJgAViX1TAygBgk8yB0IAi6NCEIQBgsISES4BhyYJ0wFV2zQhLu4FCpYTWCAAiMoQ9EQQyUYVHhTu4SYg+C4AKmIQgqQQgkQRgc4VD3tTAq4BMmQQMWwAEUwR3ED1VhYQbidRi2AGNtQxMA4aySgQpAYBbMwQ5KwQp2oRnO9eK8ALQS4gSGYQh4wRHK4BWgoAYcQVBTljDQYBruYBGeYRwKgUoLCB0IISEKYBWkEWkloxPO4FQ5AQgs4BQotQuvIVsbohC64Q3tgBYsgBLETxGOAWezli0wYBAegQsENCMuIRVuZQ7AAQX/5dYwNGAZfgAhTOAdCgEAMkETEOIDzqBsGWIFegEXEGKyogAB/iCnDiIbLg9wKQQC7mAYkqAF1sAcyuBBO3cnOkEdxEAR6mAZJgEDBqAYvgAhMsAeEBAjhEAcOCAPhGAbSoEBQiAWsgEhcGEbbhV10QMHniEVHCEWNoEUk3cwMoARduETnABLBkAPwosPaCB6G6IA8sAbdkEaKqFILWAGhgcAkkAWLFR61aMBEqEKXOB031cnFoAFihQhCA4hBiBqE6IBWMB9CwC/COB/7ReBE1iBF5iBG9iBHxiCI1iCJ5iCK9iCLxiDM1iDN5iDO9iDPxiEQ1iER5iES9iETxiF/1NYhVeYhZ2IDBdCXzcihgvDf99jhlHzhREihzNVCSqBE6Kg4CrgFgjBGDhxJ8DgHEbhYkeDAJrNCLzgCg6YARrBGWoqKwRgDtqACS6UAD6AgPb3DWThBHJACIQAGNLAegTgA8ZYE/qgELJgQXt0AWwhAODhDhNiDfJBHvKgKjkCB9BhGZBXJxDgQf0gbcjBEdpmKPYgHhTZJwbADfwBXzeiAFgy8x5gEnQglx5gFPABCnyACJwAFqxheDDACvhhFG6AFJaBF4CuSodAGQJgC/BrAVwBH1ohYXdiAL7gGgQZJxgAGB63IQhAF+BFATxghxViDdyBXMbCBZThEjZiAf+yIcUSUAagIR3E7SDygB3iNJtUoAZa4Y5BAR/abQDC4B+CoH5RMxF04A9aIcXooA2EQR1wFwV84ChOYwee4AIGwABAAAVI5AFegA4wBwBi4AzuggDgAA9gAFSklAFYAA9MFCFcIAmUQEMe4BKwwQdG5sKwwJKx4B2s4AoEuQAe4AISgA3mQH/dIB0+wAVuQNmGIAmSQJYGAA6qQAP6ogFEQAE0IBBwbQfagRQuAA/AYC1agA7YoC8WABScNfkAAAICoQr6GKMQgBraABp08iAUIR8I8yCwIB7K4VLqIB4YxQLuwB54tEdVoAuiIAB0QSwSgBCioA364WoEYAlIgRr/gMAIBEAESqEbpmQBYgAZGAAFOiAKiuAUlgOhTaIBZOESmMAKzABLJgARHgEUgCAVpoQAbmEPRmAKuCABhoAZ1CEHpiMQZqASPsEVzopBh6EaAuAOwEghbGAL0GEGGKEVhoE/cgEcYsAI/uATD2IEXGE7hwEFBaAH6mAMzCADDKAPdoEQkGEZamBZdgAbWOEEUuAdJOgKvCADpCAGHqAEJuEQHgEmXoAacCETrED6WAwHauECMgEeuBAAvBqsD+IZ1AoAzJr0+MAdPKFFq1QJjiACuqEaroYNoMABSqEf5ogOuMEzqCEATMNLTEM14eQH8gEBEsARnKFFHhsAhAAW/yxCBaqBFQDgDeLBE1YADczhGaT6H6LZFr5BnTYaDAoADoKAgHpAEBUCASqAD0TBHdoBHxOCBbRBHm4BDTpBHuxgkPYBGTwVGpABAJSACnLKAV6hFUxABK4hUEyBCAxAFgLAElRgDmIhFjCgBc5gErDABJjhGCzgAHoBy+UAGsCsEnphDmYlCJzFDeJ6nX9mBiQBAHpAHtCoq/MBGBSCC/gBTuoAH3ABBMjAF+CBXQdVCToAAIogAFCkEAAyCNjBIgjBETqhE3IAFQQpAagAxvjgBFiDDsJFCWogHDQEoSWgAu5gExCCBuKBAkLgDLwHAMTAEQpAASABBDBACNgBBf814Qy6QxMcQRJ6gBTMIQawUA74AV8HgEUNACmcoBdixQzcoQJG4BvAiBlgbBPIQX9fAB804QGwgRsMYuzCwB7g5Yf2YQkkoBmiGQC4oBlaQACiQAMa4Bb2QSqKYBw8owlQoQg6wRhqYApUlLNC4BXA4J+vARFuxasfPSGMJg8sEx+0wQnaYA9o0kxVoA0AwAWuARZWAApagAC4gR1AIAGsQQcuQANQQALOpBJaQQPkYBCYgg0kQRUwQQd0fdo1gB7c7yDc4B7IAAKwgXABwAwwQUMWQBGuIAe+YSVogBiepgyCAIF2AAIsQPIQYBKmAABuYReGwRNMwwh6YcnUgB3/SEAO7CFfDIAZdAAAhKEGnHEDlgEKCIAI7gEeJMEmRoAe+B0OoEERLqAZBAkAPmeODIAIrkAS/kFhQAEelAAAjqAcNODnScADbvhnruAO9oADfoAK/MG2Q14haEEcbMesoyACMKDQbdMQaqFFHiEAJoEamiII8gEEECATPoFoPCBMIGAbHmEGamoAiGAXDOkZSsEmEFopemHFD4IHDiENSAAbGgwAoAAQCKACtEEXBMAHxGFKLuEMWAPZLdQBahMhXAzLASJNkUFFlADg1AsDAAC44D0Y4Y4MAAOAygDQUQ/EwguoXAkQ4GfYPk4EMtDLtRAHtA8hmtFYSOgdiAN2/zgUwOKOB4A64wwB6JJK4cIKChYaPYo0qdKlTJs6fQo16sIEVgRtsLFhzDduAxYqygfs6BB1nyrsjIdSqtq1bNu6ffuWD5SFfnp907AwHLsIAC4FILKQDi6zAPbEewngAaxTADz8WbRQVyq+wtpZWHgiloIN174sbEMJgK0AMAB0ukcHgK53HgCACgCMAIAkki4YLSChwcJEk0Yo5QSPMCMdAEz6WEjJYp4Abha+2CYowpqFW5axCOPONwBTZzBIUNZnoZNrHuKwuwEgS7/jddKZABBNnhADAAzVgQA3v/79T8dMQWAUATrc88JCRNzTg1EuZNKOFgupEY92/E1IYf+FFiIVQR/pLHHAAK90AIAAWJwRQCMKuBCLPlO4ssgKRr0BDx4LNZBCP9T0cE01YYigTT5JALBCLFOYMEcmWQAwhzyzKIABJuCIEMg80jRyRAAdsHDFPJwgoYE0AZRxBCsOGhXCMyks8QIXxtCXlC73DALHILysIEAhAdRBAAr2/HGBAos4kgQOliDDAAWesMGCLq4wsEQ/lihxwyeNABCHPK88YIE2+qywwiG7RPJDAKUMMUYAW9AxxCkBMLLJLBl0dWGssi6FQiivOGBUAzEEUM4QLLgSAC1jrFGJNLvICAAIrwTgBQSwzgpttNICoIQswWTDQn0tAKBAHpzEAMr/EwAkckQmHBiUqy0LGOWHGW0gsQYtcqxwwg9ZJECtLnUU8QYABYQRTB9PoOEEJy8UoIYwRcDxwx59xmDGj0/E8IwUPx6lQB2TdDDIDQIspYs7oBiTgx8AOADMHsl4MMcPXBj0ACg5ANPIAwCUYIwiRGSzAQBy2INMDzToZEAWoxTigg0nBPOBAKacMgMOOUjxxAFOlBEIACF8kUkbcUwLdoUDaLEJKe8thAIwMTySxgqFjMJFJUKQ4gauABDwxjkxnJDEx2H/DfhbCQC4AJsLCaAbAAkcYFRRTxXAOACMJ/AxA34PsIHjBOALeQJdrQsAA4cXsNAAouf6LFIVbGAz1lOctHPBBZEbwDgCCOA7AL4LYZDtUQ1IIBsAI9SThQV2C8D5AQd8rPsCXRFA+kKgzxh84Nazlbu/uisO4AALMEA6AQsAeJT3pBvAQOrXr89+++4b9QU4JVAIERPv349//vrvz/+0cKxyiDrYZj8Y6IA+dKAB9fVvgQxsoAMfeL0wFIIaffDJfhIhhDrQYAnVg6AHPwjCEIpwhCQsoQlPiMIUqnCFLGyhC18IwxjKcIY0rKENb4jDHOpwhzzsoQ9/CMQgCnGIRCyiEY+IxCQqcYlMbOJ+AgIAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fu, Z, Wang, M, Potter, D, et al. The structure of a binary complex between a mammalian mevalonate kinase and ATP: insights into the reaction mechanism and human inherited disease. J Biol Chem 2002; 277:18134. Copyright &copy;2002 American Society for Biochemistry and Molecular Biology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_46_35553=[""].join("\n");
var outline_f34_46_35553=null;
var title_f34_46_35554="Row exercise for scapular stabilizers";
var content_f34_46_35554=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1140px;\">",
"  <div class=\"videoplayer\" h264=\"./images/EM/86027/Row_exer_scap_stabil_video.mp4?title=Row+exercise+for+scapular+stabilizers\" style=\"width:496px;height:288px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Row exercise for scapular stabilizers",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rowing exercises performed against resistance help to strengthen the muscles involved in stabilizing the scapula.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_46_35554=[""].join("\n");
var outline_f34_46_35554=null;
var title_f34_46_35555="Approach dx ascites";
var content_f34_46_35555=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77605&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77605&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 724px\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of ascites",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 704px; height: 649px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Sleisenger &amp; Fordtran's Gastrointestinal and Liver Disease: Pathophysiology/Diagnosis/Management, 7th Edition,&nbsp;Feldman, M, Scharschmidt, BF, Sleisenger, MH (Eds), WB Saunders Company 2002. Coyright &copy; 2002 WB Saunders Company.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_46_35555=[""].join("\n");
var outline_f34_46_35555=null;
var title_f34_46_35556="Brimonidine and timolol: Patient drug information";
var content_f34_46_35556=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Brimonidine and timolol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/63/8183?source=see_link\">",
"     see \"Brimonidine and timolol: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5578883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Combigan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5067249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Combigan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10022660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691860",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat glaucoma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower high eye pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701647",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to brimonidine, timolol, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703319",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Asthma, very weak heart, slow heartbeat without a working pacemaker, or wheezing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698413",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often if you have heart disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may hide the signs of low blood sugar. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698504",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your eye pressure checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695617",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 10 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11929 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-2332FC6495-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_46_35556=[""].join("\n");
var outline_f34_46_35556=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5578883\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5067249\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022660\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022662\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022661\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022666\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022667\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022669\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022664\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022665\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022670\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022671\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?7/63/8183?source=related_link\">",
"      Brimonidine and timolol: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_46_35557="Chlorthalidone: Pediatric drug information";
var content_f34_46_35557=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Chlorthalidone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"    see \"Chlorthalidone: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/21/8533?source=see_link\">",
"    see \"Chlorthalidone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F150695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Thalitone&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F150696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Chlorthalidone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1005450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Diuretic, Thiazide",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1005477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"      see \"Chlorthalidone: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents:",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: 0.3 mg/kg once daily; may titrate up to a maximum daily dose: 2 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     or 50 mg/",
"     <b>",
"      day",
"     </b>",
"     (NHBPEP, 2004; NHLBI, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: 25-100 mg/day or 100 mg 3 times/week; usual dosage range (JNC 7): 12.5-25 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Edema:",
"     </b>",
"     Initial: 50-100 mg/day or 100 mg on alternate days; maximum dose: 200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Heart failure-associated edema:",
"     </b>",
"     12.5-25 mg once daily; maximum daily dose: 100 mg (ACC/AHA 2009 Heart Failure Guidelines)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustments in renal impairment:",
"     </b>",
"     Adults: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Avoid use. Ineffective with low GFR (Aronoff, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     ACC/AHA 2009 Heart Failure Guidelines suggest that thiazides lose their efficacy when Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;40 mL/minute.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F150675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 25 mg, 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thalitone&reg;: 15 mg [DSC]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F150659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F15068954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:  Administer in the morning with food",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F15068934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1005451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of edema due to heart failure; hepatic cirrhosis; estrogen or corticosteroid therapy; various forms of renal dysfunction, including nephrotic syndrome, acute glomerulonephritis, and chronic renal failure (FDA approved in adults); management of hypertension either alone or in combination with other antihypertensive agents (FDA approved in adults);",
"     <b>",
"      Note:",
"     </b>",
"     Use in pregnancy should be reserved for those cases causing extreme discomfort and unrelieved by rest; should not be routinely used during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F150717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Photosensitivity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, dyspepsia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Agranulocytosis, aplastic anemia, cholecystitis, diabetes mellitus, gout, hypercalcemia, hyperglycemia, hypersensitivity reactions, hypochloremic alkalosis, hyponatremia, leukopenia, necrotizing angiitis, orthostatic hypotension, pancreatitis, renal impairment, thrombocytopenia, toxic epidermal necrolysis, vasculitis, xanthopsia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1005454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to chlorthalidone or any component; cross-sensitivity with other thiazides or sulfonamides; anuria",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F15068933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with severe renal disease due to decreased efficacy and may precipitate azotemia. Use with caution in patients with severe hepatic dysfunction; in cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy or coma. Use with caution in patients with prediabetes or diabetes mellitus; may alter glucose control. Use with caution in patients a history of gout; may cause hyperuricemia and in certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated.  Use with caution in patients with hypercalcemia or parathyroid disease; thiazide diuretics may decrease renal calcium excretion; pathologic changes in the parathyroid glands with hypercalcemia and hypophosphatemia have been observed with prolonged use.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1005455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hypersensitivity reactions may occur with chlorthalidone and other thiazide diuretics; risk is increased in patients with a history of allergy or bronchial asthma. Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling; a risk of crossreaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     May cause  hypokalemia; increased risk associated with aggressive diuresis, severe cirrhosis, or after prolonged therapy; alterations in adequate oral potassium intake may also increase risk; monitor serum potassium concentrations at baseline and periodically; correct hypokalemia prior to initiating therapy. Other electrolyte disorders including hyponatremia, hypomagnesemia, and hypochloremic metabolic alkalosis may occur; monitor electrolytes. SLE exacerbation or activation has been reported with other thiazide-type diuretics. Photosensitization may  occur; patients should be counseled.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F150668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1005466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid natural licorice (causes sodium and water retention and increases potassium loss).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F150670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10923684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Chlorthalidone crosses the placenta and can be detected in cord blood and amniotic fluid. Maternal use may cause may cause fetal or neonatal jaundice, thrombocytopenia, or other adverse events observed in adults. Use of thiazide diuretics during normal pregnancies is not appropriate; use may be considered when edema is due to pathologic causes (as in the nonpregnant patient); monitor.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1005484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum electrolytes, BUN, creatinine, blood pressure, fluid balance, body weight",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1005469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits sodium reabsorption in the cortical diluting segment of the ascending limb of Henle's loop causing increased excretion of sodium and water as well as potassium, hydrogen, magnesium, phosphate, calcium, and bicarbonate ions",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F15068938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Diuresis: ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration:  Diuresis: 24-72 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1005471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 0.14 L/kg; sequesters in erythrocytes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~75%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability:  Chlorthalidone: ~65%; Thalitone&reg;: 104% to 116% relative to an oral solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 40-60 hours; may be prolonged with renal impairment; Anuria: 81 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 13.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (~50% to 65% as unchanged drug)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1005488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/21/8533?source=see_link\">",
"      see \"Chlorthalidone: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with meals early in the day to avoid nocturia. A potassium supplement may be prescribed or dietary changes recommended; do not change diet while taking this medication unless recommended by prescriber, especially  with concurrent use of potassium supplements or medications to reduce potassium loss. May cause dizziness, or postural hypotension. Report palpitations, muscle cramping, or skin rash. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;American Academy of Pediatrics Committee on Drugs. The Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed, Philadelphia, PA: American College of Physicians, 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/46/35557/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, \"2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 53(15):1-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/46/35557/abstract-text/19358937/pubmed\" id=\"19358937\" target=\"_blank\">",
"        19358937",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Heart, Lung, and Blood Institute, &ldquo;Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, Clinical Practice Guidelines, 2011,\" National Institutes of Health. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf",
"      </a>",
"      . Date accessed: June 11, 2012.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, &ldquo;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/46/35557/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86691 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-340D2F8564-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_46_35557=[""].join("\n");
var outline_f34_46_35557=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150695\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150696\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1005450\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1005477\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150675\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150659\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15068954\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15068934\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1005451\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150717\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1005454\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15068933\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1005455\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299032\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150668\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1005466\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150670\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10923684\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1005484\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1005469\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15068938\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1005471\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1005488\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/86691\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/86691|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=related_link\">",
"      Chlorthalidone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/21/8533?source=related_link\">",
"      Chlorthalidone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_46_35558="ECG tutorial: Miscellaneous diagnoses";
var content_f34_46_35558=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   ECG tutorial: Miscellaneous diagnoses",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/46/35558/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/46/35558/contributors\">",
"     Jordan M Prutkin, MD, MHS, FHRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/46/35558/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/46/35558/contributors\">",
"     Ary L Goldberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/46/35558/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/46/35558/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/46/35558/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H351236425\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac or systemic diseases may have electrocardiographic manifestations that do not fit into standard categories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     LOW VOLTAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low voltage of the",
"    <strong>",
"     limb",
"    </strong>",
"    leads is present when the amplitude of the QRS complex in each of the three standard limb leads (I, II, and III) is &lt;5 mm (",
"    <a class=\"graphic graphic_waveform graphicRef74856 \" href=\"mobipreview.htm?21/23/21875\">",
"     waveform 1",
"    </a>",
"    ). Low voltage of",
"    <strong>",
"     all",
"    </strong>",
"    leads is diagnosed when the average voltage in the limb leads is &lt;5 mm and the average voltage in the chest leads is &lt;10 mm. This may be due to underlying myocardial disease (particularly amyloidosis), pericardial effusion, lung disease, severe hypothyroidism, obesity, or anasarca, in which the low voltage correlates with weight gain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35558/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EARLY REPOLARIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term early repolarization (ER), also known as \"J-waves\" or \"J-point elevation\", has long been used to characterize a QRS-T variant on the electrocardiogram (ECG). Most literature defines ER as being present on the ECG when there is J-point elevation of &ge;0.1 mV in two adjacent leads with either a slurred or notched morphology. Historically, ER has been considered a marker of good health because it is more prevalent in athletes, younger persons, and at slower heart rates. However, numerous more reports have suggested an association between ER and an increased risk for arrhythmic death and idiopathic ventricular fibrillation (VF). Early repolarization is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/38/38505?source=see_link\">",
"     \"Early repolarization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ELECTRICAL ALTERNANS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrical alternans is recognized by alternating amplitude of the QRS complexes in any or all leads (",
"    <a class=\"graphic graphic_waveform graphicRef51502 \" href=\"mobipreview.htm?16/5/16468\">",
"     waveform 2",
"    </a>",
"    ). Every other QRS complex has reduced amplitude alternating with an increased amplitude. Most often it is observed in the precordial leads where the QRS amplitude is greater.",
"   </p>",
"   <p>",
"    The most frequent cause of electrical alternans is a pericardial effusion; it is thought that the alternating amplitude is the result of a pendulum motion of the heart as it \"swings\" from beat to beat within the fluid contained in the pericardial sac; there is a change in electrical axis as the heart swings. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/7/23669?source=see_link\">",
"     \"Electrocardiogram in pericarditis and pericardial effusion\"",
"    </a>",
"    .) Frequently, there is also sinus tachycardia when there is electrical alternans from pericardial effusion. Electrical alternans may also be seen when there is severe cardiomegaly and left ventricular dysfunction, and it may occur with aortic regurgitation.",
"   </p>",
"   <p>",
"    Another setting associated with electrical alternans is supraventricular tachycardia (SVT), especially when the rate is rapid. Although it has been suggested that electrical alternans during SVT is indicative of atrioventricular re-entrant tachycardia, this finding can be seen in any rapid SVT.",
"   </p>",
"   <p>",
"    There may also be macrovolt alternans of the T waves, although this is less common. It is most often seen with long QT syndrome and is a warning sign of impending polymorphic ventricular tachycardia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/9/2202?source=see_link\">",
"     \"Clinical features of congenital long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    U wave alternans is very uncommon and is associated with electrolyte disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EARLY OR LATE TRANSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual transition zone, where the R and S wave are equal in amplitude in the precordial leads, usually occurs between V3 and V4. Early or late transition may occur due to a variety of circumstances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Early transition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The so-called &ldquo;counterclockwise rotation&rdquo; pattern is present when there is early transition of the R wave amplitude across the precordium (",
"    <a class=\"graphic graphic_waveform graphicRef79702 \" href=\"mobipreview.htm?21/0/21508\">",
"     waveform 3",
"    </a>",
"    ). It may be a normal variant, be due to lead placement, reflect a Wolff-Parkinson-White pattern, be seen in muscular dystrophies, or may represent a true posterior wall myocardial infarction. In addition, it can be due to right ventricular hypertrophy or right ventricular conduction delays. The finding of Q waves and ST segment changes in leads V7 to V9 is helpful in diagnosing a true posterior wall MI. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9317?source=see_link\">",
"     \"ECG tutorial: Myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/24/11658?source=see_link\">",
"     \"Electrocardiogram in the diagnosis of myocardial ischemia and infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An understanding of the ECG manifestations of a counterclockwise rotation involves imagining the heart as viewed from below the diaphragm. The right ventricle is anterior, and the left ventricle is leftward and slightly posterior. If the electrical axis of the heart is rotated in a counterclockwise direction around a central axis, the left ventricle is shifted more anteriorly. Thus, tall R waves are seen earlier than normal across the precordium, in lead V2 or even V1.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Late or delayed transition",
"    </span>",
"    &nbsp;&mdash;&nbsp;So-called &ldquo;clockwise rotation&rdquo; of the electrical axis of the heart in the horizontal plane is present when there is late transition of the R wave amplitude across the precordial leads. It may be seen as a normal variant (particularly in women), can represent an anterior wall infarction, or may occur in patients with lung disease or thick chests.",
"   </p>",
"   <p>",
"    If the electrical axis of the heart is rotated clockwise around a central axis, the right ventricle is shifted toward the left and the left ventricle is more posteriorly directed. Thus, the R waves remain of low amplitude and are seen in lead V1 until lead V4 or V5, at which point there is an abrupt transition to a tall R wave, representing left ventricular depolarization which is late or more leftward along the precordium (",
"    <a class=\"graphic graphic_waveform graphicRef59574 \" href=\"mobipreview.htm?33/47/34549\">",
"     waveform 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SLOW (\"POOR\") R WAVE PROGRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The R wave height normally becomes progressively taller from leads V1 through V6. In V1 to V3 there is a R wave of low amplitude and a S wave which is larger",
"    <span class=\"nowrap\">",
"     (R/S",
"    </span>",
"    &lt;1); between leads V3 to V4 there is a transition to a R wave which has a greater amplitude than the S wave",
"    <span class=\"nowrap\">",
"     (R/S",
"    </span>",
"    &gt;1). When the R wave height does not become progressively taller from leads V1 to V3 or V4, or even remains at low amplitude across the entire precordium, slow or poor R wave progression (PRWP) is present (",
"    <a class=\"graphic graphic_waveform graphicRef58053 \" href=\"mobipreview.htm?34/30/35301\">",
"     waveform 5",
"    </a>",
"    ). Several sets of criteria have been proposed to define PRWP more precisely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35558/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are many etiologies for PRWP:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lead placement",
"     </li>",
"     <li>",
"      Anteroseptal or anterior wall myocardial infarction",
"     </li>",
"     <li>",
"      Left ventricular hypertrophy",
"     </li>",
"     <li>",
"      Left anterior fascicular block",
"     </li>",
"     <li>",
"      Left bundle branch block",
"     </li>",
"     <li>",
"      Infiltrative or dilated cardiomyopathy",
"     </li>",
"     <li>",
"      Wolff-Parkinson-White patterns due to right sided or antero-septal bypass tracts",
"     </li>",
"     <li>",
"      Chronic lung disease",
"     </li>",
"     <li>",
"      Physiologic late transition or clockwise rotation of the heart",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Poor R wave progression may be more frequently seen in females. Because there are so many different causes of PRWP, this finding alone is not useful in identifying patients with a prior anterior myocardial infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35558/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIGITALIS EFFECT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A digitalis effect is manifested as changes of the ST segment and T wave which may be similar to those due to ischemia. The J point is occasionally depressed, but more commonly seen is depression or sagging of the ST segment, which is concave in an upward direction (",
"    <a class=\"graphic graphic_waveform graphicRef56737 \" href=\"mobipreview.htm?4/31/4594\">",
"     waveform 6",
"    </a>",
"    ). These changes are more apparent in the lateral precordial leads, although they may also be seen in the limb leads also.",
"   </p>",
"   <p>",
"    Other changes associated with digitalis include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The T waves are often flattened and the QT interval (ST segment) shortened.",
"     </li>",
"     <li>",
"      Usually the PR interval is slightly prolonged as a result of an enhanced vagal effect upon the AV node.",
"     </li>",
"     <li>",
"      In some cases there are abnormalities of the U wave (prominent or inverted) which may be due to digitalis itself, or can be secondary to hypokalemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIGITALIS TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Digitalis toxicity may have various ECG manifestations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/26/28072?source=see_link\">",
"     \"Basic approach to arrhythmias due to digoxin toxicity\"",
"    </a>",
"    .) Toxicity leads to an increase in central sympathetic neural activity, thereby causing an increase in myocardial automaticity and excitability and an increase in peripheral vagal tone; the latter effect causes suppression of the normal pacemaker tissue in the sinus and AV node. Thus, there may be arrhythmic disturbances, conduction block, or a combination of both.",
"   </p>",
"   <p>",
"    Abnormal rhythms due to digitalis toxicity include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ventricular premature beats",
"     </li>",
"     <li>",
"      Atrial tachycardia (automatic, accelerated, or non-paroxysmal)",
"     </li>",
"     <li>",
"      Accelerated junctional rhythm or tachycardia (automatic or non-paroxysmal)",
"     </li>",
"     <li>",
"      Accelerated idioventricular rhythm (automatic or non-paroxysmal)",
"     </li>",
"     <li>",
"      Ventricular tachycardia, including bidirectional ventricular tachycardia",
"     </li>",
"     <li>",
"      Ventricular fibrillation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Abnormal conduction due to digitalis toxicity includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sinus bradycardia",
"     </li>",
"     <li>",
"      Sinus pauses or arrest",
"     </li>",
"     <li>",
"      Sinoatrial exit block",
"     </li>",
"     <li>",
"      First degree atrioventricular block",
"     </li>",
"     <li>",
"      Second degree atrioventricular block (especially, Mobitz 1)",
"     </li>",
"     <li>",
"      Third degree atrioventricular block",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Combined arrhythmia and conduction abnormalities due to digitalis toxicity include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Atrial tachycardia with atrioventricular block (PAT with block) (",
"      <a class=\"graphic graphic_waveform graphicRef68731 \" href=\"mobipreview.htm?10/18/10536\">",
"       waveform 7",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Sinus bradycardia associated with junctional tachycardia",
"     </li>",
"     <li>",
"      Accelerated junctional rhythm associated with underlying atrial fibrillation (atrial fibrillation with regularization)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, almost any arrhythmia or conduction abnormality may be seen with digitalis toxicity. Atrial flutter, atrial fibrillation, and Mobitz type II second degree AV block are the",
"    <strong>",
"     least",
"    </strong>",
"    &nbsp;",
"    <strong>",
"     likely",
"    </strong>",
"    of all the possible abnormalities. Atrial flutter and fibrillation are frequently the reason for the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , however, so while they may not be caused by digitalis toxicity, they may still be seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ELECTROLYTE ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of electrolyte abnormalities may be associated with changes on the ECG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hyperkalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A tall peaked and symmetrical T wave is the first change seen on the ECG in a patient with hyperkalemia (",
"    <a class=\"graphic graphic_waveform graphicRef80441 \" href=\"mobipreview.htm?11/50/12068\">",
"     waveform 8",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There is progressive slowing of impulse conduction through the myocardium as the hyperkalemia becomes more severe, with several consequences:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The PR interval lengthens and the QRS duration increases. A variety of conduction disturbances, including right bundle branch block, left bundle branch block, bifascicular block, and advanced atrioventricular block may be seen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/46/35558/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The P wave may flatten or disappear as a result of atrial standstill or arrest; however, sinus node activity can persist without resulting in atrial activation. The latter occurs because the impulse generated by the sinus node may travel to the AV node along specialized intraatrial tracts, rather than through the atrial myocardium which has become unexcitable.",
"     </li>",
"     <li>",
"      ST elevation in the leads V1-2 may occur, mimicking a type 1 Brugada pattern or myocardial infarction. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28250?source=see_link\">",
"       \"Brugada syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ultimately the QRS widens further due to a severe conduction delay and may become \"sine wave,\" resulting in ventricular standstill and a flat line on the ECG with complete absence of electrical activity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The progression and severity of ECG changes do",
"    <strong>",
"     not",
"    </strong>",
"    correlate well with the serum potassium concentration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hypokalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to hyperkalemia, hypokalemia produces changes on the ECG which are not necessarily related to the serum potassium level. There is depression of the ST segment, decrease in the amplitude of the T wave, and an increase in the amplitude of the U wave, best seen in leads V4-6 (",
"    <a class=\"graphic graphic_waveform graphicRef73888 \" href=\"mobipreview.htm?18/38/19043\">",
"     waveform 9",
"    </a>",
"    ). U waves are often seen in the lateral precordial leads V4-V6.",
"   </p>",
"   <p>",
"    Other findings associated with hypokalemia include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The U wave and T wave merge in some cases to form a T-U wave which may be misdiagnosed as a prolonged QT interval.",
"     </li>",
"     <li>",
"      The P wave can become larger and wider and the PR interval may prolong slightly.",
"     </li>",
"     <li>",
"      The QRS duration may increase when the hypokalemia is more severe; in addition, the ST segment becomes markedly depressed, and T waves are inverted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hypocalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypocalcemia causes prolongation of the QT interval (",
"    <a class=\"graphic graphic_waveform graphicRef59063 \" href=\"mobipreview.htm?33/6/33888\">",
"     waveform 10",
"    </a>",
"    ). This is due to prolongation of phase 2 of the ventricular action potential and lengthening of the ST segment, while the T wave (which correlates with the time for repolarization) remains unaltered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hypercalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercalcemia causes shortening of the QT interval, primarily due to a decrease in phase 2 of the ventricular action potential and resultant decrease in the ST segment duration. There is also a decrease in duration of the proximal portion of the T wave, or upstroke, measured from the beginning of the T wave to its apex; thus, the initial portion of the T wave has an abrupt upslope (",
"    <a class=\"graphic graphic_waveform graphicRef82086 \" href=\"mobipreview.htm?41/24/42368\">",
"     waveform 11",
"    </a>",
"    ). Other findings in some patients include PR prolongation, a diffuse increase in the amplitude of the QRS complex, ST elevation in V1-2, and flattened, inverted, or biphasic T waves.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DEXTROCARDIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dextrocardia is a condition in which the heart is located on the right side of the chest. Thus, the left ventricular apex is at the right midclavicular line. The resultant changes on the ECG often include a negative P wave and QRS complex in lead 1, since atrial and ventricular depolarization begin on the left and spread to the right. There is also reverse R wave progression across the precordium; the R wave is tallest in V1 and progressively decreases in amplitude in leads V2 to V6 (",
"    <a class=\"graphic graphic_waveform graphicRef60496 \" href=\"mobipreview.htm?35/12/36039\">",
"     waveform 12",
"    </a>",
"    ). The diagnosis may be confirmed by obtaining right sided chest leads which demonstrate the normal progression of R wave amplitude.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     HYPOTHERMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothermia, defined as a temperature of less than 93 degrees (F) or 34 degrees (C), slows impulse conduction through all cardiac tissue, resulting in prolongation of all the ECG intervals, including the RR, PR, QRS, and QT. There is also elevation of the J point (only if the ST segment is unaltered), producing a characteristic J or Osborne wave, which represents distortion of the earliest phase of membrane repolarization (",
"    <a class=\"graphic graphic_waveform graphicRef80836 \" href=\"mobipreview.htm?32/61/33745\">",
"     waveform 13",
"    </a>",
"    ). The height of the Osborne wave is roughly proportional to the degree of hypothermia. These findings are most prominent in the precordial leads V2 to V5.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ARTIFACT DUE TO TREMOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tremors can cause a rhythmic irregularity of the ECG baseline and occasionally the QRS complex (",
"    <a class=\"graphic graphic_waveform graphicRef62575 \" href=\"mobipreview.htm?41/24/42374\">",
"     waveform 14",
"    </a>",
"    ). They may mimic atrial tachycardia, atrial flutter, or ventricular tachycardia. This abnormality is commonly seen in Parkinson disease, or when a patient has hypothermia. Counting the peaks of the artifact helps determine the periodicity of the muscle tremor.",
"   </p>",
"   <p>",
"    The limb which is moving can be determined from the limb leads of the ECG: the left arm is involved if the artifact is seen in I and aVL; baseline artifact in aVR suggests that the right arm may be twitching. The precordial leads can also show tremor artifact if the pectoral muscles, intercostal muscles, or sternocleidomastoid muscles have tremors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     LEAD SWITCH OR MISPLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placement of the ECG leads on the wrong limbs or incorrect positioning of the precordial leads may cause an abnormal P wave and QRS axis in the frontal plane, or unnatural R wave progression. This may be confused with dextrocardia, a pathologic left or rightward axis, or myocardial infarction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     FUSION COMPLEXES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fusion complexes are combination beats that result when two impulses simultaneously activate the same territory of the atrial or ventricular myocardium and \"fuse\" with each other (",
"    <a class=\"graphic graphic_waveform graphicRef72600 \" href=\"mobipreview.htm?4/46/4840\">",
"     waveform 15",
"    </a>",
"    ). The resultant complex is a hybrid, or intermediate in shape, with features of the patterns produced by each of the complexes. Ventricular fusion is seen when a ventricular complex is generated and begins to activate the ventricular myocardium shortly after a supraventricular impulse has been conducted through the AV node and has also begun to spread through the ventricular myocardium. In order for a sinus impulse to fuse with a ventricular premature beat, the premature beat must occur late enough to follow the P wave of the sinus beat.",
"   </p>",
"   <p>",
"    Fusion beats are often seen during sustained ventricular tachycardia; occasionally the fusion will result in complete, but episodic and transient normalization of the QRS complex, which has a morphology that resembles the complex seen in sinus rhythm. This is known as a capture or Dressler beat. Often an episode of ventricular tachycardia or an accelerated idioventricular rhythm will begin or end with a fusion beat.",
"   </p>",
"   <p>",
"    Fusion beats are also frequently seen when there is a permanent pacemaker. Fusion complexes in the ventricle occur as a result of simultaneous activation from the native conduction system and from the pacemaker. This shows a pacemaker spike at the beginning of or just after the start of the QRS.",
"   </p>",
"   <p>",
"    The typical QRS complex seen in the Wolf-Parkinson-White syndrome represents a fused beat with early activation occurring via the bundle of Kent and activation of the ventricle via the normal His-Purkinje conduction system. The end result is a short PR interval and fused QRS complex with a sloped delta wave.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     RECIPROCAL (ECHO) COMPLEXES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reciprocal or echo beats occur when a premature ventricular complex is conducted retrogradely to the atrium (ventriculoatrial conduction). Retrograde atrial activation occurs via the AV node, when dual pathways are present or as a result of an accessory bypass tract such as in the Wolff-Parkinson-White syndrome. The resulting atrial impulse is then conducted antegradely back to the ventricle via the normal conduction pathway (the AV node and His Purkinje system). Generally, a premature ventricular complex is followed by a retrograde P wave (which may be inverted), which is then conducted antegradely through the AV node and results in a normal QRS complex (",
"    <a class=\"graphic graphic_waveform graphicRef62909 \" href=\"mobipreview.htm?40/38/41569\">",
"     waveform 16",
"    </a>",
"    ). The PR interval is usually increased.",
"   </p>",
"   <p>",
"    Echo beats are often seen when there is a pacemaker and intact VA conduction. If there is a persistent pattern due to decremental AV nodal conduction, a bigeminal rhythm is seen in which every paced beat is followed by a normal QRS complex.",
"   </p>",
"   <p>",
"    In the setting of a premature atrial contraction, there may be an echo beat that conducts down the normal AV node and His-Purkinje pathways and conducts retrograde up a second AV nodal pathway or accessory bypass tract. This leads to a retrograde P wave without a QRS.",
"   </p>",
"   <p>",
"    If echo beats are able to continue conduction up or down two pathways, a re-entrant rhythm and supraventricular tachycardia occurs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39481?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     ATRIOVENTRICULAR DISSOCIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;AV dissociation is present when there is independent activation of the atrium and ventricle as a result of absent conduction through the AV node (",
"    <a class=\"graphic graphic_waveform graphicRef52123 \" href=\"mobipreview.htm?5/61/6104\">",
"     waveform 17",
"    </a>",
"    ). There is no fixed relationship between the P waves and the QRS complexes, and the PR intervals are variable in a random fashion. There are several causes of atrioventricular dissociation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Slowing of the sinus node rate with the development of an escape junctional or ventricular rhythm which does not result in retrograde conduction through the AV node or atrial activation, may result in AV dissociation. The sinus node is not depressed or overdriven. Usually the junctional or ventricular rate is faster than the sinus rate; thus, the interval between the QRS complexes is shorter than the PP interval. There may be isorhythmic dissociation if the sinus rate and rate of the junctional or ventricular rhythm are similar; in these cases there is a slightly variable and usually very short PR interval, and occasionally the P wave merges with and is buried within the QRS complex and therefore not seen.",
"     </li>",
"     <li>",
"      Block of sinus impulses within the atrium or in the AV node (third degree heart block) may cause AV dissociation. There is an escape junctional or ventricular rhythm at a rate that is slower than the sinus node. Thus, the PP interval is shorter than the RR interval.",
"     </li>",
"     <li>",
"      Acceleration or enhanced automaticity of lower or subsidiary pacemakers, such as occurs with an accelerated junctional or ventricular rhythm or with a ventricular tachycardia, and rarely with a junctional tachycardia, may cause AV dissociation. There is a retrograde block of impulse conduction through the AV node (no VA conduction); thus, there is no atrial activation and the sinus node is not suppressed. The RR interval is shorter than the PP interval.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fusion beats or capture beats may be seen when the AV dissociation results from the acceleration of a lower subsidiary focus or pacemaker which usurps the pacemaker function from the sinus node. These complexes represent intermittent AV conduction and activation of the ventricle by a sinus beat conducted antegradely through the AV node. Fusion beats are absent when there is structural block of the AV node and no AV conduction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     RETROGRADE ATRIAL ACTIVATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrograde atrial activation occurs when there is ventriculoatrial conduction through the AV node. The dominant rhythm originates in the AV junction (junctional tachycardia) or in the ventricles (ventricular tachycardia). There is a negative P wave following the QRS complex as a result of atrial activation in an inferior to superior direction (",
"    <a class=\"graphic graphic_waveform graphicRef51600 \" href=\"mobipreview.htm?35/7/35967\">",
"     waveform 18",
"    </a>",
"    ). The RP interval between the QRS and the P wave is determined by the retrograde ventriculoatrial conduction time. This interval is usually constant; however, there may be retrograde Wenckebach or Mobitz I retrograde block which manifests as a progressive lengthening of the RP interval with subsequent block of impulse conduction to the atrium, or Mobitz type 2 block (eg, 2:1 block), where the RP interval is fixed before dropping.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16447884\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    Early repolarization is present when there is J-point elevation of &ge;0.1 mV in two adjacent leads with either a slurred or notched morphology. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Early repolarization'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low voltage is defined as a voltage in the limb leads &lt;5mm and chest leads &lt;10mm.",
"     </li>",
"     <li>",
"      Electrical alternans is most concerning for pericardial effusion, but may also be seen in severe left ventricular dysfunction or supraventricular tachycardia.",
"     </li>",
"     <li>",
"      Digitalis toxicity may lead to both tachyarrhythmias and bradyarrhythmias.",
"     </li>",
"     <li>",
"      Hyperkalemia may have peaked T waves, PR interval and QRS duration increases, atrial standstill, ST elevation in V1-2, or sine wave.",
"     </li>",
"     <li>",
"      Hypokalemia may cause ST segment depression, decrease in T wave amplitude or T wave inversion, increase in U wave amplitude, merging of the T and U waves, increase in P wave size and duration, PR interval prolongation, and widening of the QRS complex.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H351236370\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UpToDate editorial staff would&nbsp;like to thank Dr. Philip J. Podrid for his contributions as an author to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35558/abstract/1\">",
"      Madias JE, Bazaz R, Agarwal H, et al. Anasarca-mediated attenuation of the amplitude of electrocardiogram complexes: a description of a heretofore unrecognized phenomenon. J Am Coll Cardiol 2001; 38:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35558/abstract/2\">",
"      Gami AS, Holly TA, Rosenthal JE. Electrocardiographic poor R-wave progression: analysis of multiple criteria reveals little usefulness. Am Heart J 2004; 148:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35558/abstract/3\">",
"      Bashour T, Hsu I, Gorfinkel HJ, et al. Atrioventricular and intraventricular conduction in hyperkalemia. Am J Cardiol 1975; 35:199.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2120 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-189.41.172.26-E56BECDC24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_46_35558=[""].join("\n");
var outline_f34_46_35558=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16447884\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H351236425\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      LOW VOLTAGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EARLY REPOLARIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ELECTRICAL ALTERNANS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EARLY OR LATE TRANSITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Early transition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Late or delayed transition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SLOW (\"POOR\") R WAVE PROGRESSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIGITALIS EFFECT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIGITALIS TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ELECTROLYTE ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hyperkalemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DEXTROCARDIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      HYPOTHERMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ARTIFACT DUE TO TREMOR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      LEAD SWITCH OR MISPLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      FUSION COMPLEXES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      RECIPROCAL (ECHO) COMPLEXES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      ATRIOVENTRICULAR DISSOCIATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      RETROGRADE ATRIAL ACTIVATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16447884\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H351236370\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/2120\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/2120|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?21/23/21875\" title=\"waveform 1\">",
"      Low voltage limb leads tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?16/5/16468\" title=\"waveform 2\">",
"      Electrical alternans tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?21/0/21508\" title=\"waveform 3\">",
"      Early transition tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?33/47/34549\" title=\"waveform 4\">",
"      Late transition tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?34/30/35301\" title=\"waveform 5\">",
"      Poor R wave progress tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?4/31/4594\" title=\"waveform 6\">",
"      Digitalis effect tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?10/18/10536\" title=\"waveform 7\">",
"      Atrial tach with block tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?11/50/12068\" title=\"waveform 8\">",
"      EKG peaked T waves in hyperkalemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?18/38/19043\" title=\"waveform 9\">",
"      Hypokalemia tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?33/6/33888\" title=\"waveform 10\">",
"      Hypocalcemia tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?41/24/42368\" title=\"waveform 11\">",
"      Hypercalcemia tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?35/12/36039\" title=\"waveform 12\">",
"      Dextrocardia tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?32/61/33745\" title=\"waveform 13\">",
"      Hypothermia tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?41/24/42374\" title=\"waveform 14\">",
"      Tremor artifact tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?4/46/4840\" title=\"waveform 15\">",
"      Fusion beats tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?40/38/41569\" title=\"waveform 16\">",
"      Echo complex tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?5/61/6104\" title=\"waveform 17\">",
"      AV dissociation tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?35/7/35967\" title=\"waveform 18\">",
"      Retrograde atrial beat tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/26/28072?source=related_link\">",
"      Basic approach to arrhythmias due to digoxin toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28250?source=related_link\">",
"      Brugada syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/9/2202?source=related_link\">",
"      Clinical features of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39481?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9317?source=related_link\">",
"      ECG tutorial: Myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/38/38505?source=related_link\">",
"      Early repolarization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/7/23669?source=related_link\">",
"      Electrocardiogram in pericarditis and pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/24/11658?source=related_link\">",
"      Electrocardiogram in the diagnosis of myocardial ischemia and infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_46_35559="Sulfonylureas and meglitinides in the treatment of diabetes mellitus";
var content_f34_46_35559=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sulfonylureas and meglitinides in the treatment of diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/46/35559/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/46/35559/contributors\">",
"     David K McCulloch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/46/35559/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/46/35559/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/46/35559/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/46/35559/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/46/35559/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two classes of oral hypoglycemic drugs stimulate release of insulin from pancreatic beta cells: the sulfonylureas and meglitinides. The pharmacology and use of these drugs will be discussed here. Other oral hypoglycemic drugs are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/26/38312?source=see_link\">",
"     \"Metformin in the treatment of diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3078?source=see_link\">",
"     \"Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21290?source=see_link\">",
"     \"Thiazolidinediones in the treatment of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SULFONYLUREAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sulfonylureas are among the most widely used drugs for the treatment of patients with type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35559/abstract/1\">",
"     1",
"    </a>",
"    ]. The sulfonylurea receptor is a component of the ATP-dependent potassium channel in the pancreatic beta cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35559/abstract/2\">",
"     2",
"    </a>",
"    ]. Sulfonylurea binding leads to inhibition of these channels, which alters the resting potential of the cell, leading to calcium influx and stimulation of insulin secretion. The net effect is increased responsiveness of beta cells to both glucose and non-glucose secretagogues (such as amino acids), resulting in more insulin being released at all blood glucose concentrations. Thus, sulfonylureas are useful only in patients with some beta cell function. Sulfonylureas may also have extrapancreatic effects, one of which is to increase tissue sensitivity to insulin, but the clinical importance of these effects is minimal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35559/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The KATP channel is a functional complex of the sulfonylurea 1 receptor (SUR1) and an inward rectifier potassium channel subunit, Kir6.2. Mutations in either the SUR1 gene or the Kir6.2 gene lead to the loss of KATP activity; as a result, the cell is persistently depolarized, resulting in calcium influx, high cytosolic calcium concentrations, and the release of insulin, producing a syndrome called persistent hyperinsulinemic hypoglycemia of infancy.",
"   </p>",
"   <p>",
"    Mutations in the Kr6.2 and, to a lesser extent, the SUR1 gene, have also been identified which activate the KATP channel, resulting in an inability to secrete insulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35559/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. These mutations have been found in patients with permanent neonatal diabetes mellitus; insulin secretion in these patients can be restored with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/6/29800?source=see_link\">",
"     glyburide",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35559/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/49/3866?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of persistent hyperinsulinemic hypoglycemia of infancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37816?source=see_link\">",
"     \"Neonatal hyperglycemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/28/40391?source=see_link\">",
"     Glipizide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/6/29800?source=see_link\">",
"     glyburide",
"    </a>",
"    (glibenclamide),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/42/34470?source=see_link\">",
"     gliclazide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8823?source=see_link\">",
"     glimepiride",
"    </a>",
"    are so-called second-generation sulfonylureas. They have structural characteristics that allow them to be given in much lower doses than the first-generation sulfonylureas. Nevertheless, the different sulfonylureas are equally effective in lowering blood glucose concentrations. There are, however, differences in absorption and metabolism, as well as in effective dose (",
"    <a class=\"graphic graphic_table graphicRef56701 \" href=\"mobipreview.htm?16/49/17180\">",
"     table 1",
"    </a>",
"    ). Comparison of plasma half-lives is misleading, since the biological effect is often much longer. For example, the hypoglycemic action of glyburide can last for more than 24 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35559/abstract/6\">",
"     6",
"    </a>",
"    ], due in part to the formation of active metabolites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35559/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Those drugs with longer half-lives (particularly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/0/6151?source=see_link\">",
"     chlorpropamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/6/29800?source=see_link\">",
"     glyburide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8823?source=see_link\">",
"     glimepiride",
"    </a>",
"    ) can be given once daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35559/abstract/6\">",
"     6",
"    </a>",
"    ]. They also cause greater suppression of overnight hepatic glucose output, thereby lowering fasting blood glucose concentrations more. These benefits may be counterbalanced by an increased risk of hypoglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35559/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Side effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sulfonylureas can be effective when used as monotherapy, or in combination with other oral hypoglycemic drugs or insulin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43577?source=see_link\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28986?source=see_link\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sulfonylureas usually lower blood glucose concentrations by about 20 percent and A1C by 1 to 2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35559/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. They are most likely to be effective in patients whose weight is normal or slightly increased. In contrast, insulin should be used in patients (regardless of age) who are underweight, are losing weight, or are ketotic despite adequate caloric intake. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/55/15225?source=see_link\">",
"     \"General principles of insulin therapy in diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30089?source=see_link\">",
"     \"Insulin therapy in type 2 diabetes mellitus\"",
"    </a>",
"    .) Some of these latter patients may actually have type 1 diabetes, which can be confirmed by the presence of islet cell antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35559/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14874?source=see_link&amp;anchor=H6#H6\">",
"     \"Classification of diabetes mellitus and genetic diabetic syndromes\", section on 'Distinguishing type 1 from type 2 diabetes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The choice of sulfonylurea is primarily dependent upon cost and availability, because their efficacy is similar. However, given the relatively high incidence of hypoglycemia in patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/6/29800?source=see_link\">",
"     glyburide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/0/6151?source=see_link\">",
"     chlorpropamide",
"    </a>",
"    , shorter acting drugs should be used, especially in elderly patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35559/abstract/8\">",
"     8",
"    </a>",
"    ]. In a patient who is not a candidate for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    or who cannot tolerate metformin as initial monotherapy, we suggest a shorter-duration sulfonylurea, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/28/40391?source=see_link\">",
"     glipizide",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43577?source=see_link\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The recommended dose range for most of the available drugs is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef56701 \" href=\"mobipreview.htm?16/49/17180\">",
"     table 1",
"    </a>",
"    ). A typical initial sulfonylurea regimen consists of 2.5 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/28/40391?source=see_link\">",
"     glipizide",
"    </a>",
"    taken 30 minutes before breakfast. If adequate glycemic control is not attained in the next two to four weeks, the dose can be increased to 5 mg and then 10 mg, given before breakfast or before breakfast and the evening meal. The maximum dose of glipizide can be up to 40",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    However, these maximum doses rarely improve glycemic control, and higher doses should generally be avoided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35559/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sulfonylureas are usually well tolerated. Hypoglycemia is the most common side effect and is more common with long-acting sulfonylureas (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/0/6151?source=see_link\">",
"     chlorpropamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/6/29800?source=see_link\">",
"     glyburide",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35559/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. As an example, in a four-year retrospective study of 14,000 patients 65 years or older with type 2 diabetes treated with different sulfonylurea drugs, episodes of serious hypoglycemia were rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35559/abstract/16\">",
"     16",
"    </a>",
"    ]. The incidence was highest in those patients taking glyburide, and lowest among those taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/49/42774?source=see_link\">",
"     tolbutamide",
"    </a>",
"    (19.9 versus 3.5 episodes per 1000 person-years, respectively). Other shorter-acting drugs, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/48/16134?source=see_link\">",
"     tolazamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/28/40391?source=see_link\">",
"     glipizide",
"    </a>",
"    , were also associated with a lower incidence, while the incidence with chlorpropamide was similar to that with glyburide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35559/abstract/8\">",
"     8",
"    </a>",
"    ]. Patients recently discharged from hospital were at the highest risk (4.5 episodes per 100 person-years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35559/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients should be cautioned about those situations in which hypoglycemia is most likely to occur. They are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      After exercise or a missed meal",
"     </li>",
"     <li>",
"      When the drug dose is too high",
"     </li>",
"     <li>",
"      With the use of longer-acting drugs (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/6/29800?source=see_link\">",
"       glyburide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/0/6151?source=see_link\">",
"       chlorpropamide",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      In patients who are undernourished or abuse alcohol",
"     </li>",
"     <li>",
"      In patients with impaired renal or cardiac function or gastrointestinal disease",
"     </li>",
"     <li>",
"      With concurrent therapy with salicylates, sulfonamides, fibric acid derivatives (such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"       gemfibrozil",
"      </a>",
"      ), and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/46/35559/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      After being in the hospital",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prevention and treatment of sulfonylurea-induced hypoglycemia are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/63/27641?source=see_link&amp;anchor=H18#H18\">",
"     \"Management of hypoglycemia during treatment of diabetes mellitus\", section on 'Strategies to prevent hypoglycemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/23/13687?source=see_link&amp;anchor=H6#H6\">",
"     \"Sulfonylurea agent poisoning\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other, infrequent side effects that can occur with all sulfonylureas include nausea, skin reactions (including photosensitivity), and abnormal liver function tests.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/0/6151?source=see_link\">",
"     Chlorpropamide",
"    </a>",
"    has two unique effects: it can cause an unpleasant flushing reaction after alcohol ingestion by inhibiting the metabolism of acetaldehyde [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35559/abstract/18\">",
"     18",
"    </a>",
"    ]; and it can cause hyponatremia, primarily by increasing the action of vasopressin&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35559/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/46/7913?source=see_link\">",
"     \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Association with coronary disease outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies suggest that sulfonylureas may be associated with poorer outcomes after a myocardial infarction. An increased mortality from cardiovascular disease in diabetic patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/49/42774?source=see_link\">",
"     tolbutamide",
"    </a>",
"    was noted over three decades ago in the University Group Diabetes Study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35559/abstract/20\">",
"     20",
"    </a>",
"    ]. While this study was not supported by results from the UKPDS, which reported no increase in fatality for patients taking sulfonylurea therapy at the time of myocardial infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35559/abstract/21\">",
"     21",
"    </a>",
"    ], others have supported the association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35559/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 185 consecutive diabetic patients undergoing percutaneous coronary intervention after myocardial infarction at the Mayo Clinic, the odds ratio for death was 2.77 for patients treated with a sulfonylurea at the time of the myocardial infarction, after correcting for other factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/46/35559/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) trial, the patients with the poorest outcome were those treated with a sulfonylurea at the time of the myocardial infarction and who were not given a glucose-insulin-potassium infusion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/46/35559/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44567?source=see_link\">",
"       \"Glycemic control for acute myocardial infarction in patients with and without diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a retrospective Canadian study using pharmaceutical data for 5795 subjects who received initial monotherapy with either a sulfonylurea or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      , deaths per 1000 person-years during the follow-up period (mean 4.8 years) were 67.6 for first-generation sulfonylurea medications, 61.4 for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/6/29800?source=see_link\">",
"       glyburide",
"      </a>",
"      , and 39.6 for metformin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/46/35559/abstract/25\">",
"       25",
"      </a>",
"      ]. The risk of death or an acute ischemic event was greater for subjects exposed to higher, compared with lower, doses of the sulfonylurea, but not metformin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/46/35559/abstract/25\">",
"       25",
"      </a>",
"      ]. The greatest risk was for subjects taking higher, compared with lower, doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/49/42774?source=see_link\">",
"       tolbutamide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/0/6151?source=see_link\">",
"       chlorpropamide",
"      </a>",
"      (hazard ratio [HR] 2.1, 95% CI 1.0-4.7).",
"     </li>",
"     <li>",
"      In a retrospective cohort study comparing cardiovascular outcomes in 253,690 US veterans who initiated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      or sulfonylurea for diabetes, the risk of a composite cardiovascular outcome (hospitalization for acute myocardial infarction or stroke, or death) was higher in sulfonylurea users (18.2 versus 10.4 per 1000 person-years [HR 1.21, 95% CI 1.13-1.30]) with median follow-up of less than one year [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/46/35559/abstract/26\">",
"       26",
"      </a>",
"      ]. There was no difference in cardiovascular disease risk in patients taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/28/40391?source=see_link\">",
"       glipizide",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/6/29800?source=see_link\">",
"       glyburide",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since ATP-dependent potassium channels are present on cardiac cells and coronary vessels, it is possible that the presence of sulfonylureas at the time of a myocardial infarction prevents adequate coronary vasodilation and thus may result in a larger area of myocardial damage. Other hypotheses for the effect of sulfonylurea medications on cardiovascular events and mortality are interference with ischemic preconditioning, or possible arrhythmogenic effects.",
"   </p>",
"   <p>",
"    Newer sulfonylureas, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/42/34470?source=see_link\">",
"     gliclazide",
"    </a>",
"    , are selective for the pancreatic sulfonylurea receptors over the cardiac receptors and do not appear to be associated with increased cardiovascular mortality compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    or other diabetes medications, although direct controlled clinical trials have not been performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35559/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. In a study of 1310 French patients with diabetes who were hospitalized for myocardial infarction, in-hospital mortality rates were significantly lower in patients previously treated with sulfonylureas compared with other oral medications, insulin, or no medication (3.9, 6.4, 9.4, and 8.4 percent, respectively, odds ratio for patients receiving sulfonylureas before admission compared with no sulfonylureas 0.50, 95% CI 0.27-0.94) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35559/abstract/27\">",
"     27",
"    </a>",
"    ]. Among the SU treated patients, mortality was significantly lower in patients receiving gliclazide or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8823?source=see_link\">",
"     glimepiride",
"    </a>",
"    rather than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/6/29800?source=see_link\">",
"     glyburide",
"    </a>",
"    , which is not selective for the pancreatic sulfonylurea receptors.",
"   </p>",
"   <p>",
"    In addition to these findings, the results of clinical trials, particularly ADVANCE, using newer sulfonylureas (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/42/34470?source=see_link\">",
"     gliclazide",
"    </a>",
"    ) are somewhat reassuring, although they were not specifically designed to address this issue. These trials are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=see_link&amp;anchor=H9#H9\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\", section on 'Macrovascular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MEGLITINIDES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The meglitinides,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/25/4503?source=see_link\">",
"     repaglinide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/21/11606?source=see_link\">",
"     nateglinide",
"    </a>",
"    , are short-acting glucose-lowering drugs for therapy of patients with type 2 diabetes alone or in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    . They are structurally different than sulfonylureas and exert their effects via different receptors, but act similarly by regulating ATP-dependent potassium channels in pancreatic beta cells, thereby increasing insulin secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35559/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical efficacy of meglitinide monotherapy is similar to that of the sulfonylureas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35559/abstract/30-33\">",
"     30-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of 15 trials to assess the efficacy of meglitinides compared with placebo,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , or in combination with insulin reported that both meglitinides reduced A1C values, with a greater reduction in A1C occurring in those receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/25/4503?source=see_link\">",
"     repaglinide",
"    </a>",
"    compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/21/11606?source=see_link\">",
"     nateglinide",
"    </a>",
"    (0.1 to 2.1 versus 0.2 to 0.6 percentage point reduction, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35559/abstract/34\">",
"     34",
"    </a>",
"    ]. Repaglinide had similar efficacy in reducing A1C values as metformin, whereas nateglinide was similar or slightly less effective.",
"   </p>",
"   <p>",
"    The meglitinides can also be given in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , resulting in superior glycemic control than with either agent used as monotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28986?source=see_link&amp;anchor=H8#H8\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\", section on 'Metformin plus meglitinides'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended starting dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/25/4503?source=see_link\">",
"     repaglinide",
"    </a>",
"    is 0.5 mg before each meal for patients who have not previously taken oral hypoglycemic drugs. The maximum dose is 4 mg before each meal; the dose should be skipped if the meal is missed. The recommended dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/21/11606?source=see_link\">",
"     nateglinide",
"    </a>",
"    is 120 mg taken immediately before each meal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35559/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Flexible meal-related dosing with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/25/4503?source=see_link\">",
"     repaglinide",
"    </a>",
"    was investigated in a study of 408 patients with type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35559/abstract/36\">",
"     36",
"    </a>",
"    ]. The patients initially received 0.5 mg at mealtimes, increasing to 1 mg after four weeks depending upon the blood glucose response. At 16 weeks, hemoglobin A1C values decreased significantly in the repaglinide group (1.1 percent) but did not change in the placebo group. The mean fasting plasma glucose concentration also declined significantly in the repaglinide groups as compared with the placebo group (mean difference 25",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.4",
"    <span class=\"nowrap\">",
"     mmol/L]).",
"    </span>",
"    In a second study, repaglinide given before each meal was more effective than the same total dose divided into morning and evening mealtime doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35559/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoglycemia is the most common adverse effect.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/21/11606?source=see_link\">",
"     Nateglinide",
"    </a>",
"    is hepatically metabolized, with renal excretion of active metabolites. With decreased renal function, the accumulation of active metabolites and hypoglycemia has occurred. This drug must therefore be used cautiously in this setting, if at all.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/25/4503?source=see_link\">",
"     Repaglinide",
"    </a>",
"    is principally metabolized by the liver, with less than 10 percent renally excreted. Dose adjustments with this agent do not appear to be necessary in patients with renal insufficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/43/7865?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of hyperglycemia in diabetics with end-stage renal disease\", section on 'Meglitinides'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no long-term studies of meglitinides to assess cardiovascular outcomes or mortality. Whether meglitinides are associated with poorer outcomes after a myocardial infarction is not known. However, since its mode of action is so similar to sulfonylureas, the same concern exists. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Association with coronary disease outcomes'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sulfonylureas are a reasonable first choice of drug for the management of patients with type 2 diabetes who are intolerant of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      and for whom lifestyle alone is not sufficient to achieve blood glucose targets. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Meglitinides are pharmacologically distinct from sulfonylureas and may be used in patients who have an allergy to sulfonylurea medications. They have a similar risk for weight gain as sulfonylureas but possibly less risk of hypoglycemia. Therefore, they may also be useful for the treatment of type 2 diabetes in elderly individuals who are unable to take insulin and in whom the goal of avoiding hypoglycemia is important. However, they are considerably more expensive than sulfonylureas, and have no therapeutic advantage over these other drugs that warrant the added cost. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Meglitinides'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The only advantage of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/25/4503?source=see_link\">",
"       repaglinide",
"      </a>",
"      over sulfonylureas is the ability to use it safely in patients with decreased glomerular filtration rate or renal failure without concern for hypoglycemia, since it has little renal clearance.",
"     </li>",
"     <li>",
"      Both sulfonylureas and meglitinides can be used in combination with other oral agents or insulin.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/1\">",
"      Bressler R, Johnson DG. Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus. Arch Intern Med 1997; 157:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/2\">",
"      Aguilar-Bryan L, Nichols CG, Wechsler SW, et al. Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science 1995; 268:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/3\">",
"      Gloyn AL, Pearson ER, Antcliff JF, et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004; 350:1838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/4\">",
"      Babenko AP, Polak M, Cav&eacute; H, et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 2006; 355:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/5\">",
"      Pearson ER, Flechtner I, Nj&oslash;lstad PR, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006; 355:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/6\">",
"      J&ouml;nsson A, Rydberg T, Ekberg G, et al. Slow elimination of glyburide in NIDDM subjects. Diabetes Care 1994; 17:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/7\">",
"      Rydberg T, J&ouml;nsson A, R&oslash;der M, Melander A. Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans. Diabetes Care 1994; 17:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/8\">",
"      Shorr RI, Ray WA, Daugherty JR, Griffin MR. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc 1996; 44:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/9\">",
"      Hermann LS, Scherst&eacute;n B, Bitz&eacute;n PO, et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994; 17:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/10\">",
"      Irvine WJ, Sawers JS, Feek CM, et al. The value of islet cell antibody in predicting secondary failure of oral hypoglycaemic agent therapy in Diabetes mellitus. J Clin Lab Immunol 1979; 2:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/11\">",
"      Kobayashi T, Itoh T, Kosaka K, et al. Time course of islet cell antibodies and beta-cell function in non-insulin-dependent stage of type I diabetes. Diabetes 1987; 36:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/12\">",
"      Stenman S, Melander A, Groop PH, Groop LC. What is the benefit of increasing the sulfonylurea dose? Ann Intern Med 1993; 118:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/13\">",
"      Tessier D, Dawson K, T&eacute;trault JP, et al. Glibenclamide vs gliclazide in type 2 diabetes of the elderly. Diabet Med 1994; 11:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/14\">",
"      Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001; 17:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/15\">",
"      Gangji AS, Cukierman T, Gerstein HC, et al. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007; 30:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/16\">",
"      Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997; 157:1681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/17\">",
"      Bressler, P, DeFronzo, RA. Drugs and diabetes. Diabetes Reviews 1994; 2:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/18\">",
"      Groop L, Eriksson CJ, Huupponen R, et al. Roles of chlorpropamide, alcohol and acetaldehyde in determining the chlorpropamide-alcohol flush. Diabetologia 1984; 26:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/19\">",
"      Kadowaki T, Hagura R, Kajinuma H, et al. Chlorpropamide-induced hyponatremia: incidence and risk factors. Diabetes Care 1983; 6:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/20\">",
"      A study of the effects of hypoglycemia agents on vascular complications in patients with adult-onset diabetes. VI. Supplementary report on nonfatal events in patients treated with tolbutamide. Diabetes 1976; 25:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/21\">",
"      Stevens RJ, Coleman RL, Adler AI, et al. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diabetes Care 2004; 27:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/22\">",
"      Rytter L, Troelsen S, Beck-Nielsen H. Prevalence and mortality of acute myocardial infarction in patients with diabetes. Diabetes Care 1985; 8:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/23\">",
"      Garratt KN, Brady PA, Hassinger NL, et al. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999; 33:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/24\">",
"      Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997; 314:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/25\">",
"      Simpson SH, Majumdar SR, Tsuyuki RT, et al. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 2006; 174:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/26\">",
"      Roumie CL, Hung AM, Greevy RA, et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med 2012; 157:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/27\">",
"      Zeller M, Danchin N, Simon D, et al. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab 2010; 95:4993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/28\">",
"      Schramm TK, Gislason GH, Vaag A, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011; 32:1900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/29\">",
"      Fuhlendorff J, Rorsman P, Kofod H, et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998; 47:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/30\">",
"      Wolffenbuttel BH, Landgraf R. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group. Diabetes Care 1999; 22:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/31\">",
"      Repaglinide for type 2 diabetes mellitus. Med Lett Drugs Ther 1998; 40:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/32\">",
"      Moses R, Slobodniuk R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999; 22:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/33\">",
"      Hollander PA, Schwartz SL, Gatlin MR, et al. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 2001; 24:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/34\">",
"      Black C, Donnelly P, McIntyre L, et al. Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007; :CD004654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/35\">",
"      Gribble FM, Manley SE, Levy JC. Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166). Diabetes Care 2001; 24:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/36\">",
"      Moses RG, Gomis R, Frandsen KB, et al. Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes. Diabetes Care 2001; 24:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35559/abstract/37\">",
"      Schmitz O, Lund S, Andersen PH, et al. Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide. Diabetes Care 2002; 25:342.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1786 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-210.101.131.232-B327878308-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_46_35559=[""].join("\n");
var outline_f34_46_35559=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SULFONYLUREAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Association with coronary disease outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MEGLITINIDES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1786\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1786|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/49/17180\" title=\"table 1\">",
"      Sulfonylureas",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3078?source=related_link\">",
"      Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14874?source=related_link\">",
"      Classification of diabetes mellitus and genetic diabetic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/55/15225?source=related_link\">",
"      General principles of insulin therapy in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=related_link\">",
"      Glycemic control and vascular complications in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44567?source=related_link\">",
"      Glycemic control for acute myocardial infarction in patients with and without diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43577?source=related_link\">",
"      Initial management of blood glucose in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30089?source=related_link\">",
"      Insulin therapy in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/43/7865?source=related_link\">",
"      Management of hyperglycemia in diabetics with end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/63/27641?source=related_link\">",
"      Management of hypoglycemia during treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28986?source=related_link\">",
"      Management of persistent hyperglycemia in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/26/38312?source=related_link\">",
"      Metformin in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37816?source=related_link\">",
"      Neonatal hyperglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/49/3866?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of persistent hyperinsulinemic hypoglycemia of infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/46/7913?source=related_link\">",
"      Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/23/13687?source=related_link\">",
"      Sulfonylurea agent poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21290?source=related_link\">",
"      Thiazolidinediones in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_46_35560="Ultrasound diagnosis of neural tube defects";
var content_f34_46_35560=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ultrasound diagnosis of neural tube defects",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/46/35560/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/46/35560/contributors\">",
"     Ana Monteagudo, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/46/35560/contributors\">",
"     Ilan E Timor-Tritsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/46/35560/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/46/35560/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/46/35560/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/46/35560/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/46/35560/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/46/35560/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central nervous system (CNS) malformations are the second most frequent category of congenital anomaly, after congenital heart disease. Ultrasound examination is an effective modality for the prenatal diagnosis of these anomalies. An accurate fetal diagnosis depends upon a precise description of the sonographic appearance of the CNS and careful evaluation for associated malformations, which are often present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A thorough understanding of the normal sonographic appearance of the CNS at different gestational ages is crucial for accurate diagnosis because the presence or absence of a structure may be deemed normal or abnormal depending upon the age of the fetus.",
"   </p>",
"   <p>",
"    As an example, a sonogram of the fetal brain at 14 weeks of gestation cannot detect agenesis of the corpus callosum since this structure does not become sonographically apparent until 18 to 20 weeks of gestation and does not acquire its final form until 28 to 30 weeks. In another example, a population-based study of 55,226 pregnancies reported 143 infants with CNS defects, 85 of whom had a prenatal sonogram at 16 to 20 weeks of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/2\">",
"     2",
"    </a>",
"    ]. The diagnosis of CNS abnormality was made prenatally in 64 (75 percent), not made in 17 (20 percent), and was questionable in 4 (5 percent). Poor timing of the examination, rather than poor sensitivity, was the most important factor in failing to detect a CNS defect.",
"   </p>",
"   <p>",
"    Three-dimensional (3D) ultrasound plays an important role in the evaluation of brain anomalies since it has the potential for further characterization of these defects. Multiplanar imaging of the brain, as well as use of a variety of display modalities, such as tomographic imaging, inversion, maximum-mode, surface rendering, and volume scanning, allows the sonologist to obtain planes and sections not possible with conventional two-dimensional (2D) sonography. The pediatric neurologist or neurosurgeon can use this additional information when counseling parents about prognosis and clinical management options.",
"   </p>",
"   <p>",
"    Fast magnetic resonance imaging (MRI) can also be used to image the fetus. However, we feel that ultrasonography continues to be the modality of choice in the evaluation of a fetus at risk for a neural tube defect (NTD), given its high detection rates (see below). Prenatal screening and diagnosis of NTDs is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/35/25145?source=see_link\">",
"     \"Prenatal screening and diagnosis of neural tube defects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Genetic amniocentesis should be offered when NTDs are identified, as there is a 5 to 7 percent rate of aneuploidy in these fetuses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. The incidence of chromosomal abnormalities is as high as 20 percent in fetuses with major CNS abnormalities plus other congenital anomalies; however, the incidence falls to about 1 to 2 percent when NTDs are isolated.",
"   </p>",
"   <p>",
"    The sonographic diagnosis of neural tube defects (NTDs) will be reviewed here. Isolated fetal ventriculomegaly and other CNS lesions are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/39/12920?source=see_link\">",
"     \"Fetal ventriculomegaly\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/44/2762?source=see_link\">",
"     \"Prenatal diagnosis of CNS anomalies other than neural tube defects and ventriculomegaly\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EXENCEPHALY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exencephaly refers to absence of the entire or a significant portion of the cranium, but brain tissue is present. It appears to be the embryologic predecessor of anencephaly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/7-13\">",
"     7-13",
"    </a>",
"    ]. In-utero diagnosis requires careful examination of both the fetal cranium and brain.",
"   </p>",
"   <p>",
"    The integrity of the fetal cranium can be assessed with transvaginal sonography (TVS) from the first trimester since ossification of cranial bone has begun [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The first trimester exencephalic fetus has an abnormal head shape with sonolucent spaces within disintegrating brain. The outer shape of the head is bilobed; this appearance has been called \"Mickey Mouse\" head (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72765 \" href=\"mobipreview.htm?4/35/4658\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Exencephaly has been detected as early as the 10th postmenstrual week.",
"   </p>",
"   <p>",
"    In the second trimester, the usual appearance of the brain is lost. It is heterogeneous (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61919 \" href=\"mobipreview.htm?22/24/22914\">",
"     image 2",
"    </a>",
"    ) and is not covered by the cranium. The fetal facial bones, however, can be clearly visualized.",
"   </p>",
"   <p>",
"    Maternal serum alpha-fetoprotein levels are highly elevated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANENCEPHALY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anencephaly is the most common NTD, occurring in approximately 1 per 1000 births prior to the era of routine prenatal screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. More recently, anencephaly has been reported in only 1 in 10,000 births in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/21\">",
"     21",
"    </a>",
"    ]. It is characterized by absence of the brain and lack of the cranial vault due to failure of the rostral neuropore to close during the 24th to 26th day post conception (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71153 graphicRef50131 \" href=\"mobipreview.htm?19/13/19671\">",
"     image 3A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11237?source=see_link\">",
"     \"Anencephaly\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The anencephalic fetus can be definitively identified by the 12th postmenstrual week by TVS, although in some cases this diagnosis has been made at 9 to 10 postmenstrual weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/22\">",
"     22",
"    </a>",
"    ]. Dystrophic brain tissue may be observed early in pregnancy, but disappears later in gestation. The fetal face from the orbits to the chin is usually normal, but there is no skull above the orbits anteriorly and above the cervical spine posteriorly. Polyhydramnios develops in up to 50 percent of the cases during the second and third trimester due to decreased fetal swallowing, but is not present during the first trimester [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/8,23-25\">",
"     8,23-25",
"    </a>",
"    ]. Craniorachischisis (congenital incomplete closure of the skull and spine) is observed in less than 10 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/25\">",
"     25",
"    </a>",
"    ]. Fetal activity is not significantly impaired.",
"   </p>",
"   <p>",
"    A relatively early and indirect sonographic sign of",
"    <span class=\"nowrap\">",
"     anencephaly/exencephaly",
"    </span>",
"    sequence is a significant amount of low-level-echogenic, particulate matter containing amniotic fluid. This results from the \"rubbing off\" of the exposed neural tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/26\">",
"     26",
"    </a>",
"    ]. Measurement of the crown-chin length and the ratio of the crown-chin to crown-rump length (CRL) at 10 to 14 postmenstrual weeks is also useful in the early recognition of anencephaly (",
"    <a class=\"graphic graphic_table graphicRef54289 \" href=\"mobipreview.htm?27/0/27661\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Up to 75 percent of anencephalic fetuses are stillborn with the remainder dying shortly after birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Preterm labor and delivery may occur due to uterine over distention from polyhydramnios or the pregnancy may extend postterm because absence of fetal brain precludes normal pathways in the fetus' initiation of labor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/30\">",
"     30",
"    </a>",
"    ]. Delivery is usually induced given the uniformly lethal prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Management of twins where one twin is anencephalic is more complicated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/46/40682?source=see_link&amp;anchor=H16#H16\">",
"     \"Twin pregnancy: Prenatal issues\", section on 'Selective fetal termination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Maternal serum alpha-fetoprotein levels are highly elevated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/35/25145?source=see_link\">",
"     \"Prenatal screening and diagnosis of neural tube defects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CEPHALOCELE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cephaloceles (eg, encephalocele) are usually, but not exclusively, midline cranial defects through which the brain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    meninges have herniated outside of the skull (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77074 graphicRef56949 \" href=\"mobipreview.htm?33/25/34200\">",
"     image 4A-B",
"    </a>",
"    ). The occipital, frontal, parietal, orbital, nasal, or nasopharyngeal region of the head can be involved, but most occur posteriorly. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/57/3991?source=see_link\">",
"     \"Primary (congenital) encephalocele\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The typical sonographic appearance of cephalocele is a defect of the bony skull with a protruding sac-like structure. The sac may be sonolucent and contain cerebrospinal fluid (meningocele) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55804 \" href=\"mobipreview.htm?42/31/43504\">",
"     image 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/33\">",
"     33",
"    </a>",
"    ], brain tissue (encephalocele), or a combination of both [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/34-36\">",
"     34-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Very early in the pregnancy, ultrasound may provide more information about the CNS than MRI, but MRI is better than ultrasound for evaluating the brain parenchyma in the late second and third trimesters and in situations in which the intracranial component of the malformation is not clear. For example, MRI is better at visualizing some brain malformations, such as migrational anomalies, which are not seen well on ultrasound.",
"   </p>",
"   <p>",
"    Posterior cephalocele has been diagnosed as early as 12 postmenstrual weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/37\">",
"     37",
"    </a>",
"    ], but early diagnosis is usually made from 13 to 14 postmenstrual weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cephalocele usually occurs as an isolated lesion, but may be a part of a syndrome such as Meckel (or Meckel-Gruber) or Walker-Warburg syndrome in a small percentage of cases. Both syndromes are autosomal recessive. Cephaloceles also can occur in association with aneuploidy; therefore, fetal karyotype should be offered.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The classical triad of Meckel syndrome is occipital cephalocele (present in 80 percent), bilateral polycystic kidneys, and post-axial polydactyly [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]. Prenatal diagnosis of Meckel-Gruber syndrome has been made in the first and early second trimesters [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/39-45\">",
"       39-45",
"      </a>",
"      ]. These abnormalities may be difficult to visualize since renal dysfunction results in severe oligohydramnios.",
"     </li>",
"     <li>",
"      Walker-Warburg syndrome is characterized by lissencephaly, cerebellar hypoplasia, Dandy-Walker cyst, and ocular abnormalities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/46,47\">",
"       46,47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cephalocele can also be due to amniotic band syndrome, in which case they can involve any part of the skull.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Maternal serum alpha-fetoprotein levels are usually highly elevated; exceptions occur when the defect is covered by scalp. There is an increased risk of chromosomal abnormalities with NTDs so determining the fetal karyotype should be offered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/35/25145?source=see_link\">",
"     \"Prenatal screening and diagnosis of neural tube defects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INIENCEPHALY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iniencephaly is a rare, lethal developmental anomaly with three major features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/48-54\">",
"     48-54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A defect in the occiput involving the foramen magnum",
"     </li>",
"     <li>",
"      Retroflexion of the entire spine, which forces the fetus to look upwards with its occiput directed towards the lumbar region",
"     </li>",
"     <li>",
"      Open spinal defects of variable degrees present in up to 50 percent of the cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This is technically not an NTD, but many textbooks list it in the CNS section.",
"   </p>",
"   <p>",
"    The malformation results from developmental arrest of the embryo during the third postmenstrual week This results in persistence of embryonic cervical retroflexion and leads to failure of the neural groove to close in the area of the cervical spine or upper thorax [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/48,54,56\">",
"     48,54,56",
"    </a>",
"    ]. Associated malformations occur in up to 84 percent of cases and include hydrocephaly, microcephaly, ventricular atresia, holoprosencephaly, polymicrogyria, agenesis of the cerebellar vermis, occipital encephalocele, diaphragmatic hernia, thoracic cage deformities, urinary tract anomalies, cleft lip and palate, omphalocele, and polyhydramnios [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/48,50,51,57,58\">",
"     48,50,51,57,58",
"    </a>",
"    ]. The sonographic diagnosis has been made as early as 12.5 to 13 postmenstrual weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/35,49\">",
"     35,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SPINAL DYSRAPHISM AND THE ARNOLD-CHIARI MALFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal dysraphism or spina bifida refers to protrusion of the spinal contents through a bony defect in the spine (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78078 graphicRef58063 graphicRef68832 graphicRef77490 \" href=\"mobipreview.htm?34/15/35066\">",
"     image 6A-D",
"    </a>",
"    ). The abnormality probably results from maldevelopment at the fourth week of gestation: the bony sheath surrounding the spinal cord does not form properly due to failure of the posterior vertebral arches to close. Associated brain abnormalities include hydrocephaly, relative microcephaly, agenesis of the corpus callosum, and diastematomyelia. Non-CNS anomalies consist of congenital scoliosis or kyphosis and hip deformities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. There is a high prevalence of karyotypic abnormalities among fetuses with NTDs, especially in the presence of other congenital anomalies so karyotyping should be offered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33767?source=see_link\">",
"     \"Pathophysiology and clinical manifestations of myelomeningocele (spina bifida)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Myelocele and myelomeningocele are two types of spinal dysraphism that develop similarly. Myelocele is a midline plaque of neural tissue (neural placode) that is flush with the fetal surface and not covered by skin. In contrast, myelomeningocele refers to a bulging defect in which the elevated neural plate and meninges are contiguous laterally with the subcutaneous tissue (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67038 \" href=\"mobipreview.htm?26/22/26976\">",
"     image 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Ten to 15 percent of spinal dysraphic defects are closed by normal skin covering the bony defect. The remainder are open and most are detectable by maternal serum alpha-fetoprotein screening. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/35/25145?source=see_link\">",
"     \"Prenatal screening and diagnosis of neural tube defects\"",
"    </a>",
"    .) Approximately 80 percent of lesions occur in the lumbar, thoracolumbar, or lumbosacral areas of the spine, with the remainder in the cervical and sacral areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnostic sensitivity of prenatal sonography for detection of myelomeningocele in a high risk population is about 97 to 98 percent with 100 percent specificity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. Determining the site and extent of the spinal lesion is important because these features correlate with neurologic outcome; more severe neurologic dysfunction is associated with higher and larger lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Sonographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sonographic diagnosis of open spina bifida typically occurs during the second trimester of the pregnancy.",
"   </p>",
"   <p>",
"    The normal fetal spine has three ossification centers within the fetal vertebrae. The centers of the neural arches are parallel, with gradual widening toward the fetal head and tapering at the sacrum. Spina bifida appears as widening of the ossification centers in the coronal plane and as a divergence of the ossification centers in the transverse plane (U-shaped vertebrae). In addition, a cystic sac may be visualized if the fetus has a myelomeningocele.",
"   </p>",
"   <p>",
"    In the second trimester, well-established sonographic findings of the fetal head (eg, lemon sign, banana sign [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/65,66\">",
"     65,66",
"    </a>",
"    ], and hydrocephaly) facilitate detection (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81929 graphicRef64380 \" href=\"mobipreview.htm?31/57/32664\">",
"     image 8A-B",
"    </a>",
"    ). A detailed scan of the spine in the sagittal and transverse planes is indicated if these cranial findings have been observed. The sagittal view shows irregularities of the bony spine, a bulging within the posterior contour of the fetal back, or obvious disruption of the fetal skin contours. Transverse sections reveal open vertebrae with a U-shape. The coronal section of the affected bony segment shows a divergent configuration replacing the normal parallel lines of the normal vertebral arches. The presence of both indirect cranial findings (small posterior fossa, enlarged foramen magnum, downward herniation of cerebellar tonsils and vermis) and a spinal defect is termed the Arnold-Chiari type ll malformation.",
"   </p>",
"   <p>",
"    The banana and lemon signs are generally not present in the first trimester, but may become apparent early in the second trimester. As an example, one fetus who was serially scanned from 10 weeks of gestation had a normal cerebellum initially, mild convexity of the cerebellum by 12 postmenstrual weeks, and typical banana and lemon signs by 14 postmenstrual weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/67\">",
"     67",
"    </a>",
"    ]. Although cases of lumbosacral spina bifida with an associated lemon sign have been reported at 12 to 14 weeks gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/68,69\">",
"     68,69",
"    </a>",
"    ], these findings may be subtle or absent in the first trimester, thus a follow-up scan later in the second trimester is indicated when spina bifida is suspected.",
"   </p>",
"   <p>",
"    The lemon sign is present in up to 98 percent of cases at less or equal to 24 postmenstrual weeks, but after 24 weeks of gestation it is only seen in 13 percent of the cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cerebellar abnormalities are present in most cases throughout the pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/59,70-72\">",
"     59,70-72",
"    </a>",
"    ]. At less than 24 weeks, the commonly seen abnormality is the banana sign present in as many as 72 percent of the cases, however, after the 24th week, inability to image the cerebellum or \"cerebellar absence\" is the more common finding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Arnold-Chiari type ll malformation is present in almost every case of thoracolumbar, lumbar, and lumbosacral myelomeningocele. The hydrocephaly probably results from a hindbrain malformation that blocks flow of cerebrospinal fluid through the fourth ventricle or posterior fossa, or from aqueductal stenosis, which is present in 40 to 75 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spina bifida can be detected before 12 weeks of gestation by noting irregularities of the bony spine or a bulging within the posterior contour of the fetal back (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66541 \" href=\"mobipreview.htm?10/46/10978\">",
"     image 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. Absence of visualization of the intracranial translucency (IT) has also been described as an early sign of open spina bifida [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. In the normal fetus, the IT is a fluid-filled area (the fourth ventricle) in the normal posterior brain in the mid-sagittal plane at the time of the nuchal translucency study at 11 to 13 weeks of gestation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75261 \" href=\"mobipreview.htm?3/31/3574\">",
"     image 10",
"    </a>",
"    ). Retrospective studies have shown that a normal IT has a high specificity for ruling out open spina bifida. In one study, the IT was seen in 79 percent of the images reviewed by two observers, with sensitivity for detecting spina bifida of 50 percent and specificity of 99 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/78\">",
"     78",
"    </a>",
"    ]. Prospective data are scant at this time, but are promising. Large prospective studies are still necessary to ascertain the real value of this new sign [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are scant data regarding prognostically useful sonographic features of fetuses with NTDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/80-83\">",
"     80-83",
"    </a>",
"    ]. The most important predictor of functional neurological outcome in spina bifida appears to be the level of the lesion, which can be approximated prenatally. Combined data from two series (n = 28 and 33 cases) showed that prenatal sonographic and postnatal assessment were concordant within one vertebral segment in 79 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/80\">",
"     80",
"    </a>",
"    ], within two vertebral segments in 92 percent of patients, and within three vertebral segments in 100 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/81\">",
"     81",
"    </a>",
"    ]. The latter study also found that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lesion level was most predictive of ambulatory function. All infants with thoracic lesions or myeloschisis were nonambulatory upon assessment at age 1 to 5 years.",
"     </li>",
"     <li>",
"      Sonography was not useful for predicting future need for shunt placement, but almost all of the subjects eventually required this procedure.",
"     </li>",
"     <li>",
"      Lesion type was correctly identified sonographically in all cases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This study did not evaluate postnatal urologic and bowel function, and mental capacity, which are other important functional outcomes.",
"   </p>",
"   <p>",
"    Others have reported that prenatal sonographic lesion level predicted postnatal neuromuscular function &lsquo;equal to or better than that expected&rsquo; in 10 of 11 patients (91 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/70\">",
"     70",
"    </a>",
"    ] or &lsquo;equal to that expected&rsquo; in 12 of 15 patients (80 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/82\">",
"     82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26344?source=see_link\">",
"     \"Overview of the management of myelomeningocele (spina bifida)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33767?source=see_link\">",
"     \"Pathophysiology and clinical manifestations of myelomeningocele (spina bifida)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The outcome of prenatally diagnosed myelomeningocele has also been correlated with findings on magnetic resonance imaging. A review of 36 pregnancies complicated by fetal myelomeningocele, referred for fetal MRI at mean gestational age 27 &plusmn; 6 weeks, and followed postnatally at a spina bifida treatment center reported the following findings at follow-up at 2.4 to 5.1 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/84\">",
"     84",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Higher lesion levels were associated with dysphagia: T-L2 (50 percent), L3-4 (45 percent), L5-S (13 percent).",
"     </li>",
"     <li>",
"      The absence of covering membrane was associated with scoliosis (36 versus 0 percent with membrane present) and with high-risk bladder dysfunction (71 versus 36 percent).",
"     </li>",
"     <li>",
"      Higher lesion level, larger segment span, and interpediculate distance greater than 10 mm were associated with full-time wheelchair use.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     FETAL ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetuses with neural tube defects or central nervous system abnormalities typically remain active; however, the quality of fetal movement is often different from that in normal fetuses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/85-89\">",
"     85-89",
"    </a>",
"    ]. In addition, these fetuses may not respond to vibroacoustic stimulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35560/abstract/90,91\">",
"     90,91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33807716\">",
"    <span class=\"h1\">",
"     MANAGEMENT AND OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management an outcome of affected pregnancies are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/35/25145?source=see_link\">",
"       \"Prenatal screening and diagnosis of neural tube defects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26344?source=see_link\">",
"       \"Overview of the management of myelomeningocele (spina bifida)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11237?source=see_link\">",
"       \"Anencephaly\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/57/3991?source=see_link\">",
"       \"Primary (congenital) encephalocele\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Central nervous system (CNS) malformations are the second most frequent category of congenital anomaly, after congenital heart disease. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anencephaly is a lethal abnormality in which the brain is absent, the fetal face from the orbits to the chin is usually normal, and there is no skull above the orbits anteriorly and above the cervical spine posteriorly. Delivery is usually induced given the uniformly lethal prognosis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Anencephaly'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cephaloceles (eg, encephalocele) are cranial defects through which the brain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      meninges have herniated outside of the skull. Cephalocele usually occurs as an isolated lesion, but may be a part of a syndrome such as Meckel (or Meckel-Gruber) syndrome or Walker-Warburg syndrome or due to amniotic bands. Three-dimensional (3D) ultrasound examination may aid in diagnosis. Karyotyping should be offered, given the high risk of aneuploidy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Cephalocele'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Spinal dysraphism or spina bifida refers to protrusion of the spinal contents through a bony defect in the spine. Hydrocephalus is usually present, as well. Three-dimensional (3D) ultrasound examination may aid in diagnosis. Karyotyping should be offered, given the high risk of aneuploidy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Spinal dysraphism and the Arnold-Chiari malformation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/1\">",
"      Stevenson RE, Seaver LH, Collins JS, Dean JH. Neural tube defects and associated anomalies in South Carolina. Birth Defects Res A Clin Mol Teratol 2004; 70:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/2\">",
"      Kohlenberg, C, Lumley, J, Yates, J, Bell, R. A prospective population-based study of CNS abnormality detection at 16 to 20 weeks by ultrasonography. J Ultrasound Med 1996; 15:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/3\">",
"      Goetzinger KR, Stamilio DM, Dicke JM, et al. Evaluating the incidence and likelihood ratios for chromosomal abnormalities in fetuses with common central nervous system malformations. Am J Obstet Gynecol 2008; 199:285.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/4\">",
"      Sepulveda W, Corral E, Ayala C, et al. Chromosomal abnormalities in fetuses with open neural tube defects: prenatal identification with ultrasound. Ultrasound Obstet Gynecol 2004; 23:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/5\">",
"      Botto LD, Moore CA, Khoury MJ, Erickson JD. Neural-tube defects. N Engl J Med 1999; 341:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/6\">",
"      Shaer CM, Chescheir N, Schulkin J. Myelomeningocele: a review of the epidemiology, genetics, risk factors for conception, prenatal diagnosis, and prognosis for affected individuals. Obstet Gynecol Surv 2007; 62:471.",
"     </a>",
"    </li>",
"    <li>",
"     O'Rahilly, R, Muller, F. Human embryology &amp; teratology. New York: Wiley-Liss Inc., 1992; 253.",
"    </li>",
"    <li>",
"     Moore, K. The nervous system. In: Moore K, Ed. The developing human. Clinically oriented embryology. Philadelphia: WB Saunders Company, 1988:364.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/9\">",
"      Vergani P, Ghidini A, Sirtori M, Roncaglia N. Antenatal diagnosis of fetal acrania. J Ultrasound Med 1987; 6:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/10\">",
"      Bronshtein M, Ornoy A. Acrania: anencephaly resulting from secondary degeneration of a closed neural tube: two cases in the same family. J Clin Ultrasound 1991; 19:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/11\">",
"      Cox GG, Rosenthal SJ, Holsapple JW. Exencephaly: sonographic findings and radiologic-pathologic correlation. Radiology 1985; 155:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/12\">",
"      Ganchrow D, Ornoy A. Possible evidence for secondary degeneration of central nervous system in the pathogenesis of anencephaly and brain dysraphia. A study in young human fetuses. Virchows Arch A Pathol Anat Histol 1979; 384:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/13\">",
"      Padmanablian, R. Is exencephaly the forerunner of anencephaly? An experimental study on the effect of prolonged gestation on the exencephaly induced after neural tube closure in the rat. Acta Anat 1991; 141:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/14\">",
"      Inman VT, de C M Saunders JB. The Ossification of the Human Frontal Bone: With Special Reference to its Presumed Pre- and Post-Frontal Elements. J Anat 1937; 71:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/15\">",
"      Kennedy KA, Flick KJ, Thurmond AS. First-trimester diagnosis of exencephaly. Am J Obstet Gynecol 1990; 162:461.",
"     </a>",
"    </li>",
"    <li>",
"     Monteagudo, A, Timor-Tritsch, I. Fetal Neurosonography of congenital brain anomalies. In: Ultrasonography of the prenatal and neonatal brain, Timor-Tritsch, IE, Monteagudo, A, Cohen, H (Eds), McGraw Hill, New York 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/17\">",
"      Nishi T, Nakano R. First-trimester diagnosis of exencephaly by transvaginal ultrasonography. J Ultrasound Med 1994; 13:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/18\">",
"      Chatzipapas IK, Whitlow BJ, Economides DL. The 'Mickey Mouse' sign and the diagnosis of anencephaly in early pregnancy. Ultrasound Obstet Gynecol 1999; 13:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/19\">",
"      Limb CJ, Holmes LB. Anencephaly: changes in prenatal detection and birth status, 1972 through 1990. Am J Obstet Gynecol 1994; 170:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/20\">",
"      Cunningham ME, Walls WJ. Ultrasound in the evaluation of anencephaly. Radiology 1976; 118:165.",
"     </a>",
"    </li>",
"    <li>",
"     Martin, JA, Hamilton, BE, Ventura SJ, et al. Births: Final data for 2009. Natl Vital Stat Rep 2009. file://www.cdc.gov/nchs/data/nvsr/nvsr60/nvsr60_01.pdf (Accessed on November 29, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/22\">",
"      Johnson SP, Sebire NJ, Snijders RJ, et al. Ultrasound screening for anencephaly at 10-14 weeks of gestation. Ultrasound Obstet Gynecol 1997; 9:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/23\">",
"      Johnson A, Losure TA, Weiner S. Early diagnosis of fetal anencephaly. J Clin Ultrasound 1985; 13:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/24\">",
"      Pretorius DH, Russ PD, Rumack CM, Manco-Johnson ML. Diagnosis of brain neuropathology in utero. Neuroradiology 1986; 28:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/25\">",
"      Salamanca A, Gonzalez-Gomez F, Padilla MC, et al. Prenatal ultrasound semiography of anencephaly: sonographic-pathological correlations. Ultrasound Obstet Gynecol 1992; 2:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/26\">",
"      Timor-Tritsch IE, Greenebaum E, Monteagudo A, Baxi L. Exencephaly-anencephaly sequence: proof by ultrasound imaging and amniotic fluid cytology. J Matern Fetal Med 1996; 5:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/27\">",
"      Sepulveda W, Sebire NJ, Fung TY, et al. Crown-chin length in normal and anencephalic fetuses at 10 to 14 weeks' gestation. Am J Obstet Gynecol 1997; 176:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/28\">",
"      Obeidi N, Russell N, Higgins JR, O'Donoghue K. The natural history of anencephaly. Prenat Diagn 2010; 30:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/29\">",
"      Jaquier M, Klein A, Boltshauser E. Spontaneous pregnancy outcome after prenatal diagnosis of anencephaly. BJOG 2006; 113:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/30\">",
"      Milic AB, Adamsons K. The relationship between anencephaly and prolonged pregnancy. J Obstet Gynaecol Br Commonw 1969; 76:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/31\">",
"      Osathanondh R, Donnenfeld AE, Frigoletto FD Jr, et al. Induction of labor with anencephalic fetus. Obstet Gynecol 1980; 56:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/32\">",
"      Thiery M, Parewijck W, Decoster JM. Prostaglandins for the management of anencephalic pregnancy. Prostaglandins 1981; 21:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/33\">",
"      Timor-Tritsch IE, Monteagudo A, Santos R. Fine-tuning the diagnosis of fetal scalp cysts: the value of high-frequency sonography. J Ultrasound Med 2008; 27:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/34\">",
"      Hidalgo H, Bowie J, Rosenberg ER, et al. Review. In utero sonographic diagnosis of fetal cerebral anomalies. AJR Am J Roentgenol 1982; 139:143.",
"     </a>",
"    </li>",
"    <li>",
"     Nyberg, D, Pretorius, D. Cerebral malformations. In: DA N, Mahoney B, Pretorius D, Eds. Diagnostic ultrasound of fetal anomalies text and atlas. Chicago: Littleton: year Book Medical Publishers, 1990:83.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/36\">",
"      Fiske CE, Filly RA. Ultrasound evaluation of the normal and abnormal fetal neural axis. Radiol Clin North Am 1982; 20:285.",
"     </a>",
"    </li>",
"    <li>",
"     Bronshtein, M, Timor-Tritsch, I, Rottern S. Early detection of fetal anomalies. In: Timor-Tritsch 1, Rottem S, and Eds. Transvaginal Sonography. New York: Chapman &amp; Hall, 1991:327.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/38\">",
"      Naidich TP, Altman NR, Braffman BH, et al. Cephaloceles and related malformations. AJNR Am J Neuroradiol 1992; 13:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/39\">",
"      Nyberg DA, Hallesy D, Mahony BS, et al. Meckel-Gruber syndrome. Importance of prenatal diagnosis. J Ultrasound Med 1990; 9:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/40\">",
"      Braithwaite JM, Economides DL. First-trimester diagnosis of Meckel-Gruber syndrome by transabdominal sonography in a low-risk case. Prenat Diagn 1995; 15:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/41\">",
"      Dumez Y, Dommergues M, Gubler MC, et al. Meckel-Gruber syndrome: prenatal diagnosis at 10 menstrual weeks using embryoscopy. Prenat Diagn 1994; 14:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/42\">",
"      Pach&igrave; A, Giancotti A, Torcia F, et al. Meckel-Gruber syndrome: ultrasonographic diagnosis at 13 weeks' gestational age in an at-risk case. Prenat Diagn 1989; 9:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/43\">",
"      Sepulveda W, Sebire NJ, Souka A, et al. Diagnosis of the Meckel-Gruber syndrome at eleven to fourteen weeks' gestation. Am J Obstet Gynecol 1997; 176:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/44\">",
"      van Zalen-Sprock RM, van Vugt JM, van Geijn HP. First-trimester sonographic detection of neurodevelopmental abnormalities in some single-gene disorders. Prenat Diagn 1996; 16:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/45\">",
"      Ickowicz V, Eurin D, Maugey-Laulom B, et al. Meckel-Gr&uuml;ber syndrome: sonography and pathology. Ultrasound Obstet Gynecol 2006; 27:296.",
"     </a>",
"    </li>",
"    <li>",
"     Jones, KL. Walker-Warburg syndrome. In: Smith's Recognizable patterns of Human Malformation, 6th ed, Elsevier Saunders, Philadelphia 2006. p. 206.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/47\">",
"      Monteagudo A, Alay&oacute;n A, Mayberry P. Walker-Warburg syndrome: case report and review of the literature. J Ultrasound Med 2001; 20:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/48\">",
"      Foderaro AE, Abu-Yousef MM, Benda JA, et al. Antenatal ultrasound diagnosis of iniencephaly. J Clin Ultrasound 1987; 15:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/49\">",
"      Sherer DM, Hearn-Stebbins B, Harvey W, et al. Endovaginal sonographic diagnosis of iniencephaly apertus and craniorachischisis at 13 weeks, menstrual age. J Clin Ultrasound 1993; 21:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/50\">",
"      Shoham Z, Caspi B, Chemke J, et al. Iniencephaly: prenatal ultrasonographic diagnosis--a case report. J Perinat Med 1988; 16:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/51\">",
"      Dobyns WB. Developmental aspects of lissencephaly and the lissencephaly syndromes. Birth Defects Orig Artic Ser 1987; 23:225.",
"     </a>",
"    </li>",
"    <li>",
"     Nishimura, H, Okamoto, N. Iniencephaly. In: Vinken P, Bruyn G, Eds. Handbook of clinical neurology. Vol. 30. Amsterdam: Elsevier-NorthHollan Publishing Co. 1976:257.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/53\">",
"      Rodriguez MM, Reik RA, Carreno TD, Fojaco RM. Cluster of iniencephaly in Miami. Pediatr Pathol 1991; 11:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/54\">",
"      Aleksic S, Budzilovich G, Greco MA, et al. Iniencephaly: a neuropathologic study. Clin Neuropathol 1983; 2:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/55\">",
"      Jo&oacute; JG, Beke A, Papp C, et al. Major diagnostic and pathological features of iniencephaly based on twenty-four cases. Fetal Diagn Ther 2008; 24:1.",
"     </a>",
"    </li>",
"    <li>",
"     Aleksic, S, Budzilovich, G. Iniencephaly. In: Myrianthopoulos N, ed. Malformations. Vol. 50. Amsterdam: Elsevier Science Publishers, 1987:129.",
"    </li>",
"    <li>",
"     Romero, R, Pilu, G, Jeanty, P, Ghidini, A, Hobbins, J. Iniencephaly. In: Romero R, Pilu G, Jeanty P, Ghidini A, Hobbins J, eds. Prenatal diagnosis of congenital anomalies. Norwalk: Appleton &amp; Lange, 1988:65.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/58\">",
"      David TJ, Nixon A. Congenital malformations associated with anencephaly and iniencephaly. J Med Genet 1976; 13:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/59\">",
"      Van den Hof MC, Nicolaides KH, Campbell J, Campbell S. Evaluation of the lemon and banana signs in one hundred thirty fetuses with open spina bifida. Am J Obstet Gynecol 1990; 162:322.",
"     </a>",
"    </li>",
"    <li>",
"     Osborn, A. Normal anatomy and congenital anomalies of the spine and d spinal cord. Diagnostic Neuroradiology. St. Louis: Mosby-Year Book, 1994:799.",
"    </li>",
"    <li>",
"     Welch, K, Winston, K. Spina bifida. In: Myrianthopoulos N, ed. Handbook of Clinical Neurology. Vol. 6. Amsterdam: Elsevier, 1987:477.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/62\">",
"      Thornton JG, Lilford RJ, Newcombe RG. Tables for estimation of individual risks of fetal neural tube and ventral wall defects, incorporating prior probability, maternal serum alpha-fetoprotein levels, and ultrasonographic examination results. Am J Obstet Gynecol 1991; 164:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/63\">",
"      Morrow RJ, McNay MB, Whittle MJ. Ultrasound detection of neural tube defects in patients with elevated maternal serum alpha-fetoprotein. Obstet Gynecol 1991; 78:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/64\">",
"      Lennon CA, Gray DL. Sensitivity and specificity of ultrasound for the detection of neural tube and ventral wall defects in a high-risk population. Obstet Gynecol 1999; 94:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/65\">",
"      Nicolaides KH, Campbell S, Gabbe SG, Guidetti R. Ultrasound screening for spina bifida: cranial and cerebellar signs. Lancet 1986; 2:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/66\">",
"      Campbell J, Gilbert WM, Nicolaides KH, Campbell S. Ultrasound screening for spina bifida: cranial and cerebellar signs in a high-risk population. Obstet Gynecol 1987; 70:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/67\">",
"      Blumenfeld, Z, Siegler, E, Bronshtein, M. The early diagnosis of neural tube defects. Prenat Diag 1993; 13:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/68\">",
"      Sebire NJ, Noble PL, Thorpe-Beeston JG, et al. Presence of the 'lemon' sign in fetuses with spina bifida at the 10-14-week scan. Ultrasound Obstet Gynecol 1997; 10:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/69\">",
"      Bernard JP, Suarez B, Rambaud C, et al. Prenatal diagnosis of neural tube defect before 12 weeks' gestation: direct and indirect ultrasonographic semeiology. Ultrasound Obstet Gynecol 1997; 10:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/70\">",
"      Penso C, Redline RW, Benacerraf BR. A sonographic sign which predicts which fetuses with hydrocephalus have an associated neural tube defect. J Ultrasound Med 1987; 6:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/71\">",
"      Nyberg DA, Mack LA, Hirsch J, Mahony BS. Abnormalities of fetal cranial contour in sonographic detection of spina bifida: evaluation of the \"lemon\" sign. Radiology 1988; 167:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/72\">",
"      Thiagarajah S, Henke J, Hogge WA, et al. Early diagnosis of spina bifida: the value of cranial ultrasound markers. Obstet Gynecol 1990; 76:54.",
"     </a>",
"    </li>",
"    <li>",
"     Volpe, J. Neuronal proliferation, migration, organization and myelination. Neurology of the newborn. Philadelphia: WB Saunders, 1995;3-42.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/74\">",
"      Braithwaite JM, Armstrong MA, Economides DL. Assessment of fetal anatomy at 12 to 13 weeks of gestation by transabdominal and transvaginal sonography. Br J Obstet Gynaecol 1996; 103:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/75\">",
"      Baxi L, Warren W, Collins MH, Timor-Tritsch IE. Early detection of caudal regression syndrome with transvaginal scanning. Obstet Gynecol 1990; 75:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/76\">",
"      Chaoui R, Benoit B, Mitkowska-Wozniak H, et al. Assessment of intracranial translucency (IT) in the detection of spina bifida at the 11-13-week scan. Ultrasound Obstet Gynecol 2009; 34:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/77\">",
"      Chaoui R, Nicolaides KH. From nuchal translucency to intracranial translucency: towards the early detection of spina bifida. Ultrasound Obstet Gynecol 2010; 35:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/78\">",
"      Fong KW, Toi A, Okun N, et al. Retrospective review of diagnostic performance of intracranial translucency in detection of open spina bifida at the 11-13-week scan. Ultrasound Obstet Gynecol 2011; 38:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/79\">",
"      Chaoui R, Benoit B, Heling KS, et al. Prospective detection of open spina bifida at 11-13 weeks by assessing intracranial translucency and posterior brain. Ultrasound Obstet Gynecol 2011; 38:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/80\">",
"      Kollias SS, Goldstein RB, Cogen PH, Filly RA. Prenatally detected myelomeningoceles: sonographic accuracy in estimation of the spinal level. Radiology 1992; 185:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/81\">",
"      Biggio JR Jr, Owen J, Wenstrom KD, Oakes WJ. Can prenatal ultrasound findings predict ambulatory status in fetuses with open spina bifida? Am J Obstet Gynecol 2001; 185:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/82\">",
"      Coniglio SJ, Anderson SM, Ferguson JE 2nd. Functional motor outcome in children with myelomeningocele: correlation with anatomic level on prenatal ultrasound. Dev Med Child Neurol 1996; 38:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/83\">",
"      Brumfield CG, Aronin PA, Cloud GA, Davis RO. Fetal myelomeningocele. Is antenatal ultrasound useful in predicting neonatal outcome? J Reprod Med 1995; 40:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/84\">",
"      Chao TT, Dashe JS, Adams RC, et al. Fetal spine findings on MRI and associated outcomes in children with open neural tube defects. AJR Am J Roentgenol 2011; 197:W956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/85\">",
"      Andonotopo W, Kurjak A, Kosuta MI. Behavior of an anencephalic fetus studied by 4D sonography. J Matern Fetal Neonatal Med 2005; 17:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/86\">",
"      Kurauchi O, Ohno Y, Furugori K, et al. Comparative study of fetal behaviour in a case of monozygotic twins, one being anencephalic. Gynecol Obstet Invest 1996; 42:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/87\">",
"      Kurauchi O, Ohno Y, Mizutani S, Tomoda Y. Longitudinal monitoring of fetal behavior in twins when one is anencephalic. Obstet Gynecol 1995; 86:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/88\">",
"      Warsof SL, Abramowicz JS, Sayegh SK, Levy DL. Lower limb movements and urologic function in fetuses with neural tube and other central nervous system defects. Fetal Ther 1988; 3:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/89\">",
"      Visser GH, Laurini RN, de Vries JI, et al. Abnormal motor behaviour in anencephalic fetuses. Early Hum Dev 1985; 12:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/90\">",
"      van Heteren CF, Boekkooi PF, Jongsma HW, Nijhuis JG. Responses to vibroacoustic stimulation in a fetus with an encephalocele compared to responses of normal fetuses. J Perinat Med 2000; 28:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35560/abstract/91\">",
"      Ohel G, Simon A, Linder N, Mor-Yosef S. Anencephaly and the nature of fetal response to vibroacoustic stimulation. Am J Perinatol 1986; 3:345.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6831 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-B2700F0D78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_46_35560=[""].join("\n");
var outline_f34_46_35560=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EXENCEPHALY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANENCEPHALY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CEPHALOCELE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INIENCEPHALY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SPINAL DYSRAPHISM AND THE ARNOLD-CHIARI MALFORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Sonographic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      FETAL ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33807716\">",
"      MANAGEMENT AND OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6831\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6831|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?4/35/4658\" title=\"diagnostic image 1\">",
"      Exencephaly2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?22/24/22914\" title=\"diagnostic image 2\">",
"      Exencephaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?32/52/33601\" title=\"diagnostic image 3A\">",
"      Anencephaly 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?25/18/25890\" title=\"diagnostic image 3B\">",
"      Anencephaly ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?30/21/31059\" title=\"diagnostic image 4A\">",
"      Cephalocele",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?38/6/39011\" title=\"diagnostic image 4B\">",
"      CephaloceleB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?42/31/43504\" title=\"diagnostic image 5\">",
"      Meningocele",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?24/13/24786\" title=\"diagnostic image 6A\">",
"      Spina bifida A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?1/7/1139\" title=\"diagnostic image 6B\">",
"      Spina bifida B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?6/9/6291\" title=\"diagnostic image 6C\">",
"      Spina bifida C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?20/48/21251\" title=\"diagnostic image 6D\">",
"      Spina bifida D",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?26/22/26976\" title=\"diagnostic image 7\">",
"      Myelomeningocele",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?31/54/32610\" title=\"diagnostic image 8A\">",
"      Lemon sign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?33/9/33940\" title=\"diagnostic image 8B\">",
"      Banana sign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?10/46/10978\" title=\"diagnostic image 9\">",
"      Open spina bifida in the first trimester",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?3/31/3574\" title=\"diagnostic image 10\">",
"      Intracranial translucency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6831|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/0/27661\" title=\"table 1\">",
"      GA by crown chin length",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11237?source=related_link\">",
"      Anencephaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/39/12920?source=related_link\">",
"      Fetal ventriculomegaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26344?source=related_link\">",
"      Overview of the management of myelomeningocele (spina bifida)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33767?source=related_link\">",
"      Pathophysiology and clinical manifestations of myelomeningocele (spina bifida)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/44/2762?source=related_link\">",
"      Prenatal diagnosis of CNS anomalies other than neural tube defects and ventriculomegaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/35/25145?source=related_link\">",
"      Prenatal screening and diagnosis of neural tube defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/57/3991?source=related_link\">",
"      Primary (congenital) encephalocele",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/46/40682?source=related_link\">",
"      Twin pregnancy: Prenatal issues",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_46_35561="Collagenous colitis Light II";
var content_f34_46_35561=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1119px;\">",
"  <div class=\"figure\" style=\"width: 481px\">",
"   <div class=\"ttl\">",
"    Collagenous colitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 461px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of a colonic biopsy from a patient with collagenous colitis. The characteristic change is thickened subepithelial collagenous band in the colonic mucosa that stains in bright blue (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Prof Dr G Herrmann, Frankfurt.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Normal colon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 172px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low (left) and high (right) power views of a biopsy of a normal colon. Low power reveals straight crypts and mild lamina propria mononuclear cell infiltration. High power shows the surface enterocytes with interspersed goblet cells (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_46_35561=[""].join("\n");
var outline_f34_46_35561=null;
var title_f34_46_35562="Autism spectrum disorders in children and adolescents: Pharmacologic interventions";
var content_f34_46_35562=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Autism spectrum disorders in children and adolescents: Pharmacologic interventions",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/46/35562/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/46/35562/contributors\">",
"     Laura Weissman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/46/35562/contributors\">",
"     Carolyn Bridgemohan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/46/35562/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/46/35562/contributors\">",
"     Marilyn Augustyn, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/46/35562/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/46/35562/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/46/35562/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/46/35562/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autism spectrum disorders (ASD) are a group of biologically based neurodevelopmental disorders characterized by impairments in three major domains: socialization, communication, and behavior. The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) categorizes autism spectrum disorders under \"pervasive developmental disorders\" (PDD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/1\">",
"     1",
"    </a>",
"    ]. These disorders include autistic disorder (classic autism, sometimes called early infantile autism, childhood autism, or Kanner's autism); Asperger disorder (also known as Asperger syndrome); pervasive developmental disorder-not otherwise specified (PDD-NOS), including atypical autism; childhood disintegrative disorder; and Rett disorder.",
"   </p>",
"   <p>",
"    The discussion that follows will focus on pharmacologic interventions for autism and PDD-NOS. Related topics are presented separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/41/664?source=see_link\">",
"       \"Clinical features of autism spectrum disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/3/38969?source=see_link\">",
"       \"Diagnosis of autism spectrum disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/54/872?source=see_link\">",
"       \"Autism spectrum disorders in children and adolescents: Overview of management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/1/4122?source=see_link\">",
"       \"Autism spectrum disorders in children and adolescents: Behavioral and educational interventions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/54/16234?source=see_link\">",
"       \"Autism spectrum disorders in children and adolescents: Complementary and alternative therapies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4698?source=see_link\">",
"       \"Terminology, epidemiology, and pathogenesis of autism spectrum disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41801?source=see_link\">",
"       \"Asperger disorder: Management and prognosis in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of autism spectrum disorders (ASD) vary in intensity, and treatment plans must be individualized. Psychopharmacologic interventions may be a useful adjunct to",
"    <span class=\"nowrap\">",
"     behavioral/environmental",
"    </span>",
"    interventions in children with ASD after behavioral and educational supports have been maximized. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/1/4122?source=see_link\">",
"     \"Autism spectrum disorders in children and adolescents: Behavioral and educational interventions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Psychopharmacologic agents do not treat autism itself and should be initiated only after educational and behavioral interventions are in place. The potential benefits and risks of pharmacologic therapy for children with ASD must be weighed on a case-by-case basis. Parents and caregivers should be informed if the medication is being used off-label (only",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/5/32857?source=see_link\">",
"     risperidone",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/35/7737?source=see_link\">",
"     aripiprazole",
"    </a>",
"    are approved by the United States Food and Drug Administration for use in children with ASD).",
"   </p>",
"   <p>",
"    The principles for the psychopharmacologic management of individuals with ASD are the same as for individuals with other psychiatric conditions. Medications should be used to target specific symptoms that are clearly defined, and the symptoms should be measured over time (preferably using rating scales) to monitor treatment efficacy.",
"   </p>",
"   <p>",
"    Children with ASD are more sensitive to psychopharmacotherapy and more likely to have adverse effects than children without ASD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In addition, given their weaknesses communicating and identifying their emotions, it can be difficult to determine the predominant target symptom (eg, anxiety, impulsivity, anger) and, therefore, the best psychopharmacologic agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pretreatment evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before initiating pharmacologic therapy for target behaviors in children with ASD, each target behavior should be identified and characterized (with input from parents, other caregivers, and school staff, if possible) in terms of [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      How long has it been present? How severe is it?",
"     </li>",
"     <li>",
"      What brings it on or makes it worse? (eg, time, setting, demands, etc); is it amenable to behavioral interventions?",
"     </li>",
"     <li>",
"      Are medical factors contributing (eg, dental or other pain, infection, sleep, seizures, menstrual cycle, etc)?",
"     </li>",
"     <li>",
"      What makes it better? How does it respond to behavioral interventions?",
"     </li>",
"     <li>",
"      What is the course? Is it getting better or worse?",
"     </li>",
"     <li>",
"      Does it interfere with function?",
"     </li>",
"     <li>",
"      What supports are available (eg, behavioral services, educational program, respite care, family support)?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of a standardized instrument (eg, Vanderbilt scales for attention or the Aberrant Behavior Checklist) facilitates the gathering of data and monitoring of target symptoms over time, but these tools have not been standardized in the autism spectrum population so should be used in conjunction with appropriate historical and other available data. They may be more useful for tracking symptoms than evaluating for secondary morbidities. Target symptoms of children receiving intensive behavioral interventions can be monitored using the data collection techniques included in their programming. Behavioral symptoms generally are regularly monitored in children with ASD who are receiving intensive behavioral therapy; if so, it may be possible to include the behaviors targeted by pharmacologic therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/1/4122?source=see_link&amp;anchor=H8#H8\">",
"     \"Autism spectrum disorders in children and adolescents: Behavioral and educational interventions\", section on 'Intensive behavioral interventions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the symptoms meet criteria for a comorbid psychiatric condition (eg, depression, attention deficit hyperactivity disorder), the disorder should be managed accordingly, with the caveat that the response to medication may differ in children and adolescents for whom this is a secondary rather than a primary diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/26/13738?source=see_link\">",
"     \"Overview of treatment for adolescent depression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/61/32730?source=see_link&amp;anchor=H268239#H268239\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis\", section on 'Overview of management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic therapy for children with ASD may be warranted for the treatment of comorbid psychiatric or neurodevelopmental conditions or for behavioral symptoms that interfere with learning, socialization, health, safety, quality of life, or overall functioning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. When considering the use of medications for target symptoms in children with ASD, the potential benefits and risks must be weighed on a case-by-case basis. Pharmacologic therapy generally is initiated after behavioral and environmental interventions are in place and have been maximized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Who should prescribe?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychopharmacotherapy for children and adolescents with ASD ideally is prescribed by specialists familiar with ASD (eg, developmental-behavioral pediatricians, child psychiatrists, child neurologists, etc). However, access to such specialists is not always available. Primary care clinicians who undertake the prescription of psychotropic agents for children with ASD should do so in consultation with a developmental-behavioral pediatrician, child psychiatrist, child neurologist, or another mental health professional who is familiar with ASD to ensure that an appropriate medication is chosen and efficacy and adverse effects are appropriately monitored.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Choice of agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors to consider in choosing pharmacologic therapy for children with ASD include (",
"    <a class=\"graphic graphic_table graphicRef80456 \" href=\"mobipreview.htm?19/62/20461\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Likelihood of improvement in the target symptom",
"     </li>",
"     <li>",
"      Potential adverse effects",
"     </li>",
"     <li>",
"      Practical considerations (available formulations, dosing schedule, cost, requirement for laboratory monitoring)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/5/32857?source=see_link\">",
"     Risperidone",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/35/7737?source=see_link\">",
"     aripiprazole",
"    </a>",
"    are the only psychotropic medications approved by the United States Food and Drug Administration (FDA) for individuals with ASD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/7\">",
"     7",
"    </a>",
"    ]. However, many other medications are used off-label. Parents and caregivers should be informed if the medication is being used off-label.",
"   </p>",
"   <p>",
"    The study of psychopharmacologic interventions in children with ASD is ongoing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Most of the existing evidence is extrapolated from studies on comorbid conditions (eg, attention deficit hyperactivity disorder, obsessive compulsive disorder, anxiety, etc) in children without ASD. Studies of pharmacotherapy in children with ASD generally are small, retrospective, and nonblinded; they are hampered by the lack of diagnostic tools that have been standardized in the ASD population. Notable exceptions include",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/5/32857?source=see_link\">",
"     risperidone",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/35/7737?source=see_link\">",
"     aripiprazole",
"    </a>",
"    for the treatment of disruptive behaviors and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/40/10890?source=see_link\">",
"     methylphenidate",
"    </a>",
"    for the treatment of disruptive behaviors and",
"    <span class=\"nowrap\">",
"     hyperactivity/inattention",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3151821\">",
"     'Risperidone'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H3152019\">",
"     'Aripiprazole'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H3151563\">",
"     'Stimulants'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with ASD are more sensitive to medication effects and more likely to have adverse effects than children without ASD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Medications should be started at lower doses, and doses should be increased more slowly than in patients without ASD.",
"   </p>",
"   <p>",
"    The efficacy and adverse effects of pharmacologic agents should be monitored systematically during therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In addition to clinical history, an appropriate tool should be used to monitor outcome if such a tool is available. The schedule for follow-up should permit an adequate trial of therapy, as well as a timely modification (different dose, different medication, discontinuation) if the desired effect does not occur. After successful control of the target symptom for 6 to 12 months, withdrawal of the medication for a period of time may be warranted to determine whether it is still necessary.",
"   </p>",
"   <p>",
"    The parents and caregivers should be provided with information about the prescribed medication and its potential adverse effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TARGET SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic therapy may be warranted for symptom control in children with autism spectrum disorders (ASD) if",
"    <span class=\"nowrap\">",
"     behavioral/environmental",
"    </span>",
"    interventions are ineffective or insufficient for target symptoms. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Pretreatment evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Target symptoms that may respond to psychotropic medications include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hyperactivity, impulsivity, and inattention",
"     </li>",
"     <li>",
"      Disruptive behaviors (eg, aggression, explosive outbursts, self-injury)",
"     </li>",
"     <li>",
"      Repetitive behaviors and rigidity",
"     </li>",
"     <li>",
"      Anxiety",
"     </li>",
"     <li>",
"      Mood lability",
"     </li>",
"     <li>",
"      Depression",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Inattention and hyperactivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with ASD may be inattentive, hyperactive, and disorganized. These behaviors may be related to comorbid attention deficit hyperactivity disorder (ADHD) or to other factors that affect function in children with ASD (eg, overarousal, anxiety). If the behaviors do not improve with environmental or behavioral interventions, they may respond to pharmacotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Potential therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential therapies for symptoms of inattention and hyperactivity in children with ASD include stimulant medications (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/40/10890?source=see_link\">",
"     methylphenidate",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?6/7/6263?source=see_link\">",
"     dextroamphetamine",
"    </a>",
"    ), alpha-2 adrenergic agonists (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/53/42839?source=see_link\">",
"     guanfacine",
"    </a>",
"    ),",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/46/12007?source=see_link\">",
"     atomoxetine",
"    </a>",
"    , atypical antipsychotics (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/5/32857?source=see_link\">",
"     risperidone",
"    </a>",
"    ), and anticonvulsant mood stabilizers (eg, valproic acid). There is strong evidence that stimulants and risperidone are beneficial for hyperactivity, and marginal evidence for the benefit of other atypical antipsychotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Selective serotonin reuptake inhibitor (SSRI) may be helpful if anxiety is contributing to symptoms. SSRI also may be used for repetitive behaviors, and depression. They are discussed separately. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Anxiety'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H3152246\">",
"     'SSRI'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H21\">",
"     'Depression'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3151563\">",
"    <span class=\"h4\">",
"     Stimulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized controlled trials and meta-analyses indicate that stimulant medication improves symptoms in approximately 80 percent of children with attention deficit hyperactivity disorder (ADHD) without ASD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23082?source=see_link&amp;anchor=H2007898700#H2007898700\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications\", section on 'Stimulants versus other medications'",
"    </a>",
"    .) In randomized crossover trials,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/40/10890?source=see_link\">",
"     methylphenidate",
"    </a>",
"    also improved symptoms of hyperactivity and inattention in children with ASD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. However, the response rate to methylphenidate is lower in children with ASD than it is in children with ADHD without ASD.",
"    <br/>",
"    <br/>",
"    In the largest crossover trial, approximately 50 percent of children with ASD responded to methylphenidate (as measured on the hyperactivity subscale of the Aberrant Behavior Checklist); the effect size ranged from 0.29 to 0.54, depending upon dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/16\">",
"     16",
"    </a>",
"    ], with greater improvement at higher doses (0.25 to 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    versus 0.125",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/17\">",
"     17",
"    </a>",
"    ]. Methylphenidate also may have beneficial effects on social communication and self-regulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/18\">",
"     18",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Studies of amphetamines (",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?6/7/6263?source=see_link\">",
"     dextroamphetamine",
"    </a>",
"    , amphetamine-dextroamphetamine) in the treatment of attentional symptoms in children with ASD are lacking. It is not clear that the results from trials of methylphenidate can be generalized to amphetamines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/19\">",
"     19",
"    </a>",
"    ]. However, amphetamines frequently are used in clinical practice. The side effects of stimulant medications in children with ASD are similar to those in other patients. However, they occur with greater frequency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In the trial of methylphenidate described above, 18 percent of subjects withdrew because of adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/16\">",
"     16",
"    </a>",
"    ]. Adverse effects of stimulant medications include, but are not limited to, sleep disturbance, decreased appetite, irritability, tics, sadness, dullness, and social withdrawal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/19/14650?source=see_link&amp;anchor=H12#H12\">",
"     \"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents\", section on 'Stimulant adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3151587\">",
"    <span class=\"h4\">",
"     Alpha agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alpha-2-adrenergic agonists (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/53/42839?source=see_link\">",
"     guanfacine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/14/13545?source=see_link\">",
"     clonidine",
"    </a>",
"    ) also are used to manage symptoms of inattention, hyperactivity, and impulsivity in children with ASD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/3,8,19,20\">",
"     3,8,19,20",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Studies of alpha-2-adrenergic agonists are limited, and sample sizes are small. In an open-label prospective trial of guanfacine in 25 children whose hyperactive symptoms did not respond to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/40/10890?source=see_link\">",
"     methylphenidate",
"    </a>",
"    , 47 percent responded to guanfacine (decrease in the mean parent- and teacher-rated hyperactivity subscale of the Aberrant Behavior Checklist (ABC) from 31.3 to 19.9 and 29.2 to 22.3, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/21\">",
"     21",
"    </a>",
"    ]. Retrospective analysis of guanfacine therapy in 80 children with ASD found guanfacine to be well tolerated with response rates of 27 and 21 percent for symptoms of hyperactivity and inattention, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/20\">",
"     20",
"    </a>",
"    ]. Adverse effects of guanfacine include sedation, constipation, irritability, and aggression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Two small crossover trials using clonidine suggest decreased irritability, stereotypy, hyperactivity, inappropriate speech, and oppositional behavior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. However, side effects included hypotension and sedation. It is uncertain whether some of the reduction in symptoms could be attributed to the sedative effect. Children who are treated with alpha-2-adrenergic agonists should have their blood pressure and heart rate monitored at each visit. Adverse effects of alpha-2-adrenergic agonists include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sedation",
"     </li>",
"     <li>",
"      Hypotension",
"     </li>",
"     <li>",
"      Rebound hypertension if discontinued abruptly",
"     </li>",
"     <li>",
"      Dry mouth",
"     </li>",
"     <li>",
"      Dizziness",
"     </li>",
"     <li>",
"      Irritability",
"     </li>",
"     <li>",
"      Increased aggression and self-injury",
"     </li>",
"     <li>",
"      Decreased appetite",
"     </li>",
"     <li>",
"      Sleep disturbance",
"     </li>",
"     <li>",
"      Headache",
"     </li>",
"     <li>",
"      Nocturnal enuresis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Alpha-2-adrenergic agonists can pose significant harm if provided in excess. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/50/22313?source=see_link\">",
"     \"Clonidine and related imidazoline poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3151771\">",
"    <span class=\"h4\">",
"     Atomoxetine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/46/12007?source=see_link\">",
"     atomoxetine",
"    </a>",
"    for symptoms of hyperactivity and inattention in children with ASD are limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/24\">",
"     24",
"    </a>",
"    ]. In a randomized trial in 97 children (6 to 17 years) with ASD and ADHD, atomoxetine resulted in moderate improvement in ADHD symptoms (eg, reduction in ADHD Rating Scale [ADHD-RS] scores compared with baseline of 8.2 points versus 1.2 point reduction in the placebo group); among the atomoxetine treated patients, improvement was greater on the hyperactivity-impulsivity than on the inattention subscore [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/25\">",
"     25",
"    </a>",
"    ]. However, the proportion of patients &ldquo;improved&rdquo; or &ldquo;much improved&rdquo; on the Clinical Global Impression of ADHD Improvement Scale was not statistically significantly different [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/25\">",
"     25",
"    </a>",
"    ]. Another small randomized crossover trial suggested some improvement in hyperactivity symptoms compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/26\">",
"     26",
"    </a>",
"    ]. However, as with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/40/10890?source=see_link\">",
"     methylphenidate",
"    </a>",
"    , the overall effect size for atomoxetine in children with ASD and symptoms of ADHD is smaller than for children with ADHD without ASD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/8,27,28\">",
"     8,27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <br/>",
"    Side effects of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/46/12007?source=see_link\">",
"     atomoxetine",
"    </a>",
"    include, but are not limited to, gastrointestinal symptoms, fatigue, sleep problems, mood swings, suicidal ideation, dizziness, and change in appetite. Rare but potentially serious adverse effects include suicidal ideation and hepatotoxicity. These adverse effects are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/19/14650?source=see_link&amp;anchor=H21#H21\">",
"     \"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents\", section on 'Atomoxetine adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3151779\">",
"    <span class=\"h4\">",
"     Other drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other drugs that may be beneficial for symptoms of hyperactivity and inattention in children with ASD include",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/5/32857?source=see_link\">",
"     risperidone",
"    </a>",
"    and antiepileptic drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/19\">",
"     19",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    The use of risperidone for symptoms of hyperactivity in children with ASD is supported by open-label and randomized controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/19,29,30\">",
"     19,29,30",
"    </a>",
"    ]. In a multicenter, placebo-controlled trial of 101 children with autism, treatment with risperidone (1.8",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for eight weeks was associated with decreased mean scores on the hyperactivity subscale of the Aberrant Behavior Checklist compared with baseline (32 to 17 versus 32 to 28 in the placebo group) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/29\">",
"     29",
"    </a>",
"    ]. Risperidone also may be used for disruptive behaviors and is discussed separately. (See",
"    <a class=\"local\" href=\"#H3151821\">",
"     'Risperidone'",
"    </a>",
"    below.)",
"    <br/>",
"    <br/>",
"    The evidence for antiepileptic agents (",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/54/27497?source=see_link\">",
"     valproate",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/60/21448?source=see_link\">",
"     topiramate",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?3/34/3626?source=see_link\">",
"     lamotrigine",
"    </a>",
"    ) is limited to small, open-label, or observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;When after a discussion of the potential risks and benefits, the clinician and parents agree that pharmacotherapy is indicated for symptoms of inattention, hyperactivity, and impulsivity that continue to impair function despite behavioral and environmental interventions and are not thought to be related to other symptoms (eg, anxiety), a trial of a stimulant (usually",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/40/10890?source=see_link\">",
"     methylphenidate",
"    </a>",
"    ) may be beneficial. An alternative agent may be chosen if stimulant therapy is not effective, or there are other target symptoms that require pharmacologic intervention (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/5/32857?source=see_link\">",
"     risperidone",
"    </a>",
"    if disruptive behaviors also require treatment). This approach is consistent with that in the Autism Speaks Autism Treatment Network Psychopharmacology Committee clinical practice pathway for evaluation and medication choice for ADHD symptoms in children with ASD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/40/10890?source=see_link\">",
"     methylphenidate",
"    </a>",
"    is not tolerated, a trial of another stimulant,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/46/12007?source=see_link\">",
"     atomoxetine",
"    </a>",
"    , or another class of medication used for ADHD may be warranted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/6,34\">",
"     6,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23082?source=see_link&amp;anchor=H2007898686#H2007898686\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications\", section on 'Choice of agent'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/19/14650?source=see_link&amp;anchor=H1#H1\">",
"     \"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Disruptive behaviors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disruptive behaviors in children with ASD include aggression, explosive outbursts (tantrums), and self-injury. These behaviors may occur in response to anxiety or frustration, which should be the first targets of management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/2\">",
"     2",
"    </a>",
"    ]. Disruptive behaviors can be due to anxiety, mood disorders, or impulse control problems. Pharmacotherapy may be indicated if nonpharmacologic therapies are unsuccessful. Combined pharmacologic and nonpharmacologic interventions may be more beneficial than medication alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. The pharmacologic agent of choice to treat the behavior depends upon the postulated cause of the disruptive behavior.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Potential agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The atypical antipsychotic agents,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/5/32857?source=see_link\">",
"     risperidone",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/35/7737?source=see_link\">",
"     aripiprazole",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/7\">",
"     7",
"    </a>",
"    ], are the only medications approved by the United States Food and Drug Administration (FDA) to treat irritability and self-injurious and aggressive behaviors in children with ASD. Agents that are used off-label include other atypical antipsychotics (",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34185?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/31/13817?source=see_link\">",
"     clozapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/33/23064?source=see_link\">",
"     ziprasidone",
"    </a>",
"    ),",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/51/38711?source=see_link\">",
"     haloperidol",
"    </a>",
"    (a typical antipsychotic), antiepileptics, alpha-2 agonists, mood stabilizers, selective serotonin reuptake inhibitors (SSRI), and beta-blockers. There is strong evidence that risperidone is beneficial for disruptive behaviors and marginal evidence for benefit with other atypical antipsychotics, antiepileptics, psychostimulants, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3151821\">",
"    <span class=\"h4\">",
"     Risperidone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/5/32857?source=see_link\">",
"     Risperidone",
"    </a>",
"    is the most commonly used antipsychotic for the treatment of disruptive behaviors in children with ASD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/37\">",
"     37",
"    </a>",
"    ]. It is approved by the FDA for the treatment of irritability and aggression in children (&ge;5 years) with ASD.",
"    <br/>",
"    <br/>",
"    Randomized controlled trials and systematic reviews indicate a positive response to risperidone in individuals with autism and disruptive behaviors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/29,30,38-42\">",
"     29,30,38-42",
"    </a>",
"    ]. In a multicenter, placebo-controlled trial of 101 children with autism, treatment with risperidone (1.8",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for eight weeks was associated with [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/29,43\">",
"     29,43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Higher treatment response; treatment response was defined as 25 percent or greater decrease in the irritability score and rating of \"much improved\" or \"very much improved\" on the Clinical Global Impression-Improvement (CGI-I) scale (69 versus 12 percent)",
"     </li>",
"     <li>",
"      Greater proportion \"much improved\" or \"very much improved\" on the CGI-I scale compared with baseline (75 versus 11 percent)",
"     </li>",
"     <li>",
"      Greater decrease in mean irritability score compared with baseline (57 versus 14 percent)",
"     </li>",
"     <li>",
"      Improvements in repetitive behaviors and restricted interests, but no effects on social function or communication (in secondary analysis) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/43\">",
"       43",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Repetitive behaviors and rigidity'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dosing of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/5/32857?source=see_link\">",
"     risperidone",
"    </a>",
"    is discussed separately. (See",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/5/32857?source=see_link\">",
"     \"Risperidone: Pediatric drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <br/>",
"    Adverse effects of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/5/32857?source=see_link\">",
"     risperidone",
"    </a>",
"    included weight gain, increased appetite, fatigue, drowsiness, dizziness, drooling, tremor, and constipation. However, they were mild and resolved over a few weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/29\">",
"     29",
"    </a>",
"    ]. There was no increase in tardive dyskinesia or other extrapyramidal symptoms compared with the placebo group. No additional adverse effects were noted during the four-month open-label continuation phase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/44\">",
"     44",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Adverse effects of atypical antipsychotics and monitoring for adverse effects are discussed in greater detail below. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Side effects of antipsychotics'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3152019\">",
"    <span class=\"h4\">",
"     Aripiprazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/35/7737?source=see_link\">",
"     Aripiprazole",
"    </a>",
"    is approved by the FDA for the treatment of irritability in children (aged 6 to 17 years) with ASD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/7\">",
"     7",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    In multicenter randomized trials, flexible and fixed dosing regimens of aripiprazole for eight weeks were beneficial in reducing irritability, stereotypy, and hyperactivity in children (aged 6 to 17 years) with autism (as measured by the Aberrant Behavior Checklist and Clinical Global Impressions-Severity scale) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/11,45,46\">",
"     11,45,46",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Adverse effects of aripiprazole included fatigue, vomiting, somnolence, weight gain, tremor, and extrapyramidal symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/11,45,46\">",
"     11,45,46",
"    </a>",
"    ]. With the fixed-dose regimen, approximately 10 percent of subjects withdrew because of adverse events; serious adverse events occurred in two subjects (presyncope and aggression) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/46\">",
"     46",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Adverse effects of atypical antipsychotics and monitoring for adverse effects are discussed in greater detail below. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Side effects of antipsychotics'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3152108\">",
"    <span class=\"h4\">",
"     Olanzapine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several small prospective studies (only one of which was blinded) demonstrated clinical improvement in disruptive behaviors in children with ASD who were treated with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34185?source=see_link\">",
"     olanzapine",
"    </a>",
"    (an atypical antipsychotic) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/47-50\">",
"     47-50",
"    </a>",
"    ]. However, weight gain and other side effects, such as sedation, often prohibit continued use of olanzapine. The risk of extrapyramidal side effects with olanzapine appears to be low.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3152116\">",
"    <span class=\"h4\">",
"     Other atypical antipsychotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other atypical antipsychotics (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/31/13817?source=see_link\">",
"     clozapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/33/23064?source=see_link\">",
"     ziprasidone",
"    </a>",
"    ) are used in clinical practice to treat disruptive behaviors in children with ASD. The evidence to support the use of these agents consists primarily of open-label studies or case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/51-54\">",
"     51-54",
"    </a>",
"    ]. Additional research is needed before they can be recommended as the initial medical therapy for disruptive behavior in children with ASD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3152124\">",
"    <span class=\"h4\">",
"     Haloperidol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized controlled trials suggest that",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/51/38711?source=see_link\">",
"     haloperidol",
"    </a>",
"    , a typical antipsychotic, is effective in the treatment of behavioral symptoms (tantrums, aggression, hyperactivity, social withdrawal, and stereotypies) in children with ASD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. However, it is less effective than",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/5/32857?source=see_link\">",
"     risperidone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/56\">",
"     56",
"    </a>",
"    ]. In addition, the risk of dyskinesia and other extrapyramidal symptoms (in approximately one-third of patients) limits its use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/57\">",
"     57",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Children who are treated with haloperidol should be monitored closely. A drug holiday may be warranted to avoid dyskinesia. Haloperidol should be slowly weaned to prevent withdrawal dyskinesia. The optimal duration of drug holiday is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3152132\">",
"    <span class=\"h4\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alpha-2 agonists, antiepileptics, mood stabilizers (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/38/1639?source=see_link\">",
"     lithium",
"    </a>",
"    ), SSRI, and beta blockers have been used to treat disruptive behaviors in children and adolescents with ASD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/8,58\">",
"     8,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Side effects of antipsychotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of antipsychotic agents often is limited by their side effect profile. Side effects of atypical antipsychotics may include, but are not limited to [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/6,59,60\">",
"     6,59,60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased appetite",
"     </li>",
"     <li>",
"      Weight gain",
"     </li>",
"     <li>",
"      Elevated blood sugar secondary to insulin resistance",
"     </li>",
"     <li>",
"      Dyslipidemia",
"     </li>",
"     <li>",
"      Blood pressure changes",
"     </li>",
"     <li>",
"      Electrocardiogram (EKG) changes, such as prolongation of QTc (more common with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/33/23064?source=see_link\">",
"       ziprasidone",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fatigue and drowsiness",
"     </li>",
"     <li>",
"      Dizziness",
"     </li>",
"     <li>",
"      Drooling",
"     </li>",
"     <li>",
"      Liver function abnormalities",
"     </li>",
"     <li>",
"      Increase in prolactin (of unknown clinical significance)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Less common, but serious, side effects include dystonic reactions, tardive dyskinesia, akathisia (subjective sense of restlessness, often accompanied by voluntary movements of the limbs or trunk), neuroleptic malignant syndrome, and agranulocytosis (with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/31/13817?source=see_link\">",
"     clozapine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/29,38,54,61\">",
"     29,38,54,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children who are treated with atypical antipsychotic agents should be monitored regularly. At baseline, the child's weight and height should be measured and body mass index (BMI) calculated ((",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?35/14/36070?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) [for boys] and (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?34/60/35782?source=see_link\">",
"     calculator 2",
"    </a>",
"    ) [for girls]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/62\">",
"     62",
"    </a>",
"    ]. Given the cardiometabolic side effects, it is important to take a thorough patient and family history, asking specifically about obesity, diabetes, dyslipidemia, hypertension, and cardiovascular disease. A baseline EKG should be obtained; the EKG should be repeated when the patient has reached the steady state (particularly in patients treated with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/33/23064?source=see_link\">",
"     ziprasidone",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Follow-up visits should include measurement of weight and blood pressure and evaluation for extrapyramidal findings (the use of a scale, such as the",
"    <a class=\"external\" href=\"file://www.cqaimh.org/pdf/tool_aims.pdf\">",
"     Abnormal Involuntary Movement Scale",
"    </a>",
"    [AIMS] is helpful). Baseline and follow-up laboratory studies may include fasting plasma glucose, fasting lipids, complete blood count (CBC), liver function tests, thyroid stimulating hormone (TSH), prolactin, and electrolytes.",
"   </p>",
"   <p>",
"    The optimal frequency of laboratory monitoring is not clear. We suggest follow-up at three months after starting medication and every six months thereafter for most of the studies listed above and when doses are increased. Prolactin and TSH may be monitored less frequently unless symptoms of abnormalities arise. More frequent testing may be necessary if metabolic abnormalities are identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Treatment approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no current published clinical guidelines regarding medication use for disruptive behavior in children with ASD. The treatment of disruptive behaviors in children with ASD involves a tradeoff between benefits and risks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/63\">",
"     63",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/5/32857?source=see_link\">",
"     Risperidone",
"    </a>",
"    may be beneficial for aggression and self-injury that are not thought to be related to other symptoms (eg, anxiety) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/30,40\">",
"     30,40",
"    </a>",
"    ]. Other medications (eg, stimulants, SSRI, alpha adrenergic agonists) may be more appropriate, depending upon the underlying cause of aggression and self-injury (eg, hyperactivity, anxiety, impulsivity).",
"   </p>",
"   <p>",
"    Other atypical antipsychotic agents (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/35/7737?source=see_link\">",
"     aripiprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/31/13817?source=see_link\">",
"     clozapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34185?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/33/23064?source=see_link\">",
"     ziprasidone",
"    </a>",
"    ) and different classes of drugs (eg, alpha-2 agonists, antiepileptics, mood stabilizers, selective serotonin reuptake inhibitor, and beta blockers) have been used to treat disruptive behaviors in children and adolescents with ASD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/8\">",
"     8",
"    </a>",
"    ]. However, there is less evidence to support the use of these agents for this indication.",
"   </p>",
"   <p>",
"    Switching to another antipsychotic agent is commonly recommended if there is excessive weight gain or other adverse effects. However, discontinuation of medication may be warranted depending upon symptom severity. This is especially true if the individual has been treated for a long interval (ie, a year or more) and would benefit from a trial off medications to reassess efficacy and need for treatment. Withdrawal of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/5/32857?source=see_link\">",
"     risperidone",
"    </a>",
"    and other antipsychotics is often accompanied by a period of greater behavioral dysregulation. Successful discontinuation of risperidone and other antipsychotic agents requires a gradual taper over several weeks to months. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'General principles'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Repetitive behaviors and rigidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repetitive behaviors, stereotypies, and rigidity in children with autism spectrum disorders (ASD) often interfere with function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Potential treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of repetitive behaviors and rigidity in children with ASD involves a tradeoff between benefits and risks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/63\">",
"     63",
"    </a>",
"    ]. Potential treatments for repetitive behaviors in children with ASD include selective serotonin reuptake inhibitors (SSRI),",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/37/11864?source=see_link\">",
"     clomipramine",
"    </a>",
"    , atypical antipsychotics, and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/54/27497?source=see_link\">",
"     valproate",
"    </a>",
"    . There is marginal evidence from randomized trials that SSRI are beneficial for repetitive behaviors and rigidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/13\">",
"     13",
"    </a>",
"    ]. However, in a meta-analysis of trials of serotonin receptor inhibitors (SRI, which include SSRI and tricyclic antidepressants, such as clomipramine) the small benefit of SRI on repetitive behavior disappeared after adjustment for publication bias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/64\">",
"     64",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/16/39173?source=see_link\">",
"     Naltrexone",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/45/20179?source=see_link\">",
"     secretin",
"    </a>",
"    , and stimulants have been shown to be ineffective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the lack of high-quality evidence that SSRI are beneficial, we suggest",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/63/33785?source=see_link\">",
"     fluoxetine",
"    </a>",
"    (or another SSRI) as the initial medication for repetitive behaviors that require pharmacologic intervention. SSRI have fewer side effects than the other agents and may be helpful in the treatment of coexisting anxiety. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Anxiety'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3152246\">",
"    <span class=\"h4\">",
"     SSRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of SSRI for repetitive behaviors in children with ASD is based upon the effectiveness of SSRI in individuals with obsessive-compulsive disorder (OCD), demonstrated in meta-analysis of randomized controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/65\">",
"     65",
"    </a>",
"    ]. Rigorous studies of SSRI in children with ASD are lacking. The available evidence suggests that",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/63/33785?source=see_link\">",
"     fluoxetine",
"    </a>",
"    may be beneficial for repetitive behaviors and rigidity and that",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/16/38152?source=see_link\">",
"     citalopram",
"    </a>",
"    is not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/41\">",
"     41",
"    </a>",
"    ]. However, citalopram is sometimes used in clinical practice for anxiety. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Anxiety'",
"    </a>",
"    below.) Evidence for other SSRI in children is insufficient to make a firm recommendation, but they are used clinically.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/63/33785?source=see_link\">",
"       Fluoxetine",
"      </a>",
"      &ndash; In a randomized, placebo-controlled crossover study in 44 children with ASD, fluoxetine was beneficial in reducing repetitive behaviors as measured on the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/22/41320?source=see_link\">",
"       Fluvoxamine",
"      </a>",
"      &ndash; In an unpublished randomized trial in children, fluvoxamine had limited efficacy in reducing repetitive behaviors and was poorly tolerated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/67\">",
"       67",
"      </a>",
"      ]. However, it may be beneficial in adults with ASD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/18/7465?source=see_link\">",
"       Sertraline",
"      </a>",
"      &ndash; Open-label trials of sertraline in adults with ASD have noted improvements in repetitive and disruptive behaviors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/69,70\">",
"       69,70",
"      </a>",
"      ]. There are no randomized controlled trials in adults or children.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/59/18361?source=see_link\">",
"       Paroxetine",
"      </a>",
"      &ndash; Studies of paroxetine in children with ASD are lacking. Small open label studies in individuals with intellectual disability (mental retardation) suggest that it may be beneficial in reducing aggression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/16/38152?source=see_link\">",
"       Citalopram",
"      </a>",
"      &ndash; In a multicenter randomized trial in 149 children with ASD, citalopram did not improve repetitive behaviors and was associated with increased risk of adverse events, including increased energy level, impulsiveness, decreased concentration, hyperactivity, stereotypy, diarrhea, insomnia, dry skin, and pruritus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/21/36184?source=see_link\">",
"       Escitalopram",
"      </a>",
"      &ndash; An open-label trial of escitalopram demonstrated some improvement in irritability, lethargy, stereotypy, hyperactivity, and inappropriate speech [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/73\">",
"       73",
"      </a>",
"      ]. There was a wide variability in therapeutic dose that was not related to patient weight.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children taking SSRI should be monitored for adverse effects, including sedation, anorexia, agitation, headaches, aggression, anxiety activation, insomnia, GI upset, and drowsiness. Blood pressure and heart rate should be monitored at follow-up visits.",
"    <br/>",
"    <br/>",
"    When used in children and adolescents with depression, SSRI have been associated with increased suicidal ideation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15736?source=see_link\">",
"     \"Effect of antidepressants on suicide risk in children and adolescents\"",
"    </a>",
"    .) Increased suicidal ideation has not been demonstrated in studies of SSRI in individuals with ASD. However, most studies did not assess suicidal ideation and included too few subjects to detect rare adverse effects, such as suicidal ideation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3152339\">",
"    <span class=\"h4\">",
"     Clomipramine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/37/11864?source=see_link\">",
"     Clomipramine",
"    </a>",
"    is a serotonin-selective tricyclic antidepressant. The use of clomipramine for repetitive behaviors in children with ASD is based upon its effectiveness in individuals with OCD, demonstrated in controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/74\">",
"     74",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    However, studies of clomipramine for repetitive behavior in children with ASD have inconsistent findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]. The use of clomipramine often is limited by its side effects, which may include lethargy, tremors, tachycardia, insomnia, diaphoresis, nausea, decreased appetite, urinary retention, and severe constipation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3152347\">",
"    <span class=\"h4\">",
"     Risperidone",
"    </span>",
"    &nbsp;&mdash;&nbsp;In secondary analysis of a multicenter placebo-controlled trial of 101 children with autism, treatment with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/5/32857?source=see_link\">",
"     risperidone",
"    </a>",
"    (1.8",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for eight weeks was associated with greater decrease in mean CY-BOCS compulsion scale (15.5 to 11.65 versus 15.2 to 14.2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/43\">",
"     43",
"    </a>",
"    ]. Adverse effects of risperidone are discussed above. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Side effects of antipsychotics'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3152355\">",
"    <span class=\"h4\">",
"     Valproate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/54/27497?source=see_link\">",
"     Valproate",
"    </a>",
"    , an antiepileptic medication, is also used to treat repetitive behaviors in children with ASD. It use is supported by a small, blinded randomized controlled trial that demonstrated improvement in repetitive behaviors as measured by the CY-BOCS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/78\">",
"     78",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Side effects of valproic acid may include, but are not limited to, irritability, weight gain, anxiety, and aggression. The pharmacology and use of valproate is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link&amp;anchor=H19#H19\">",
"     \"Pharmacology of antiepileptic drugs\", section on 'Valproate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Anxiety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anxiety is common in individuals with autism spectrum disorders (ASD) and may contribute to aggressive, explosive, or self-injurious behaviors. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Disruptive behaviors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Anxiety in children with ASD is treated with the same therapies that are used to treat anxiety in other children. Pharmacotherapy is one arm of a multimodal approach that may include individual therapy, cognitive behavioral therapy, behavioral",
"    <span class=\"nowrap\">",
"     interventions/incentives;",
"    </span>",
"    accommodations to address sensory sensitivities; and special education services [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/79\">",
"     79",
"    </a>",
"    ]. The components of the multimodal therapy may vary from patient to patient.",
"   </p>",
"   <p>",
"    Symptoms related to anxiety in children with ASD often are treated with selective serotonin reuptake inhibitors (SSRI). There are no randomized trials that specifically assess the efficacy of SSRI in individuals with ASD. However, in a meta-analysis of randomized controlled trials in children without ASD, SSRI were more effective than placebo in reducing core symptoms of anxiety in children and adolescents (58 versus 31 percent, relative risk of response 1.9, 95% CI 1.6-2.26) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of SSRI in children with repetitive behaviors is discussed above. (See",
"    <a class=\"local\" href=\"#H3152246\">",
"     'SSRI'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/55/11126?source=see_link\">",
"     Buspirone",
"    </a>",
"    (an anxiolytic) is another agent that may be used to treat anxiety in children with ASD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/81,82\">",
"     81,82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Mood lability",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of agents have been used to treat dysregulated mood and symptoms related to dysregulated mood in children and adolescents with autism spectrum disorder (ASD).",
"   </p>",
"   <p>",
"    These include atypical antipsychotics, selective serotonin reuptake inhibitors (SSRI), and mood-stabilizing agents (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/38/1639?source=see_link\">",
"     lithium",
"    </a>",
"    ). None of these agents has been studied specifically for mood regulation in children with ASD.",
"   </p>",
"   <p>",
"    Atypical antipsychotics also may be used to treat disruptive behaviors. Their use is discussed above. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Treatment approach'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H15\">",
"     'Side effects of antipsychotics'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    SSRI also may be used to treat repetitive behaviors and anxiety. Their use is discussed above. (See",
"    <a class=\"local\" href=\"#H3152246\">",
"     'SSRI'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antidepressant therapy may be indicated if depressive symptoms persist despite counseling and psychosocial interventions. The same medications that are used for depression in typical children can be used to treat symptoms of depression in children with ASD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/52/30538?source=see_link\">",
"     \"Psychopharmacological treatment for adolescent depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of SSRI and serotonin norepinephrine reuptake inhibitors (SNRI) in the treatment of children with ASD has not been documented through a sufficient number of randomized controlled trials to draw any firm conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/83\">",
"     83",
"    </a>",
"    ]. Nonetheless,",
"    <span class=\"nowrap\">",
"     SSRI/SNRI",
"    </span>",
"    may be warranted for patients who demonstrate clear symptoms of depression (eg, terminal insomnia, psychomotor disturbance, anorexia, changes in mood from baseline, etc). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/10/5289?source=see_link\">",
"     \"Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When using antidepressants to treat depressive symptoms in children and adolescents with ASD, the clinician must be mindful of the increased incidence of behavioral activation (impulsivity, silliness, agitation, and disinhibition) and other side effects, including a potentially increased risk of suicidal ideation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/52/30538?source=see_link&amp;anchor=H18#H18\">",
"     \"Psychopharmacological treatment for adolescent depression\", section on 'Adverse reactions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15736?source=see_link\">",
"     \"Effect of antidepressants on suicide risk in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Individuals with ASD may respond to very low doses of",
"    <span class=\"nowrap\">",
"     SSRI/SNRI,",
"    </span>",
"    but typical pediatric doses may be necessary. It is important to \"start low and go slow.\" (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Overview'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     INVESTIGATIVE THERAPIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Social deficits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic agents that demonstrated potential benefit for social deficits in individuals with autism spectrum disorders (ASD) in small open-label studies include oxytocin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/84,85\">",
"     84,85",
"    </a>",
"    ], D-cycloserine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/86\">",
"     86",
"    </a>",
"    ], tetrahydrobiopterin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/87\">",
"     87",
"    </a>",
"    ], and cognition enhancers used in the treatment of Alzheimer disease (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/27/6582?source=see_link\">",
"     galantamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/16/24837?source=see_link\">",
"     memantine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/26/6567?source=see_link\">",
"     rivastigmine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/13,88-92\">",
"     13,88-92",
"    </a>",
"    ]. Additional controlled studies are necessary to confirm efficacy and safety before these therapies can be recommended.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/16/39173?source=see_link\">",
"     Naltrexone",
"    </a>",
"    has been shown to be ineffective in the treatment of social deficits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/13\">",
"     13",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     ASSOCIATED CONDITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures are more common in children with ASD than in the general population. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4698?source=see_link&amp;anchor=H11#H11\">",
"     \"Terminology, epidemiology, and pathogenesis of autism spectrum disorders\", section on 'Associated conditions'",
"    </a>",
"    .) Pharmacologic management of seizures in children with ASD is similar to that of seizures in children without ASD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/32/37386?source=see_link\">",
"     \"Overview of the treatment of seizures and epileptic syndromes in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     GI problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of the evidence regarding gastrointestinal (GI) problems in children with ASD found a lack of high-quality data [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/93\">",
"     93",
"    </a>",
"    ]. The authors concluded that the frequency and types of GI disorders observed in children with ASD are similar to those in children without ASD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/93\">",
"     93",
"    </a>",
"    ]. The American Academy of Pediatrics and Scottish Intercollegiate Guidelines Network (SIGN) recommended that GI disorders in children with an ASD generally should be managed in the same way as in children without an ASD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/6,94\">",
"     6,94",
"    </a>",
"    ]. However, because children with ASD may not tolerate certain aspects of the examination or types of diagnostic studies (eg, rectal examination), trials of pharmacologic therapy for constipation or gastroesophageal reflux may be undertaken based upon symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pharmacologic interventions for specific GI problems in children are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Constipation (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/28/36298?source=see_link\">",
"       \"Treatment of chronic functional constipation and fecal incontinence in infants and children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Gastroesophageal reflux disease (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/33/19994?source=see_link\">",
"       \"Management of gastroesophageal reflux disease in children and adolescents\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Chronic abdominal pain (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/52/6984?source=see_link\">",
"       \"Management of the child and adolescent with chronic abdominal pain\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Chronic diarrhea (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/43/35511?source=see_link\">",
"       \"Approach to the diagnosis of chronic diarrhea in children in developed countries\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Sleep disturbance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many children with ASD have sleep disturbance, including late onset, frequent waking, and restlessness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/95\">",
"     95",
"    </a>",
"    ]. Sleep disturbance may be related to abnormalities in melatonin, serotonin, or gamma-aminobutyric acid (GABA).",
"   </p>",
"   <p>",
"    The evaluation of sleep disturbance in children with ASD should include a thorough sleep history and screen for obstructive apnea and other sleep disorders. Referral to a specialist (eg, sleep specialist, neurologist, otolaryngologist) may be warranted if a specific sleep disorder is identified or suspected. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/50/5929?source=see_link\">",
"     \"Assessment of sleep disorders in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/38/44649?source=see_link\">",
"     \"Evaluation of suspected obstructive sleep apnea in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to ensure appropriate sleep hygiene and use behavioral interventions to decrease sleep associations before considering pharmacologic interventions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/96\">",
"     96",
"    </a>",
"    ]. Medications are unlikely to be effective in the absence of an appropriate sleep schedule.",
"   </p>",
"   <p>",
"    There is little evidence for pharmacologic management of sleep disturbance in children. No medications are approved by the United States Food and Drug Administration for use for sleep in ASD. However, several are used in clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Melatonin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of melatonin for sleep onset and maintenance in children with ASD have been suggested in observational, open-label studies, and two small randomized placebo-controlled crossover trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/97-101\">",
"     97-101",
"    </a>",
"    ]. The doses ranged from 0.75 to 10",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    and the duration of treatment ranged from 14 days to 6 months. In one randomized trial, melatonin (5",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for four weeks was associated with decreased mean sleep latency (1.06 versus 1.91 hours), decreased mean night wakings (0.08 versus 0.26), and increased mean total sleep duration (9.84 versus 8.75 hours) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/100\">",
"     100",
"    </a>",
"    ]. Sleep latency and total sleep in both groups improved compared with baseline (sleep latency 2.6 hours and 8.05 hours total sleep). In the second randomized trial, melatonin (2 to 10",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    titrated to effect by parents) for three months was associated with decreased sleep latency (mean difference of 47 minutes) and increased total sleep (mean difference of 52 minutes), but not number of night wakings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/101\">",
"     101",
"    </a>",
"    ]. These studies suggest that in the short-term (ie, up to six months), 1 to 10 mg of melatonin may be effective in helping children with ASD to fall asleep or stay asleep when provided 30 minutes before bedtime. However, there are no dosing guidelines for administration and no information on long-term use or side effects.",
"   </p>",
"   <p>",
"    Side effects of melatonin may include difficulty waking, daytime sleepiness, and enuresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/98,99\">",
"     98,99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest melatonin for patients with ASD who have difficulty falling asleep and staying asleep despite appropriate sleep hygiene and behavioral or environmental interventions. We usually start with 0.5 to 1 mg, depending upon age, and increase by 1 mg as needed to a maximum of 10 mg (although in clinical practice, others may use a higher dose).",
"   </p>",
"   <p>",
"    Melatonin is sold over the counter and does not require a prescription. It is not regulated by the FDA. When",
"    <span class=\"nowrap\">",
"     parents/caregivers",
"    </span>",
"    purchase melatonin, they should seek a formulation that contains melatonin as the only active ingredient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some data suggest that low serum ferritin levels in children with ASD may contribute to symptoms of restless sleep (even in children with normal iron levels) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/102\">",
"     102",
"    </a>",
"    ]. In an observational study, oral iron supplementation was beneficial in improving restless sleep in children with ASD and decreased serum ferritin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other agents that have been studied in the management of sleep disturbance (increased sleep latency, night wakings, and decreased total sleep) in children with ASD include niaprazine,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/14/13545?source=see_link\">",
"     clonidine",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/5/32857?source=see_link\">",
"     risperidone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/13\">",
"     13",
"    </a>",
"    ]. In addition, for children who require antiepileptic or antidepressant medications, the timing of administration can be manipulated to take advantage of the sedative effects.",
"   </p>",
"   <p>",
"    There are few data to support the use of these medications for sleep in children with ASD. When used, they should be started at the lowest available dose and titrated as necessary.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Niaprazine is a histamine H1-receptor antagonist with sedative properties that is available in Europe [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/103,104\">",
"       103,104",
"      </a>",
"      ]. In an open study in 25 patients with ASD and sleep disorder, niaprazine (1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for 60 days) was associated with improvement in behavior and sleep disorders; no side effects were observed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/104\">",
"       104",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/14/13545?source=see_link\">",
"       Clonidine",
"      </a>",
"      (an alpha2-adrenergic receptor agonist) has sedative effects. In an observational study, clonidine was effective in reducing sleep latency and nighttime awakening in children with ASD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/105\">",
"       105",
"      </a>",
"      ]. Side effects of clonidine include hypotension.",
"     </li>",
"     <li>",
"      If a patient who presents with sleep difficulties also is prescribed a medication with a sedating effect (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/5/32857?source=see_link\">",
"       risperidone",
"      </a>",
"      , some antiepileptics, some antidepressants), the sedating medication could be administered at bedtime; or, if more than one dose is recommended, the higher dose can be administered at bedtime, if appropriate. However, given the potential adverse effects, the use of sedating medications for sleep disturbance alone is not recommended.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Parasomnias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parasomnias or nonrapid eye movement (NREM) arousal disorders include sleep walking, sleep terrors, and confusional arousals. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/51/28473?source=see_link&amp;anchor=H27172788#H27172788\">",
"     \"Sleepwalking and other parasomnias in children\", section on 'Disorders of arousal from non-rapid eye movement (NREM) sleep'",
"    </a>",
"    .)&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/7/11383?source=see_link\">",
"     Clonazepam",
"    </a>",
"    and tricyclic antidepressants have been used to treat NREM arousal disorders in children with ASD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/46/35562/abstract/96\">",
"     96",
"    </a>",
"    ]. However, high-quality evidence to support their use is lacking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     General",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The target symptom(s) for pharmacotherapy in children with autism spectrum disorders (ASD) should be clearly defined. Medical causes for the behavior should be excluded, and behavioral interventions should be maximized before pharmacotherapy is initiated. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pretreatment evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When considering the use of medications for target symptoms, the potential benefits and risks must be weighed on a case-by-case basis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Psychopharmacotherapy for children and adolescents with ASD ideally is prescribed by specialists familiar with ASD (eg, developmental pediatrician, child psychiatrist, child neurologist). Primary care clinicians who undertake the prescription of psychotropic agents for children with ASD should do so in consultation with a specialist. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Who should prescribe?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with ASD who are receiving pharmacologic therapy for target symptoms must be monitored regularly for efficacy and side effects. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Targeted symptoms",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When after careful assessment of the patient and a discussion of the potential risks and benefits, the clinician and",
"      <span class=\"nowrap\">",
"       parents/patient",
"      </span>",
"      agree that pharmacotherapy is indicated for target symptoms in children with ASD:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For inattention and hyperactivity that are not thought to be related to other symptoms, such as anxiety, we suggest",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/40/10890?source=see_link\">",
"       methylphenidate",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). Other stimulants, alpha-agonists, and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/46/12007?source=see_link\">",
"       atomoxetine",
"      </a>",
"      also have been used. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For maladaptive behaviors including aggression and self-injury that are not thought to be related to other symptoms, we suggest",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/5/32857?source=see_link\">",
"       risperidone",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). Other medications (eg, stimulants, selective serotonin reuptake inhibitors [SSRI], alpha adrenergic agonists) may be more appropriate, depending upon the underlying cause of aggression (eg, hyperactivity, anxiety, impulsivity). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For repetitive behaviors, we suggest",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/63/33785?source=see_link\">",
"       fluoxetine",
"      </a>",
"      (or another SSRI) as the initial medication (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Repetitive behaviors and rigidity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For anxiety, we suggest an SSRI as the initial medication (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Anxiety'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For dysregulated mood, we suggest an atypical antipsychotic or SSRI as the initial medication (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Mood lability'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For depressive symptoms, we suggest an SSRI or serotonin norepinephrine reuptake inhibitor as the initial medication (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Depression'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Associated conditions",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pharmacologic management of seizures in children with ASD is similar to that of seizures in children without ASD. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/32/37386?source=see_link\">",
"       \"Overview of the treatment of seizures and epileptic syndromes in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gastrointestinal disorders in children with ASD generally should be managed in the same way as in children without ASD. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'GI problems'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Melatonin may be beneficial for sleep disturbance (late onset, frequent waking, restlessness) that persists despite appropriate sleep hygiene and behavioral interventions. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Melatonin'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Psychiatric Association. Pervasive Developmental Disorders. In: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR&reg;)., American Psychiatric Association, Washington, DC  p.70.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/2\">",
"      Towbin KE. Strategies for pharmacologic treatment of high functioning autism and Asperger syndrome. Child Adolesc Psychiatr Clin N Am 2003; 12:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/3\">",
"      Aman MG, Farmer CA, Hollway J, Arnold LE. Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders. Child Adolesc Psychiatr Clin N Am 2008; 17:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/4\">",
"      Myers SM, Johnson CP, American Academy of Pediatrics Council on Children With Disabilities. Management of children with autism spectrum disorders. Pediatrics 2007; 120:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/5\">",
"      Myers SM. The status of pharmacotherapy for autism spectrum disorders. Expert Opin Pharmacother 2007; 8:1579.",
"     </a>",
"    </li>",
"    <li>",
"     Scottish Intercollegiate Guidelines Network. Assessment, diagnosis and clinical interventions for children and young people with autism spectrum disorders. A national clinical guideline. Scottish Intercollegiate Guidelines Network, Edinburgh 2007. www.sign.ac.uk/guidelines/fulltext/98/index.html (Accessed on November 10, 2011).",
"    </li>",
"    <li>",
"     Drugs@FDA. Abilify. Available at: www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&amp;DrugName=ABILIFY. (Accessed on April 21, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/8\">",
"      Leskovec TJ, Rowles BM, Findling RL. Pharmacological treatment options for autism spectrum disorders in children and adolescents. Harv Rev Psychiatry 2008; 16:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/9\">",
"      West L, Waldrop J, Brunssen S. Pharmacologic treatment for the core deficits and associated symptoms of autism in children. J Pediatr Health Care 2009; 23:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/10\">",
"      Parikh MS, Kolevzon A, Hollander E. Psychopharmacology of aggression in children and adolescents with autism: a critical review of efficacy and tolerability. J Child Adolesc Psychopharmacol 2008; 18:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/11\">",
"      Ching H, Pringsheim T. Aripiprazole for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2012; 5:CD009043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/12\">",
"      Oswald DP, Sonenklar NA. Medication use among children with autism spectrum disorders. J Child Adolesc Psychopharmacol 2007; 17:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/13\">",
"      Huffman LC, Sutcliffe TL, Tanner IS, Feldman HM. Management of symptoms in children with autism spectrum disorders: a comprehensive review of pharmacologic and complementary-alternative medicine treatments. J Dev Behav Pediatr 2011; 32:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/14\">",
"      Quintana H, Birmaher B, Stedge D, et al. Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord 1995; 25:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/15\">",
"      Handen BL, Johnson CR, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord 2000; 30:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/16\">",
"      Research Units on Pediatric Psychopharmacology Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 2005; 62:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/17\">",
"      Posey DJ, Aman MG, McCracken JT, et al. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures. Biol Psychiatry 2007; 61:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/18\">",
"      Jahromi LB, Kasari CL, McCracken JT, et al. Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. J Autism Dev Disord 2009; 39:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/19\">",
"      Hazell P. Drug therapy for attention-deficit/hyperactivity disorder-like symptoms in autistic disorder. J Paediatr Child Health 2007; 43:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/20\">",
"      Posey DJ, Puntney JI, Sasher TM, et al. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol 2004; 14:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/21\">",
"      Scahill L, Aman MG, McDougle CJ, et al. A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006; 16:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/22\">",
"      Fankhauser MP, Karumanchi VC, German ML, et al. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry 1992; 53:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/23\">",
"      Jaselskis CA, Cook EH Jr, Fletcher KE, Leventhal BL. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol 1992; 12:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/24\">",
"      Ghanizadeh A. Atomoxetine for Treating ADHD Symptoms in Autism: A Systematic Review. J Atten Disord 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/25\">",
"      Harfterkamp M, van de Loo-Neus G, Minderaa RB, et al. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry 2012; 51:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/26\">",
"      Arnold LE, Aman MG, Cook AM, et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry 2006; 45:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/27\">",
"      Svanborg P, Thernlund G, Gustafsson PA, et al. Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in stimulant-na&iuml;ve Swedish children and adolescents. Eur Child Adolesc Psychiatry 2009; 18:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/28\">",
"      Geller D, Donnelly C, Lopez F, et al. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry 2007; 46:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/29\">",
"      McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002; 347:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/30\">",
"      Barnard L, Young AH, Pearson J, et al. A systematic review of the use of atypical antipsychotics in autism. J Psychopharmacol 2002; 16:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/31\">",
"      Hollander E, Dolgoff-Kaspar R, Cartwright C, et al. An open trial of divalproex sodium in autism spectrum disorders. J Clin Psychiatry 2001; 62:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/32\">",
"      Hardan AY, Jou RJ, Handen BL. A retrospective assessment of topiramate in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2004; 14:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/33\">",
"      Belsito KM, Law PA, Kirk KS, et al. Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 2001; 31:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/34\">",
"      Mahajan R, Bernal MP, Panzer R, et al. Clinical practice pathways for evaluation and medication choice for attention-deficit/hyperactivity disorder symptoms in autism spectrum disorders. Pediatrics 2012; 140:S125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/35\">",
"      Frazier TW. Friends not foes: combined risperidone and behavior therapy for irritability in autism. J Am Acad Child Adolesc Psychiatry 2012; 51:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/36\">",
"      Aman MG, McDougle CJ, Scahill L, et al. Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2009; 48:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/37\">",
"      McVoy M, Findling R. Child and adolescent psychopharmacology update. Psychiatr Clin North Am 2009; 32:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/38\">",
"      Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004; 114:e634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/39\">",
"      Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol 2006; 21:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/40\">",
"      Jesner OS, Aref-Adib M, Coren E. Risperidone for autism spectrum disorder. Cochrane Database Syst Rev 2007; :CD005040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/41\">",
"      McPheeters ML, Warren Z, Sathe N, et al. A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics 2011; 127:e1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/42\">",
"      Dove D, Warren Z, McPheeters ML, et al. Medications for adolescents and young adults with autism spectrum disorders: a systematic review. Pediatrics 2012; 130:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/43\">",
"      McDougle CJ, Scahill L, Aman MG, et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 2005; 162:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/44\">",
"      Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry 2005; 162:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/45\">",
"      Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 2009; 124:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/46\">",
"      Marcus RN, Owen R, Kamen L, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 2009; 48:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/47\">",
"      Potenza MN, Holmes JP, Kanes SJ, McDougle CJ. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 1999; 19:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/48\">",
"      Malone RP, Cater J, Sheikh RM, et al. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry 2001; 40:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/49\">",
"      Kemner C, Willemsen-Swinkels SH, de Jonge M, et al. Open-label study of olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol 2002; 22:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/50\">",
"      Hollander E, Wasserman S, Swanson EN, et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol 2006; 16:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/51\">",
"      Malone RP, Delaney MA, Hyman SB, Cater JR. Ziprasidone in adolescents with autism: an open-label pilot study. J Child Adolesc Psychopharmacol 2007; 17:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/52\">",
"      Chavez B, Chavez-Brown M, Sopko MA Jr, Rey JA. Atypical antipsychotics in children with pervasive developmental disorders. Paediatr Drugs 2007; 9:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/53\">",
"      Posey DJ, Stigler KA, Erickson CA, McDougle CJ. Antipsychotics in the treatment of autism. J Clin Invest 2008; 118:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/54\">",
"      Zuddas A, Ledda MG, Fratta A, et al. Clinical effects of clozapine on autistic disorder. Am J Psychiatry 1996; 153:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/55\">",
"      Campbell M, Anderson LT, Small AM, et al. The effects of haloperidol on learning and behavior in autistic children. J Autism Dev Disord 1982; 12:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/56\">",
"      Miral S, Gencer O, Inal-Emiroglu FN, et al. Risperidone versus haloperidol in children and adolescents with AD : a randomized, controlled, double-blind trial. Eur Child Adolesc Psychiatry 2008; 17:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/57\">",
"      Campbell M, Armenteros JL, Malone RP, et al. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry 1997; 36:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/58\">",
"      Hellings JA, Weckbaugh M, Nickel EJ, et al. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2005; 15:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/59\">",
"      Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009; 302:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/60\">",
"      Luby J, Mrakotsky C, Stalets MM, et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J Child Adolesc Psychopharmacol 2006; 16:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/61\">",
"      Arnold LE, Vitiello B, McDougle C, et al. Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. J Am Acad Child Adolesc Psychiatry 2003; 42:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/62\">",
"      American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27:596.",
"     </a>",
"    </li>",
"    <li>",
"     Parr J. Autism. In: Clinical Evidence Handbook, BMJ Publishing Group, London 2008. p.69.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/64\">",
"      Carrasco M, Volkmar FR, Bloch MH. Pharmacologic treatment of repetitive behaviors in autism spectrum disorders: evidence of publication bias. Pediatrics 2012; 129:e1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/65\">",
"      Soomro GM, Altman D, Rajagopal S, Oakley-Browne M. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev 2008; :CD001765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/66\">",
"      Hollander E, Phillips A, Chaplin W, et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 2005; 30:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/67\">",
"      McDougle CJ, Kresch LE, Posey DJ. Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors. J Autism Dev Disord 2000; 30:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/68\">",
"      McDougle CJ, Naylor ST, Cohen DJ, et al. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 1996; 53:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/69\">",
"      McDougle CJ, Brodkin ES, Naylor ST, et al. Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation. J Clin Psychopharmacol 1998; 18:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/70\">",
"      Hellings JA, Kelley LA, Gabrielli WF, et al. Sertraline response in adults with mental retardation and autistic disorder. J Clin Psychiatry 1996; 57:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/71\">",
"      Davanzo PA, Belin TR, Widawski MH, King BH. Paroxetine treatment of aggression and self-injury in persons with mental retardation. Am J Ment Retard 1998; 102:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/72\">",
"      King BH, Hollander E, Sikich L, et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry 2009; 66:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/73\">",
"      Owley T, Walton L, Salt J, et al. An open-label trial of escitalopram in pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 2005; 44:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/74\">",
"      Clomipramine in the treatment of patients with obsessive-compulsive disorder. The Clomipramine Collaborative Study Group. Arch Gen Psychiatry 1991; 48:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/75\">",
"      Gordon CT, State RC, Nelson JE, et al. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 1993; 50:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/76\">",
"      Remington G, Sloman L, Konstantareas M, et al. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol 2001; 21:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/77\">",
"      Hurwitz R, Blackmore R, Hazell P, et al. Tricyclic antidepressants for autism spectrum disorders (ASD) in children and adolescents. Cochrane Database Syst Rev 2012; 3:CD008372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/78\">",
"      Hollander E, Soorya L, Wasserman S, et al. Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. Int J Neuropsychopharmacol 2006; 9:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/79\">",
"      White SW, Oswald D, Ollendick T, Scahill L. Anxiety in children and adolescents with autism spectrum disorders. Clin Psychol Rev 2009; 29:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/80\">",
"      Ipser JC, Stein DJ, Hawkridge S, Hoppe L. Pharmacotherapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev 2009; :CD005170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/81\">",
"      Posey DJ, Guenin KD, Kohn AE, et al. A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. J Child Adolesc Psychopharmacol 2001; 11:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/82\">",
"      Buitelaar JK, van der Gaag RJ, van der Hoeven J. Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: results of an open-label study. J Clin Psychiatry 1998; 59:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/83\">",
"      Posey DJ, Erickson CA, Stigler KA, McDougle CJ. The use of selective serotonin reuptake inhibitors in autism and related disorders. J Child Adolesc Psychopharmacol 2006; 16:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/84\">",
"      Hollander E, Novotny S, Hanratty M, et al. Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders. Neuropsychopharmacology 2003; 28:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/85\">",
"      Andari E, Duhamel JR, Zalla T, et al. Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. Proc Natl Acad Sci U S A 2010; 107:4389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/86\">",
"      Posey DJ, Kem DL, Swiezy NB, et al. A pilot study of D-cycloserine in subjects with autistic disorder. Am J Psychiatry 2004; 161:2115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/87\">",
"      Danfors T, von Knorring AL, Hartvig P, et al. Tetrahydrobiopterin in the treatment of children with autistic disorder: a double-blind placebo-controlled crossover study. J Clin Psychopharmacol 2005; 25:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/88\">",
"      Hardan AY, Handen BL. A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 2002; 12:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/89\">",
"      Chez MG, Aimonovitch M, Buchanan T, et al. Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate. J Child Neurol 2004; 19:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/90\">",
"      Nicolson R, Craven-Thuss B, Smith J. A prospective, open-label trial of galantamine in autistic disorder. J Child Adolesc Psychopharmacol 2006; 16:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/91\">",
"      Chez MG, Burton Q, Dowling T, et al. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol 2007; 22:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/92\">",
"      Erickson CA, Posey DJ, Stigler KA, et al. A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl) 2007; 191:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/93\">",
"      Buie T, Campbell DB, Fuchs GJ 3rd, et al. Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report. Pediatrics 2010; 125 Suppl 1:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/94\">",
"      Buie T, Fuchs GJ 3rd, Furuta GT, et al. Recommendations for evaluation and treatment of common gastrointestinal problems in children with ASDs. Pediatrics 2010; 125 Suppl 1:S19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/95\">",
"      Brimacombe M, Chaaban J, Zimmerman-Bier B, et al. Autism spectrum disorders: concurrent clinical disorders. J Child Neurol 2008; 23:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/96\">",
"      Johnson KP, Giannotti F, Cortesi F. Sleep patterns in autism spectrum disorders. Child Adolesc Psychiatr Clin N Am 2009; 18:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/97\">",
"      Andersen IM, Kaczmarska J, McGrew SG, Malow BA. Melatonin for insomnia in children with autism spectrum disorders. J Child Neurol 2008; 23:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/98\">",
"      Paavonen EJ, Nieminen-von Wendt T, Vanhala R, et al. Effectiveness of melatonin in the treatment of sleep disturbances in children with Asperger disorder. J Child Adolesc Psychopharmacol 2003; 13:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/99\">",
"      Giannotti F, Cortesi F, Cerquiglini A, Bernabei P. An open-label study of controlled-release melatonin in treatment of sleep disorders in children with autism. J Autism Dev Disord 2006; 36:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/100\">",
"      Garstang J, Wallis M. Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child Care Health Dev 2006; 32:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/101\">",
"      Wright B, Sims D, Smart S, et al. Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial. J Autism Dev Disord 2011; 41:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/102\">",
"      Dosman CF, Brian JA, Drmic IE, et al. Children with autism: effect of iron supplementation on sleep and ferritin. Pediatr Neurol 2007; 36:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/103\">",
"      Johnson KP, Malow BA. Assessment and pharmacologic treatment of sleep disturbance in autism. Child Adolesc Psychiatr Clin N Am 2008; 17:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/104\">",
"      Rossi PG, Posar A, Parmeggiani A, et al. Niaprazine in the treatment of autistic disorder. J Child Neurol 1999; 14:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/46/35562/abstract/105\">",
"      Ming X, Gordon E, Kang N, Wagner GC. Use of clonidine in children with autism spectrum disorders. Brain Dev 2008; 30:454.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 603 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-B3B70EFBF6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_46_35562=[""].join("\n");
var outline_f34_46_35562=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pretreatment evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Who should prescribe?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Choice of agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TARGET SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Inattention and hyperactivity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Potential therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3151563\">",
"      Stimulants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3151587\">",
"      Alpha agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3151771\">",
"      Atomoxetine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3151779\">",
"      Other drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Disruptive behaviors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Potential agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3151821\">",
"      Risperidone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3152019\">",
"      Aripiprazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3152108\">",
"      Olanzapine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3152116\">",
"      Other atypical antipsychotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3152124\">",
"      Haloperidol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3152132\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Side effects of antipsychotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Treatment approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Repetitive behaviors and rigidity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Potential treatments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3152246\">",
"      SSRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3152339\">",
"      Clomipramine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3152347\">",
"      Risperidone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3152355\">",
"      Valproate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Anxiety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Mood lability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      INVESTIGATIVE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Social deficits",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      ASSOCIATED CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      GI problems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Sleep disturbance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Melatonin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Parasomnias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      General",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Targeted symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Associated conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/603\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/603|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/62/20461\" title=\"table 1\">",
"      Pharmacotherapy ASD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?35/14/36070?source=related_link\" title=\"calculator 1\">",
"      Calculator: Body Mass Index (BMI) percentiles for boys (2 to 20 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?34/60/35782?source=related_link\" title=\"calculator 2\">",
"      Calculator: Body Mass Index (BMI) percentiles for girls (2 to 20 years)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/43/35511?source=related_link\">",
"      Approach to the diagnosis of chronic diarrhea in children in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41801?source=related_link\">",
"      Asperger disorder: Management and prognosis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/50/5929?source=related_link\">",
"      Assessment of sleep disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/61/32730?source=related_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23082?source=related_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/1/4122?source=related_link\">",
"      Autism spectrum disorders in children and adolescents: Behavioral and educational interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/54/16234?source=related_link\">",
"      Autism spectrum disorders in children and adolescents: Complementary and alternative therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/54/872?source=related_link\">",
"      Autism spectrum disorders in children and adolescents: Overview of management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/41/664?source=related_link\">",
"      Clinical features of autism spectrum disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/50/22313?source=related_link\">",
"      Clonidine and related imidazoline poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/10/5289?source=related_link\">",
"      Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/3/38969?source=related_link\">",
"      Diagnosis of autism spectrum disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15736?source=related_link\">",
"      Effect of antidepressants on suicide risk in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/38/44649?source=related_link\">",
"      Evaluation of suspected obstructive sleep apnea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/33/19994?source=related_link\">",
"      Management of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/52/6984?source=related_link\">",
"      Management of the child and adolescent with chronic abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/32/37386?source=related_link\">",
"      Overview of the treatment of seizures and epileptic syndromes in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/26/13738?source=related_link\">",
"      Overview of treatment for adolescent depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/19/14650?source=related_link\">",
"      Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/52/30538?source=related_link\">",
"      Psychopharmacological treatment for adolescent depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/5/32857?source=related_link\">",
"      Risperidone: Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/51/28473?source=related_link\">",
"      Sleepwalking and other parasomnias in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4698?source=related_link\">",
"      Terminology, epidemiology, and pathogenesis of autism spectrum disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/28/36298?source=related_link\">",
"      Treatment of chronic functional constipation and fecal incontinence in infants and children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_46_35563="CF carriers by ethnic origin";
var content_f34_46_35563=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cystic fibrosis carrier risk by ethnic origin",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Group",
"      </td>",
"      <td class=\"subtitle1\">",
"       Incidence of cystic fibrosis",
"      </td>",
"      <td class=\"subtitle1\">",
"       Carrier frequency of CFTR gene mutation",
"      </td>",
"      <td class=\"subtitle1\">",
"       &Delta;F508, percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Caucasians",
"      </td>",
"      <td>",
"       1/3300",
"      </td>",
"      <td>",
"       1/25",
"      </td>",
"      <td>",
"       70",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hispanics",
"      </td>",
"      <td>",
"       1/8000-9000",
"      </td>",
"      <td>",
"       1/46",
"      </td>",
"      <td>",
"       46",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ashkenazi Jews",
"      </td>",
"      <td>",
"       1/3300",
"      </td>",
"      <td>",
"       1/24",
"      </td>",
"      <td>",
"       30",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Native Americans",
"      </td>",
"      <td>",
"       1/3970",
"      </td>",
"      <td>",
"       1/31 Pueblo",
"      </td>",
"      <td rowspan=\"2\">",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1/1500",
"      </td>",
"      <td>",
"       1/20 Zuni",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       African Americans",
"      </td>",
"      <td>",
"       1/15,300",
"      </td>",
"      <td>",
"       1/65",
"      </td>",
"      <td>",
"       48",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Asian Americans",
"      </td>",
"      <td>",
"       1/32,100",
"      </td>",
"      <td>",
"       1/94",
"      </td>",
"      <td>",
"       30",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CFTR: cystic fibrosis conductance transmembrane regulator.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from data from National Institutes of Health. Genetic testing for cystic fibrosis. NIH Consensus Statement 1997; 15:1 and ACOG Committee Opinion, Update on carrier screening for cystic fibrosis, December 2005.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_46_35563=[""].join("\n");
var outline_f34_46_35563=null;
var title_f34_46_35564="Severity of MR in adults";
var content_f34_46_35564=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Severity of mitral regurgitation (MR) in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mild",
"       </td>",
"       <td class=\"subtitle1\">",
"        Moderate",
"       </td>",
"       <td class=\"subtitle1\">",
"        Severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Structural parameters",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Left atrial (LA) size",
"       </td>",
"       <td>",
"        Normal, unless other causes of left atrial dilation",
"       </td>",
"       <td>",
"        Normal or dilated",
"       </td>",
"       <td>",
"        Dilated, except acute MR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Left ventricular size",
"       </td>",
"       <td>",
"        Normal, unless other causes of left ventricular dilation",
"       </td>",
"       <td>",
"        Normal or dilated",
"       </td>",
"       <td>",
"        Dilated, except acute MR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mitral leaflets or support apparatus",
"       </td>",
"       <td>",
"        Normal or abnormal",
"       </td>",
"       <td>",
"        Normal or abnormal",
"       </td>",
"       <td>",
"        Abnormal/flail leaflet, ruptured papillary muscle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Doppler parameters",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Color Doppler jet area",
"       </td>",
"       <td>",
"        Small, central jet, (&lt;4 cm2 or &lt;20 percent of LA area)",
"       </td>",
"       <td>",
"        Greater than mild but no criteria for severe MR",
"       </td>",
"       <td>",
"        Vena contracta width &gt;0.7 cm with large central MR jet (area 40 percent of LA area or a wall impinging jet of any size, swirling in LA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Doppler vena contracta width",
"       </td>",
"       <td>",
"        &lt;3 mm",
"       </td>",
"       <td>",
"        3&nbsp;to 6.9 mm",
"       </td>",
"       <td>",
"        &ge;7 mm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Quantitative parameters",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Regurgitant volume",
"       </td>",
"       <td>",
"        &lt;30 mL/beat",
"       </td>",
"       <td>",
"        30 to 59 mL/beat",
"       </td>",
"       <td>",
"        &ge;60 mL/beat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Regurgitant fraction",
"       </td>",
"       <td>",
"        &lt;30 percent",
"       </td>",
"       <td>",
"        30 to 49 percent",
"       </td>",
"       <td>",
"        &ge;50 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Regurgitant orifice area",
"       </td>",
"       <td>",
"        &lt;0.20 cm2",
"       </td>",
"       <td>",
"        0.20 to 0.39 cm2",
"       </td>",
"       <td>",
"        &ge;0.40 cm2",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Zoghbi WA, Enriquez-Sarano M, Foster E, et al. American Society of Echocardiography Report. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003; 16:777; and Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_46_35564=[""].join("\n");
var outline_f34_46_35564=null;
var title_f34_46_35565="T4 suppression of goiter";
var content_f34_46_35565=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F54294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F54294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thyroxine suppresses goiter growth",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 238px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relative changes in thyroid volume in patients with nontoxic goiter treated with placebo, thyroxine (T4) plus carbamizole (CBZ), or thyroxine alone for nine months and then followed for an additional nine months. Thyroxine suppressed thyroid volume, an effect that persisted only during the phase of active treatment. Carbimazole was of no added benefit.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Berghout A, Wiersinga WM, Drexhage HA, et al. Comparison of placebo with L-thyroxine alone or with carbimazole for treatment of sporadic non-toxic goitre.&nbsp;Lancet 1990; 336:193.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_46_35565=[""].join("\n");
var outline_f34_46_35565=null;
var title_f34_46_35566="Complement pathways";
var content_f34_46_35566=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F56374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F56374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Complement pathways",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 261px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The goal of the complement system is to deposit large quantities of C3b on a target. In the classical pathway, immune-complexes bind C1 and its C1s protease subunit cleaves C4 and C2. The large fragments of C4 and C2 bind together to form an enzyme (the C3 convertase) that cleaves C3 to C3b.",
"    <br>",
"     The lectin pathway is an analogous system except that lectin sugar complexes are formed and mannan associated serine protease (MASP) takes the place of C1.",
"     <br>",
"      The alternative pathway tickover mechanism continuously generates C3b. If C3b binds to a target lacking complement regulators, the feedback loop is initiated. The deposited C3b engages the alternative pathway components to form a convertase (C3bBb), which in turn cleaves more C3 to C3b. Properdin (P) is a positive regulator that stabilizes the alternative pathway C3 convertase. C3b generation is the gateway to inflammation and membrane attack complex formation in addition to serving as the major complement derived opsonin. A slight modification of the C3 convertase, incorporation of an additional C3b, creates the C5 convertase.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_46_35566=[""].join("\n");
var outline_f34_46_35566=null;
var title_f34_46_35567="Growth in intrinsic shortness";
var content_f34_46_35567=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F80244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F80244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intrinsic shortness",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 302px; height: 390px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Growth curve in a male with intrinsic shortness. The growth velocity is normal from age 5 onward with the height being below, but parallel to, the third percentile.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Rogol, AD, Lawton, EL. Body measurements. In: Pediatric Outpatient Procedures, Lohr, J (Ed), JB Lippincott, Philadelphia 1990, p.1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_46_35567=[""].join("\n");
var outline_f34_46_35567=null;
        